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Abstract
Elucidation of the mechanism by which P-gp can interact with multiple drugs, and harness 
the energy from hydrolysis of ATP to mediate transbilayer movement of drug, has been the 
goal of this thesis. Using radioligand binding studies, four distinct binding sites for drug 
have been identified on P-gp, explaining the molecular basis of its broad ‘substrate’ 
specificity. Two of the sites have been classified as transport sites and have been assigned 
the sites of interaction for vinblastine and paclitaxel respectively. A third site identified was 
capable of binding both drugs that are transported (Hoechst 33342) by P-gp, and those that 
are modulatory only (XR9576 and XR9051). The fourth binding site has been classified as 
a modulatory site, and has been assigned to the modulators nicardipine and GF120918. The 
existence of a negative heterotropic allosteric network between the sites, suggests that P-gp 
does not simultaneously bind multiple drugs. In order for transport of drug to occur, the 
drug binding site must undergo ‘re-orientation’, switching from a high to a low affinity 
conformation. This transition must be associated with ATP hydrolysis, given the ATP 
dependency of P-gp transport function. Therefore, binding of vinblastine was measured at 
discrete steps of the catalytic cycle of P-gp, to ascertain when changes are wrought on the 
drug binding site. Binding of ATP, prior to hydrolysis, triggered a shift in the high affinity 
site to a single class of low affinity site. The low affinity conformation for the vinblastine 
binding site persisted immediately post-hydrolysis of nucleotide. Release of Pi from the P- 
gp.Mg.ADP.Pi complex, fully restored the drug binding site to high affinity once more. 
This has provided the first evidence to show that the binding of ATP is sufficient to instigate 
a transport event. Hydrolysis of ATP is most likely necessary to restore the drug binding 
site to high affinity in order to complete a transport cycle.
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Chapter 1
General Introduction
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Chapter 1 Introduction
1.1 Cancer chemotherapy
Chemotherapy as a treatment modality in cancer has been in use since 1942 when 
nitrogen mustard was first administered to a lymphoma patient. The goal of this 
anticancer treatment strategy is to use cytotoxic drugs to target rapidly proliferating cells, 
thereby arresting tumour growth and metastasis. Malignancies of the type presented in 
Hodgkin’s disease, acute myeloid leukaemia in children and testicular cancer have been 
particularly amenable to treatment and cure using chemotherapeutic regimens. However, 
chemotherapy is quite often used as an adjuvant treatment being administered in 
conjunction with surgery and radiotherapy, or as a palliative measure in advanced 
cancers.
There has been a rapid expansion in the range of anticancer agents used in the treatment 
of cancer and in most cases many have been designed to work around the cell cycle. 
Anticancer agents are broadly classified according to their modus operandi as 
summarised in figure 1.1. Alkylating agents such as nitrogen mustards and 
cyclophosphamide generate highly reactive positively charged intermediates that form 
cross-links with nucleophilic groups on biological molecules, particularly the nucleotide 
bases of DNA. Drugs of this class have been shown to be maximally effective as cells 
proceed from G2 phase of cell cycle to mitosis, and at the transition from G1 to S-phase, 
or the DNA synthesis stage of the cell cycle. The antimetabolites arc anticanccr drugs 
that block DNA synthesis. Antimetabolites such as the purine analogue 5-fluorouracil do 
so through a direct interaction. On the other hand, the folic acid analogue methotrexate 
indirectly affects DNA synthesis through competitive inhibition of the enzyme 
dihydrofolate reductase, which is required in the conversion of dUMP to dTMP and in 
the synthesis of purines. Drugs in this category are cell cycle specific and are most 
active against cells in S-phase. A third classification incorporates agents that disrupt
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microtubule function. These include the vinca alkaloids e.g vinblastine, also classified as 
natural product cytotoxics, which bind to tubulin and prevent microtubule formation thus 
interfering with mitosis. These agents have been shown to be most efficacious during the 
S-phase of the cell cycle as microtubule formation may be initiated at this stage. 
Taxanes, e.g. paclitaxel, also bind tubulin but at an alternative site to the vinca alkaloids 
resulting in stabilisation of microtubules formed and disruption of mitosis. There are 
also a number of anticancer drugs (many of them natural product compounds) that 
specifically target different aspects of the DNA replication process. For instance, 
camptothecin inhibits topoisomerase I activity. Topoisomerase II activity is blocked by 
the epipodophylotoxin etoposide which first results in single and then double strand 
breaks thus blocking DNA replication. These agents are specific to cells within S-phase.
Classification of anticancer drugs
alkylating antimetabolites microtubule
disruption
inhibitors of 
DNA replication
Nitrogen mustard
Cyclophosphamide
Nitrosoureas
Methotrexate
5 ’-Fluorouracil 
6 ’-thioguanine
6 ‘-mercaptopurme
Vinca alkaloids 
e.g.vinblastine 
vincristine 
Taxanes 
e.g.paclitaxel
Anthracvclines
e.g.doxorubicin
Epipodophvlotoxins
e.g.etoposide
Camptothecins
Figure 1.1 Classification of anticancer agents commonly used in chemotherapy
1.2 Drug resistance in cancer chemotherapy
A significant problem associated with using chemotherapy in the treatment of cancer is 
the resistance of tumour cells to the anticancer agents administered. ^Resistance of
3
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cancers to cytotoxic drug can be classified as unicellular or multicellular. Unicellular 
resistance arises from mechanisms within individual tumour cells that prevent anticancer 
agents from effecting their cytotoxic action. Multicellular resistance is a phenomenon 
often associated with tumour populations because of the physical barrier posed by the 
three-dimensional arrangement of cells and the heterogeneity of layers that comprise a 
tumour mass. Some malignancies (e.g. colorectal and renal) are constitutively resistant 
to chemotherapeutic drugs during the first treatment course and are described as having 
intrinsic resistance to chemotherapy. Other cancers that respond initially to treatment 
with cytotoxics, but later develop resistance to anticancer agents, are said to have 
acquired resistance, as is the case in leukaemias, lymphomas, myeloma and breast and 
ovarian carcinomas (133).
1.2.1 Mechanisms of unicellular drug resistance
There are many ways by which cells can impede the efficacy of anticancer agents as 
outlined in figure 1.2. Cellular mechanisms leading to drug resistance are varied and 
include decreased uptake mechanisms, increased drug metabolism pathways, increase in 
DNA repair systems, reduced activation of drug and increased drug efflux processes 
(68). Some of these mechanisms, for example efflux pumps and altered topoisomerase II 
activity, can mediate cross-resistance to a variety of chemically and functionally different 
anticancer drugs. Cross-resistance of tumours to cytotoxics mediated by drug efflux 
pumps has been recognised as an important mechanism impeding chemotherapeutic 
efficacy in the clinic. A number of efflux pumps have been identified as mediators of 
resistance to a variety of anticancer agents. These proteins include P-glycoprotein (P-gp) 
or MDR1, Multidrug Associated Protein (MRP) and Lung Resistance Protein (LRP). P- 
glycoprotein (P-gp) is the most extensively studied of the efflux pumps and at present
4
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there is more evidence supporting a role for P-gp in drug resistance in cancer 
chemotherapy than either MRP or LRP.
r
I
Mechanisms of drug resistance
i
Efflux
pumps uMetabolisingenzymesI
anthracyclines 
vinca alkaloids 
taxanes 
etoposide
antimetabolites
T
tDNA repair
T
Topoisomerase n  
 ^ activity
alkylating agents 
cisplatin 
anthracyclines 
etoposide
anthracyclines
etoposide
I
lApoptoticability
\
alkylating agents 
anthracyclines 
etoposide 
cisplatin
Figure 1.2 Different mechanisms by which tumour cells develop resistance to anticancer drugs
1.3 P-gp and the MDR phenomenon
To understand the role of efflux mechanisms in mediating resistance to chemotherapy, 
numerous in vitro studies were conducted in the late 1970s in cell lines that were grown 
in the presence of increasing concentrations of a single cytotoxic agent. A common 
feature of these cells was cross-resistance to a broad spectrum of dissimilar drugs with 
distinct cellular targets. • Some of these agents included commonly used 
chemotherapeutic agents such as the vinca alkaloids and anthracyclines. Initial analysis 
of resistant cell lines revealed over-expression of a 170-180KDa membrane glycoprotein 
termed P-glycoprotein, as identified by Juliano and Ling (59). It was soon established 
that over-expression of P-glycoprotein was associated with an ATP-dependent decrease 
in the accumulation of a range of cytotoxics. This was thought to be due to an increase 
in drug efflux rates rather than a decrease in drug uptake. Although it appeared that P-gp 
was capable of transporting a diverse range of drugs, they all shared common physico
5
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chemical features such as lipophilicity, the presence of a complex ring structure and a 
positively charged nitrogen group (refer to table 1.1). The term multi-drug resistance 
(MDR) has been devised to describe the resistance phenomenon attributable to P-gp.
Table 1.1 Compounds involved in P-gp mediated MDR and other ligands for P-gp transport
Physico-chemical properties of P-gp ligands
Lipophilic weak bases Neutral polvcvclic compounds
Doxorubicin paclitaxel
vinblastine colchicine
verapamil progesterone
nicardipine Àmphiphiles
trifluoperazine • Triton-X-100
tamoxifen Hvdrophobic peptides
Lipophilic cations Gramicidin C
Rhodamine 123 valinomycin
Hoechst 33342 Cyclosporin A
PSC 833
1.3.1 Relevance of P-gp to the clinical resistance problem
Despite evidence from studies conducted with drug resistant cell lines, there has been 
considerable debate over the precise contribution of P-gp to the clinical problem of cross- 
resistance, due primarily to difficulties experienced in relating resistance levels in 
tumours to P-gp expression (for detailed review (13)). In more recent years better 
detection methods have allowed quantitation of the proportion of P-gp positive cells in 
clinical samples. High levels of P-gp expression have been associated with tumours 
derived from tissues that normally express P-gp. These included tumours of adrenal 
glands, colon, kidney, liver and acute myelogenous lymphoma. There are now 
numerous studies that have showed a direct correlation between P-gp expression and 
prognostic outcome in chemotherapy (14, 112, 160). Other studies of patients with 
multiple myeloma have demonstrated high levels of P-gp expression thought to be 
specifically related to drug resistance (136, 149) and another which showed that P-gp
Chapter 1 Introduction
expression is frequently acquired following exposure to chemotherapeutic agents such as 
vincristine and doxorubicin (43).
1.3.2 Reversal ofMDR through blockade of P-gp activity
One of the approaches adopted to circumvent the clinical problem posed by P-gp 
mediated multidrug resistance has been the development of inhibitors of drug efflux. 
This approach made use of P-gp’s broad ligand specificity and involved co- 
administration of known pharmacological agents, which might block P-gp anticancer 
drug efflux activity, in combination with cytotoxic drugs in the hope that this would re­
sensitise resistant cells. Early screening for potential reversal agents involved in vitro 
cytotoxicity assays, conducted in cell lines that over-expressed P-gp and displayed high 
levels of resistance to many different types of chemotherapeutic agents. The efficacy of 
a range of known pharmacological agents to inhibit P-gp transport activity was assessed 
by looking at the increased ability of cytotoxics to kill cells over-expressing P-gp. A 
diverse range of structurally and functionally distinct compounds, capable of reversing P- 
gp mediated MDR, was identified in these kinds of assays and have been termed 
chemosensitisers or modulators. These include calcium channel blockers (verapamil, 
nifedipine), calmodulin antagonists, steroids such as progesterone and 
immunosuppressive agents such as cyclosporin A (refer to table 1.2). The mechamsm(s) 
underlying the ability of such a diverse range of functionally distinct compounds to block 
the efflux activity of P-gp is not understood. However, given the broad range of reversal 
agents identified it is quite probable that various aspects of P-gp function are targeted.
Some of these early reversal agents, also termed first generation, did enter phase I 
clinical trials to assess maximum dosages tolerated and to investigate the 
pharmacokinetics of drug behaviour when added in combination with anticancer agents
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in humans. What emerged was that most of the reversal agents could not be 
administered in doses high enough to resensitise cells due to toxic side effects associated 
with their administration. For instance, verapamil was identified by Tsuro et al. (143) 
and was the first modulatory compound to be used in the clinic. However, it was not 
possible to administer verapamil at doses high enough to bring about complete reversal 
ofMDR because of the level of cardiac toxicity associated with its administration (9,23).
In light of the toxicities associated with administration of first generation modulators, a 
second generation of reversal agent was developed in which many of the compounds that 
emerged were analogues of the first generation modulatory compounds, but lacked the 
normal cellular role of the parent compound. For example, SDZ PSC833 is an analogue 
of cyclosporin A but lacks immunosuppressive activity, rendering its administration less 
toxic (10). It is currently undergoing clinical evaluation in phase I and II trials (11, 31). 
Many of these newer second generation agents were efficacious in the low micro-molar 
range and displayed fewer limiting side-effects:
However, application of modulators such as dexverapamil and PSC 833 to the reversal of 
MDR in the clinic has also been limited due to their effect on the pharmacokinetics of 
cytotoxics, e.g. paclitaxel, leading to increases in toxicity and necessitating reduction in 
the dose of cytotoxic drug administered (32, 107). Since the first and second generation 
reversal agents have not been specifically designed to reverse P-gp mediated MDR, a 
third generation of modulator compound has emerged. This generation of agent was 
bom from systematic modifications of prototype MDR inhibitors in medicinal chemistry 
programmes, in the hope of developing greater selectivity for P-gp. One of the first 
compounds to emerge from such programmes was the acridone-carboxamide derivative 
GF120918 (GG918). This compound was shown to potently re sensitise
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Table 1.2 Compounds used to resensitise MDR cells through inhibition of P-gp
Modulator Chemical class Pharmacological
role
Reference
1st Generation
verapamil phenylalkylamine Ca2+ channel blocker Tsuro etal., 1981
nicardipine 1,4 dihydropyridine Ca2+ antagonist Tsuro etal., 1983
trifluoperazine calmodulin antagonist Fordefa/., 1989
Cyclosporin A cyclic peptide immunosuppressive Spoelstra et al., 
1991
2nd Generation
dexverapamil R-enantiomer o f  verapamil Nawrath & 
Raschack (1997)
PSC 833 analogue o f  cyclosporin A Watanabe et al., 
1996
3rd Generation
LY 335979 cyclopropyldibenzosuberone P-gp inhibition Dantzig et al, 
1996
GF120918 acridonecarboxamide P-gp inhibition Hyafil et a l, 1993
XR9051 diketopiperazine P-gp inhibition Dale e ta l, 1998
XR9576 anthranilic acid P-gp inhibition Mistry et a l, 1998
(EC50 = 0.02pM) the P-gp positive cell lines CHrC5, OV1/DXR and MCF7/ADR to the 
cytotoxics doxorubicin and vincristine. GF120918 also effectively restored in vivo 
sensitivity to doxorubicin in a mouse model where mice were implanted with MDR 
P388/DOX tumour cells (57). Cells from acute myeloid leukaemia patients were re­
sensitised to daunorubicin at low pM concentrations of GF120918 (100% samples tested) 
whereas verapamil at 100-fold higher concentrations could only restore drug sensitivity 
to 50% of samples (160). It has been shown that GF 120918 has a longer duration of
9
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action as compared to verapamil, which is effluxed by P-gp, and may help account for 
the more potent reversing activity of the former(57).
Many more compounds have emerged that also display greater potency (100-200 times) 
than earlier modulators such as verapamil and cyclosporin A. Reversal agents that hold 
great promise to potently and specifically block P-gp activity have been systematically 
developed, based on compounds such as GF120918, by the Medicinal Chemistry 
department of Xenova Ltd., Slough (see figure 1.3). These include the diketopiperazine 
derivative XR9051 (22) and the anthranilic acid derivative XR9576 (8 8 , 140). In fact, 
XR9576 was developed through systematic modification of the physico-chemical 
properties of XR9051 that included the introduction of an anthranilamide nucleus. 
XR9051 was shown in vitro to reverse resistance to a number of MDR cytotoxics 
including doxorubicin, etoposide and vincristine using low pM concentrations in a 
number of murine and human cell lines. Co-administration of XR9051 with MDR 
cytotoxics in vivo, in murine and human tumour models, potentiated their anti-tumour 
activity (8 8 ).
This re-sensitisation was shown to be due to a direct interaction with P-gp as XR9051 
could displace the binding of [3H]-azidopine and [3H]-vinblastine to P-gp (EC50 in nM 
range) (22). XR9576 was also shown to modulate resistance specific to P-gp for a 
number of cytotoxics (doxorubicin, paclitaxel, etoposide and vincristine) at low nM 
concentrations in cell lines derived from different tumour types (140). The potency of 
XR9576 to modify MDR was 15 times greater than PSC 833 and several fold greater 
than verapamil and CsA (89). This compound exhibited a long duration of action, 
displaying activity up to 24 hours post removal of excess XR9576 from the medium. 
This is in contrast to verapamil and CsA, which lose their activity within 60 minutes post
10
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XR9576 GF120918
XR9051
Figure 1.3 Third generation modulators of P-gp mediated MDR
administration (89). The difference in the duration of activity of these modulators may 
be due to the fact that verapamil and CsA may be transported by P-gp whereas XR9576 
may not. XR9567 is one of the most potent MDR reversers reported on to date arid is 
currently undergoing Phase I clinical trials in healthy volunteers. It would seem that 
compounds such as XR9576 hold great promise for the treatment of P-gp mediated MDR 
and it is hoped that as more information is obtained concerning the mechanistics of P- 
gp’s drug efflux activity more potent and selective modulators will be designed.
V
In fact the compounds XR9576, XR9051 and GF120918 were donated by Xenova Ltd., 
to enable study of the molecular pharmacology of these agents with P-gp and forms a
substantial proportion of the studies reported in chapters 3 and 4 of this thesis.
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1.4. P-glycoprotein: product of a multigene family
Over-expression of P-gp has been correlated with cross-resistance of tumours to diverse 
classes of anticancer drug, thus leading to poor chemotherapeutic outcome. There is 
considerable evidence to show that P-gp functions as a membrane bound transporter that 
actively translocates drugs out of cancer cells, preventing their intracellular 
accumulation. Therefore, blockade of P-gp drug efflux activity has been a strategy 
commonly adopted to overcome MDR in the clinic. However, little was known 
regarding the characteristics or the mechanism underlying the transport activity of P-gp. 
The first step towards elucidating the function of P-gp was to sequence the gene
MDR2MDR1 MDR3MDR1 MDR2
Mouse
MDR2/3
Multidrug
transport
Multidrug
transport
Multidrug
transport
Hamster
RodentHuman
Lipid
translocase
Lipid
translocase
Lipid
translocase
MDR IB 
(MDR1)
MDR 1A 
(MDR3)
MDR gene family
Figure 1.4 Nomenclature and function of P-glycoprotein family in humans and rodents
?
encoding P-gp in both human (MDR1) (18) and mouse (MDR3) (44). P-gp is a member 
of a multigene family encoded by variants of the multidrug resistance (MDR) gene (refer 
to figure 1.4). There are two classes of P-gp protein in humans, Class I (MDR1) and 
Class HI (MDR2/3) (18). Rodents on the other hand, have three classes of P-gp (44).
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Class I & II in rodents and Class I in humans confer multidrug resistance. Class HI P-gp 
has been shown to display flippase activity in transporting phosphatidylcholine from 
inner to outer leaflets of the plasma membrane (108, 134). The P-glycoproteins are a 
highly conserved family and there is a high level of amino acid similarity, particularly 
between mammalian P-gps (69%-94%) (21).
1.5 P-glycoprotein, a member of the ABC superfamily of membrane transporters
Alignment studies of the primary amino acid sequence of P-gp classified it as a member 
of the ATP Binding Cassette (ABC) superfamily of transport proteins. This broad family 
of proteins is made up of a diverse spectrum of prokaryotic and eukaryotic transporters 
(47). There is high sequence similarity amongst the entire family particularly within the 
nucleotide binding domains (NBDs) that display an overall amino acid identity of 30% or 
more. Some of the conservation is made up of functional units located in the ATP 
binding pockets and are known as the Walker A (G-X-X-G-X-G-K-S-S/T) and B (h-h-h- 
h-D) motifs, necessary in ATP binding and hydrolysis (153). An additional important 
sequence, diagnostic of ABC proteins, is the ‘signature’ motif (L-S-G-G-Q-(Q/R/K)-Q- 
R) located upstream of the Walker B motif which can be up to 15 residues in length. It is 
the most highly conserved sequence amongst the entire ABC family. This sequence is 
critical to the functioning of ABC proteins as mutations of any of the residues results in a 
complete disruption of protein function. The precise role for the signature sequence in 
the functioning of P-gp is not known. It is speculated that it may play a role in 
communication between the NBDs during catalysis, as the NBDs of P-gp have been 
shown to interact with a high degree of co-operativity as discussed in later sections.
Most ABC proteins are plasma membrane transporters and have been found in a variety 
of organisms from microbes to man (see (49) for review) and translocate a wide
13
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spectrum of ligand. The minimal functional requirement for an active ABC protein 
comprises two transmembrane domains (TMDs), each one usually composed of six 
membrane-spanning segments, and two NBDs [TMD-NBD]2 (47). However, there is 
diversity within this family of transporters in the modular organisation of the domains 
that comprise each protein (as illustrated in figure 1.5). For instance, the [TMD-NBD] 
repeat can be made up of a single fused polypeptide as is the case for P-gp, MRP1 and 
the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) or from oligomers 
of different polypeptides, e.g. heterodimers in the TAP transporter of humans and the 
tetrameric prokaryotic histidine uptake transporter. Indeed, there is further 
diversification amongst the transporters whose domains arise from a single polypeptide. 
For example, CFTR contains an R domain (not found in any other ÀBC protein) that 
links the first NBD with the TMD of the second [TMD-NBD] repeat. The R domain 
when phosphorylated, modulates the influence of nucleotide on the gating of the chloride 
channel (35). MRP1 is distinguished by the presence of an additional TMD (TMDO) 
located N-terminal of the first [TMD-NBD] repeat.
The diversity in the modular composition of ABC . proteins accommodates the presence 
of a range of transporter types within one family. Some proteins are involved in ion 
transport such as CFTR» which is a chloride channel, or the sulfonyl-urea receptor (SUR) 
that actively modulates K+ ion flux through the associated channel Kirô.l. Some ABC 
proteins display specificity for a single ligand for transport, whereas there are other 
members of this superfamily that are poly-specific. Many prokaryotic ABC proteins 
function as importers such as the Histidine permease and Maltose transporters, involved 
in the import of histidine and maltose respectively. These transporters are generally 
specific for a single ligand for transport. Many prokaryotic importers contain an
14
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additional feature, which are called accessory proteins, and they are involved in ligand 
presentation. There are however, no known importers amongst eukaryotic ABC proteins.
Single polypeptide transporters
H 11
P-gp MRP1
Oligomeric transporters
§! If
HisQM [P]2 TAP1/TAP2
Figure 1.5 Diversity in domain composition amongst members of the ABC family of transporters.
All ABC proteins in eukaryotes, and many in prokaryotes, are involved in export 
processes such as anticancer drugs by P-gp and MRP1, antigenic peptides by TAPI and 2 
and multiple drugs by LmrA. The poly-specificity exhibited by the multi-drug 
transporting proteins P-gp and LmrA contrasts with more specific proteins such as 
TAP 1/2 and CFTR.
In recent years there has been an explosion in the number of ABC proteins reported, and 
interest stems from the fact that some have been implicated in diseases such as cystic 
fibrosis (CFTR), adrenoleukodystrophy (ALDP) and hyperinsulinemia hypoglycemia
CFTR
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(SURI). In general, the TMDs of ABC proteins confer specificity for ligand recognition 
and binding. Hydrolysis of ATP at the NBDs drives the transmembrane movement of 
ligand, although the mechanisms co-ordinating ligand binding with ATP hydrolysis to 
effect translocation, remain to be elucidated.
1.6 Structural studies of P-gp
1.6.1 Low resolution structure of P-gp
Determining the three-dimensional structure of any membrane bound protein is the holy 
grail of all studies concerned with elucidation of plasma membrane transport processes.
top bottom
TMTM
NBDNBD
Figure 1.6 Electron microscopy and single particle analysis of purified reconstituted P-gp. (Top 
panel) Images produced from 3D reconstructions of single particle analysis and Fourier projection 
maps of small 2D crystalline arrays. Top, represents view from above the plane of the bilayer. 
Bottom, the protein as viewed from below the plane of the bilayer. A cartoon representation of 
‘goblet’ like P-gp molecule has been derived from low resolution structure (adapted from Rosenberg 
et al., 1997).
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This is also the case with P-gp as our understanding of the mechanistics of the transport 
function of this protein will not be complete without full knowledge of its structure. The 
only solid structural information on P-gp available to date is a low resolution structure 
for hamster P-gp, the fruits of an on-going collaborative project between our laboratory 
in Oxford and Dr Robert Ford’s group at UMIST in Manchester. The structure for P-gp 
has been determined to low (2.5nm) resolution by electron microscopy and single 
particle analysis of both detergent solubilized and reconstituted protein. This was further 
refined by three-dimensional reconstructions from single particle analysis and Fourier 
projection maps of small two-dimensional crystalline arrays (104). When the image 
produced is viewed from above the plane of the membrane a toroidal protein shape is 
visible (figure 1.6) that has 6-fold symmetry and a diameter of lOnm. A large central 
aqueous pore of diameter 5nm spans the membrane but narrows towards the cytoplasmic 
face of the membrane. Projection maps perpendicular to the membrane surface revealed 
two 3nm lobe like structures purported to be the NBDs.
1.6.2 Arrangement of TM segments of P-gp
This is the most detailed structural information for any ABC protein to date and 
accommodates P-gp as having a structure of 6 + 6 TMs arranged around a central pore 
that has been adopted as a working model for the study of other ABC proteins. Loo and 
Clarke have used cysteine-scanning mutagenesis (CSM) to directly look at packing of 
TM spanning elements in P-gp. They found that the topology of P-gp was consistent 
with six TM segments in each homologous half of P-gp (77) a finding that was also 
confirmed in a study conducted by Kast et al., (63-65) where a small antigenic peptide 
epitope was inserted at various positions within mouse P-gp. Loo and Clarke extended 
their cross-linking studies to show that TM6 and TM12 are in close proximity as shown 
by formation of disulfide cross-links between residues located towards the cytoplasmic
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end of the TMs. A model was proposed where TM arrangement in P-gp forms a mirror 
symmetry and this fitted in with the toroidal model proposed based on the low resolution 
structure of Rosenberg et al. But this was later refuted in a more recent crosslinking 
study that looked at the ability of a single cysteine residue in TM12 to crosslink with 
single cysteines in TM1-6 or cysteine in TM6 to crosslink to single cysteines in TM7-12. 
From the results of this study, a cyclone model depicting arrangement of TM segments in 
the membrane has been proposed (79). This model suggests that TM12 is in close 
proximity to TM 4,5 and 6 whereas TM6 is close to TM12, 11 and 10 (see figure 1.7(c)). 
The authors claim that no crosslinks could be formed between TM6 and TM7, 8 and 9 or 
TM12 and TM1,2,3. However, crosslinking agents .of differing lengths were not 
employed in these studies, which is an important consideration given that any particular 
TM segment may not be equidistant from all other TM segments. The cyclone model is 
based on the fact that no crosslinks were formed with TM1-3 or 7-9. However, a mirror 
symmetry model may also be applied to the data produced as suggested in figure 1.7(b).
c) Cyclone modelb) Mirror symmetrya) Rotational symmetry
Figure 1.7 Proposed models depicting proximity and arrangement of TM spanning segments 
around aqueous pore of P-gp.
18
Chapter 1 Introduction
Crosslinking studies do pose a useful tool in determining intra- and inter-domain 
arrangements within multimeric proteins. However, in order to obtain a complete picture 
of the structural arrangement of domains it is necessary to systematically conduct an 
exhaustive range of crosslinks employing agents of differing lengths and flexibilities.
An alternative interpretation of the low resolution data produced has been proffered. 
This model proposes that the 12 membrane spanning segments of P-gp fold as 2 X p 
barrels that are arranged back to back in the membrane and are attached by short loops to 
bundles of a-helices formed by the large cytoplasmic loops connecting the TM segments 
(58). These cytoplasmically located loops are purported to form the ligand binding sites 
and move into the p barrel during ATP dependent translocation. These authors have not 
provided firm experimental evidence supporting their interpretation of P-gp studies, and 
have based their model on hydropathy analysis and algorithms for predicting secondary 
structural features. They have also cited work conducted by Sonveaux et al. (137) who 
used an infra-red spectroscopy technique to look at secondary and tertiary structure of P- 
gp. These authors report a high percentage of p barrel structure in the overall structure of 
P-gp, but a significant contribution is also made by a-hehcal components sufficient to 
support an a-hehcal TM model for P-gp. However, this issue cannot be truly resolved 
without higher resolution structure or until the periodicity of the membrane spanning 
segments has been determined.
1.6.3 Structure of isolated NBDs of ABC proteins
There have been many attempts to express and purify the NBDs of P-gp in order to 
determine their structure and have a closer look at the function of each. This has proved 
to be a difficult task due to the lack of solubility of the NBDs of ABC proteins and their 
propensity to aggregate in inclusion bodies when expressed without the membrane
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domain. An additional difficulty arises in attempting to assess the functionality of 
expressed NBD proteins due to the requirement of two NBDs to hydrolyse ATP. 
However, high resolution crystal structures of the NBDs of at least three different 
bacterial ABC proteins have been achieved, and may help contribute to our 
understanding of NBD structure, and particularly the location of the catalytic pocket 
within the 3D structure.
The crystal structure of the catalytic subunit of the maltose transporter of Thermococcus 
litoralis, MalK, was obtained in the presence of bound MgADP (figure 1.8) (26). The 
MalK subunit is described as an ellipsoidal planeconvex lens and is proposed to form an 
asymmetric dimer subunit (figure 1.9). The monomeric subunit is described as having 
three layers.
A-N-Term.
Lid
Walker-A Walker-B \
Signature motif
Switch
D-Loop
F igure 1.8 Crystal structure of the catalytic subunit of the maltose transporter (MalK) of 
Thermococcus litoralis (from Diederichs et al., 2000).
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The top layer comprises anti-parallel p sheets and the middle layer is made up of mixed 
sheets and includes the P-loop, which contains the Walker A motif necessary for ATP 
binding. A third layer contains the signature sequence and D-loop (which contains the 
Walker B motif) and is thought to form an interface with the translocation pore MalFG.
Two of the four helices in this layer may also form an interface between the monomeric 
subunits.
The crystal structure of the ÀTP binding subunit of the histidine uptake system of 
S.typhimurium, His P, was derived from crystals produced in the presence of ATP but 
lacking Mg2+ ion. As shown in figure 1.9, the His P dimer is proposed to comprise back 
to back L-shaped monomers (56). ‘Arm F is proposed to form the interface with the 
cytoplasmic face of the membrane domain whilst ‘Arm IF of each monomer unit forms 
the dimer interface.
Finally, a third dimérisation model has emerged from high resolution crystal structure of 
the DNA repair protein Rad50 (52). This protein comprises a single catalytic domain but 
functions as a dimer where the ATPase domains are joined by a coiled coil. The 
crystallisation studies revealed a unique feature of the Rad50 catalytic domain (Rad50cd) 
that showed it was comprised of two separate polypeptides. The ATP and AMP-PNP 
bound crystal forms showed that two RadSOcd domains dimerise in a head to tail 
orientation (figure 1.9). In this model, both ATP molecules are buried in the dimer 
interface, sandwiched between the P-loop (Walker A motif) and the signature motif of 
the opposing Rad50 catalytic domain. Mutational analysis revealed that ATP and an 
intact signature motif were essential for dimérisation. The requirement for ATP in dimer 
formation is suggestive of allosteric changes in the Rad50 catalytic domain due to ATP 
binding and the model proposed here may help explain the co-operativity and close x
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cross-talk that takes place between the NBDs of P-gp. This model also suggests a crucial 
role for the signature sequence in NBD:NBD interaction.
Arm I
His P RadSOcd
M alK
Figure 1.9 Cartoon representation of the different dimérisation models for bacterial NBDs arising 
from purification and crystallisation trials. ‘S’ signifies signature sequence and P’ denotes P-loop.
The publication of three different models depicting possible dimérisation of the NBDs of 
ABC transporters has excited the imagination of all those concerned with elucidating the 
function of this family of transporters. All of the models produced have come from 
crystallization trials where different conditions have been used. However, in light of the 
extensive biochemical data produced to date regarding NBD:NBD interaction, the MalK 
and RadSOcd dimer models seem more plausible. These models portray a more intimate 
association of the catalytic pockets of each NBD (figure 1.9), which fits in with the high 
degree of co-operativity shown to exist between the NBDs of P-gp, for instance. 
Recently, Sharom et al., (131) used a fluorescence resonance energy transfer (F.R.E.T) 
technique to show that the catalytic sites of P-gp are in close proximity, which would 
also favour the RadSOcd or Mal K dimer structure over that of HisP.
However, a high resolution structure of P-gp is required to elucidate the disposition of 
the NBDs with respect to the membrane domain and help determine whether additional
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structural elements such as the cytoplasmic loops are involved in signal transduction 
between the NBDs and TMDs on P-gp. Higher resolution will also help to clarify how 
membrane spanning elements are arranged around the pore observed in the low 
resolution structure. More detailed structural information may help to pin-point 
location(s) of drug interaction sites within the membrane domain and help clarify 
ongoing uncertainty over the mode of ligand translocation.
1.7 Location of drug binding sites within the membrane domains of P-gp.
Given that the TMDs of ABC transporters contain elements involved in determining 
substrate specificity, efforts have focussed on identifying regions within the TMDs of P- 
gp that may be involved in the binding of ligand. Early studies employed the technique 
of photoaffmity labelling to detect membrane regions involved in binding. This 
procedure uses analogues of known transported ligands and modulators of P-gp that have 
a photoactivatable group (e.g. azido) attached. Following equilibration of drug with 
protein, the photoactive moiety, upon exposure to U.V. light, covalently attaches close to 
the drug binding site. Initial studies of Bruggeman et al., (15) used [3H]-azidopine, a 
1,4-dihydropyridine photoactive derivative, to label P-gp. Azidopine labelled protein 
was subjected to protease digestion and labelled regions identified by antibody mapping 
of digested fragments. Azidopine labelled TM regions in both halves of the P-gp 
molecule and it was proposed that the two halves of the protein come together to form 
the drug binding site. Additional photoaffinity labelling studies have refined the findings 
of this study to implicate specific TM spanning segments in drug binding. For example, 
labelling of P-gp with the prazosin analogue 125I-iodoarylazidoprazosin ([125I]-IAAP), 
identified a TM region in each half of the molecule comprising TM segments 6 and 12 
(refer to topology of P-gp in figure 1.10) (42). An analogue of forskolin only labelled 
TM segments 5 and 6 located in the N-terminal region of the protein (91).
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The use of chimeric P-gp molecules supported and augmented the findings of the photo­
affinity labelling studies of P-gp. Chimeric molecules have been constructed where the 
C-terminal membrane region of human MDR1 P-gp was systematically replaced from 
TM10 onwards with equivalent residues from the MDR3 isoform of human P-gp that 
does not confer MDR. The effect of these changes on drug specificity and resistance was 
assessed in in vitro cytotoxicity assays and by photolabelling studies. Replacement of 
TM12 reduced labelling with [125I]-IAAP and abrogated resistance to a range of drugs 
such as doxorubicin and vincristine. Re-introduction of TM12 and the intracellular loop 
connecting I'M segments 11 and 12 into the MDR1 molecule restored binding and drug 
sensitivity (157). In a similar study, TM segments of the MDR conferring P-gp (MDR1) 
were introduced into the backbone of MDR2 P-gp that is involved in phospholipid 
transport and does not mediate MDR. Introduction of TM6 and TM segments 11 and 12, 
allowed the MDR2 protein to transport drugs normally effluxed by MDR1 P-gp. 
Therefore, the results from photolabelling of intact MDR1 protein and study of chimeric 
P-gp molecules have suggested a role for TM segments 5, 6, 11 and 12 in drug 
recognition.
These studies have provided a good starting point for investigation of residues within the 
TMDs that may be important in conferring ligand specificity. The main approach 
adopted to identify residues important in ligand recognition has been site-directed 
mutagenesis. This allows the introduction of changes at precise locations within the 
cDNA of P-gp. Point mutations have been systematically introduced throughout TM 
segments 5,6, 11 and 12 of mouse, human and hamster P-gp as summarised in table 1.3 
and illustrated in figure 1.10. Other membrane spanning segments have been also been
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mutated, and the effects are summarised in a detailed review of residues involved in 
ligand specificity by Ambudkar et al. (4).
Realisation of the importance of residues in TM11 in ligand recognition originated from 
studies that showed that a single ser941 to phe941 substitution in mouse MDR1 and ser939 
to phe939 in mouse MDR3 altered the drug-resistance profiles to a range of drugs, 
abrogated photoaffmity labelling with [3H]-azidopine and [125I]-IAAP and attenuated the 
chemosensitising effect of the modulatory drugs verapamil and progesterone (45, 46, 61). 
Replacement of serine with phenylalanine involves introduction of a large bulky group at 
the mutated position and may cause a gross perturbation of the region around the 
substitution. This kind of approach can be useful in determining regions sensitive to 
mutation and worthy of further examination using more conservative amino acid 
substitutions. In a subsequent study, all of the amino acid residues in predicted TM11 of 
mouse MDR3 were mutated to alanine (alanine scanning mutagenesis).
T M  1-6 T M  7-12
out
NBD1 NBD2
Figure 1.10 Location of membrane spanning regions of P-gp important in drug recognition. The 
positions of some point mutations that alter substrate specificity of P-gp are indicated by filled 
circles. Bars above model denote regions identified in photoaffinity labelling studies. TM segments 
5, 6 ,1 1  and 12 are highlighted in different colours and are purported to be directly involved in drug 
binding.
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Substitutions of amino acid residues with alanine is commonly used, as it introduces 
modest perturbations due to the relatively small inert R group on alanine. The effect of 
the mutations on drug resistance profiles (vinblastine, adriamycin, colchicine and. 
actinomycin D) were assessed in stable transfectants. More than half of the mutant 
proteins showed 2-10 fold reduction in the degree of resistance to one or two of the drugs 
investigated. However, the most deleterious effect was seen with mutants Y949A and 
F953A that were proposed by these authors to be essential for drug recognition (46).
Loo and Clarke have used cysteine-scanning mutagenesis (CSM) to determine amino 
acid residues involved in drug recognition. This was achieved by mutating the seven 
endogenous cysteines of human P-gp (MDR1) to alanines to create a cysteine-less P-gp 
template. Single cysteine residues were systematically introduced into TM segments 5, 
6, 11 and 12. Interaction of the thiol-reactive reagent dibromobimane (dBBn) with the 
introduced cysteine residues results in inhibition of ATPase activity due to the formation 
of a cross-link by this probe. The ability of P-gp transport ligands vinblastine and 
colchicine and the modulator verapamil to block dBBn induced inhibition of ATPase 
activity is used to assess role of mutated residues in drug recognition. As shown in table 
1.3, amino acid residues thought to be directly involved in drug binding, have been 
identified in all of the TM regions investigated using CSM analysis. Interestingly, two 
different mutagenic (CSM and ASM see table 1.3) approaches have each implicated 
three residues in TM12 as being directly involved in drug recognition (L975, V982, A983).
In summary, slow progress has been made since the early photoaffinity labelling studies 
that first suggested a role for TM segments 5, 6, 11 and 12 in determining the ligand 
specificity of P-gp. The overall picture emerging from mutagenesis studies is that many 
amino acid residues located in each half of the P-gp molecule contribute to ligand
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specificity. It has not been possible to determine from such studies whether there is a 
single binding pocket or discrete sites for ligand interaction. The effect of the introduced 
mutations have been assessed in a variety of ways, but no thorough characterisation of 
the introduced mutation on binding characteristics or ability of drug to stimulate ATP 
hydrolysis has been conducted. Many studies have used cytotoxicity assays to assess the 
effect of introduced mutations, but these assays merely report on the phenotype produced 
and not specific effects on drug binding. Assays of P-gp ATPase activity have 
commonly been used to analyse the effect of mutations on P-gp activity. However, in 
many cases only a single saturating concentration of drug has been used rather than 
complete dose-response analysis to look for changes in drug interaction and cannot be 
used to report changes in drug affinity, for example. Some of the reported changes in
Table 1.3 Mutations in P-gp that alter drug specificity
Mutated
residue
Region Source Functional effect Reference
Y949A
F953A
TM11 MDR3 mouse Altered drug resistance profiles • 
Vinblastine, adriamycin, colchicine
Hanna et al., 
1996
S941F
S939F
TM11 MDR1 mouse 
MDR3 mouse
Decreased labelling [125I]-IAAP & 
[3H]-azidopine; reduced resistance 
adriamycin, decreased reversal activity 
by verapamil
Kajiji et al., 1993 
Gros et al., 1991
F942C
T945C
TM11 MDR1 human Verapamil, vinblastine & colchicine 
block inhibition ATPase by 
thiolreactive agent dibromobimane
Loo & Clarke, 
1999
L339C
A342C
TM6 MDR1 human As above Loo & Clarke, 
1997
L975C
V982C
A985C
TM12 MDR1 human As above Loo & Clarke, 
1997
I306C TM5 MDR1 human As above Loo & Clarke, 
2000
V982A
F983A
L975A
TM12 MDR1 human No transport rhodamine 123 & 
daunomycin, decreased stimulation 
ATPase by verapamil, decreased [125I]- 
IAAP labelling
Hafkemeyer et 
al, 1998
27
Chapter 1 Introduction
drug specificity attributed to mutations introduced into P-gp may also reflect allosteric 
alteration of a drug binding site distant from the mutated residue. Furthermore, the use 
of photoactive drug analogues to detect alterations in drug binding is also fraught with 
difficulties due to the flexibility.and high reactivity of the photoactive group that can 
sometimes cross-link to non-pharmacophoric regions of proteins (38). More refined 
studies need to be conducted on mutant P-gp isoforms. For example, the environment of 
the mutated residue could be examined using a range of cross-linking probes comprising 
differing chemical features and looking at the effect of high affinity ligands to interfere 
with labelling. Such an approach may help determine the distance of drug from any 
particular residue. However, the residues highlighted to date from site-directed 
mutagenesis and photoaffinity labelling studies, provide a good starting point from which 
to conduct more detailed analysis of the role of individual residues or TM segments in 
drug binding.
1.8 Mechanism of drug interaction by P-gp
Although there is convincing evidence from mutagenesis and photoaffinity labelling 
studies that the TMDs of P-gp are involved in ligand recognition, there was uncertainty 
surrounding how drugs access the binding domain(s) on P-gp. P-gp ligands can be 
defined by common features such as hydrophobicity, lipophilicity or the presence of 
aromatic rings (see table 1.1). These features allow P-gp ligands to readily partition 
across the membrane bilayer and enter the cytoplasm by passive diffusion (28, 121). 
Does ligand interact with P-gp from the cytoplasm or from the lipid bilayer? There are at 
present several lines of evidence suggesting that drugs do access P-gp from the lipid 
phase.
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Raviv et al. (97) used the photoactive lipophilic probe 5 - [125I] -iodonaphthalene-1 -azide 
([125I]-INA), which specifically cross-links membrane-spanning components of proteins, 
to show that drugs do interact with P-gp from the bilayer. The authors demonstrated 
energy transfer between the fluorescent ligands doxorubicin and rhodamine 123 and the 
membrane probe, which can only occur over a relatively short distance suggesting that 
the drugs must be interacting with P-gp in the bilayer. Other evidence has come from 
studies using acetoxy-methyl (AM) ester derivatives of fluorescent ligands such as the 
transported ligand calcein-AM. These compounds only fluoresce when the AM group 
has been cleaved by intracellular esterases. P-gp containing cells have no fluorescence 
unless the protein is inhibited. Addition of reversal agents has been shown to increase 
fluorescence, thereby demonstrating that drug-AM derivatives have not reached the 
cytoplasm, and must therefore be extracted from the bilayer (50). Evidence that P-gp 
transports drugs out of the lipid bilayer is also presented in a paper looking at transport of 
the lipophilic compound Hoechst 33342 in inside-out membrane vesicles prepared from 
P-gp over-expressing CHrB30 cells. Hoechst 33342 is only fluorescent when membrane 
bound, and efflux was measured by following the reduction in fluorescence intensity due 
to the build up of Hoechst 33342 in the membrane vesicle interior (122, 126). These 
authors also further suggested in a subsequent study, that drugs are extracted from the 
inner leaflet of the bilayer. This was interpreted from studies where fluorescence 
resonance energy transfer (F.R.E.T) from donor Hoechst 33342 molecules to acceptor 
NBD-C6-HPC molecules located in the cytoplasmic leaflet of membrane vesicles was 
measured. Decreased fluorescence of Hoechst 33342 following addition of ATP was 
concomitant with decreases in energy-transfer related fluorescence of NBD-C6-HPC. 
Although initial rates were measured, the authors did not determine the percentage of 
vesicles in an inside-out orientation to determine (i) how much acceptor molecule was 
affected by actively transported Hoechst 33342 and (ii) had not distinguished between
29
Chapter 1 Introduction
F.R.E.T. due to passive Hoechst 33342 diffusion in vesicles in an ‘outside-in’ 
orientation. However, taken together the studies outlined above do provide strong 
evidence indicating that ligands most likely access the binding domain of P-gp from the 
lipid bilayer.
1.8.1 Models depicting ligand interaction with P-gp
Given that P-gp interacts with a wide range of ligands from undefined site(s) within the 
bilayer, different models have been proposed to describe the drug binding and efflux 
activities of P-gp. These include (i) the hydrophobic vacuum cleaner (ii) flippase (hi) 
multiple site and (iv) membrane potential (Av|/)/intracellular pH (pHj) alteration models. 
The hydrophobic vacuum cleaner model was first proposed to explain the broad substrate 
specificity of P-gp based on the hydrophobic nature of many P-gp ligands and the fact 
that drugs are extracted directly from the membrane (41). This model did not 
accommodate the presence of distinct drug interaction sites within the TMDs of P-gp, but 
rather suggested that the TMDs from each half contributed to a large central binding 
pocket of undefined specificity (refer to figure 1.11(a)).
A variation of the hydrophobic vacuum cleaner model is the flippase model for P-gp 
transport activity (see (48) for review). The underlying feature of this model is that P-gp 
interacts with drug from the inner leaflet of the bilayer mediating translocation of drug 
molecules to the outer leaflet, where the drug molecules dissociate to the extracellular 
space (figure 1.11(b)). However, flippase or more correctly bilayer-translocase activity 
is normally attributed to phospholipids. Phospholipid translocation performs an 
important role physiologically in maintaining membrane asymmetry which is necessary 
in many processes including endo- and exocytosis and cell signalling. Translocase 
activity was ascribed to the mechanism by which P-gp might mediate MDR based on the
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suggestion that MDR1 should display functional similarity to the closely related MDR2 
protein, which is known to mediate ATP dependent translocation of short-chain 
phosphatidylcholine (PC) lipids (108). A recent study demonstrated transport of MDR1 
ligands such as paclitaxel and vinblastine in kidney cell monolayers transfected with 
MDR3 protein that was inhibited by a range of MDR1 reversal agents (135). However, 
MDR3/MDR2 protein has never been shown to be involved in the MDR phenomenon as 
is the case for MDR1 (P-gp). Conversely, efforts have focussed on establishing whether 
MDR1 protein can translocate lipids. Van Helvoort et al (150) investigated the 
translocation of membrane phospholipids and sphingolipids by addition of lipid 
precursors to epithelial cell lines transfected with human MDR1 or human 
MDR2(MDR3). There was an asymmetric distribution for PC phospholipids in MDR2 
cells and for a range of phospholipids in MDR1 cells. However, this study was indirect 
as there was no unequivocal evidence for movement of phospholipids provided. A 
recent investigation using a direct assay on purified reconstituted hamster MDR1 
displayed no lipiid translocase activity (105).
In order for the flippase model of drug binding and transport by P-gp to work, drugs must 
be able to discriminate between the leaflets of the bilayer. The central tenet of this model 
states that drugs are extracted from the inner leaflet prior to movement to the 
extracellular leaflet. This has largely been based on a number of observations rather than 
direct measurement of ‘flipping’ activity, (i) As stated in the previous section, Shapiro 
and Ling (126) suggest that drug is extracted from the cytoplasmic leaflet of the bilayer, 
(ii) Other authors report that the cytotoxic drug doxorubicin partitions between the 
leaflets of the bilayer by a ‘flip-flop’ movement (28, 98). However, these authors did not 
clearly show that the ‘flip-flop’ movement observed was not due to rebinding of 
doxorubicin to the extracellular leaflet following diffusion across the bilayer. The
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hydrophobicity of drugs transported by P-gp means that unlike phospholipids, they can 
readily diffuse across membranes, making it difficult to detect flipping.
(a) Hydrophobic vacuum cleaner (b) Flippase model
(c) M ultiple binding sites
Figure 1.11 Proposed models depicting how drugs interact with and are effluxed by P -gp . P-gp is 
represented in cartoon form based on low resolution structure presented in Rosenberg et al., 1997 
(a) Hydrophobic vacuum cleaner model where different drugs are extracted non-specifically from 
bilayer and extruded, (b) Flippase model where drug translocated from inner leaflet of bilayer to 
outer leaflet prior to release to extracellular milieu, (c) Multiple site model shows defined interaction 
sites for drug within the TMDs of P-gp.
The molecular basis of P-gp’s broad substrate specificity has not been encompassed by 
either the hydrophobic vacuum cleaner or flippase models. Is there a single site of 
undefined specificity or distinct sites of interaction for ligand? The presence of multiple 
distinct sites for drug on the P-gp molecule was inferred from transport assays using 
combinations of drugs where the interactions were not consistent with a single binding 
site (6, 123, 127). For example, Shapiro and Ling (1997) showed that the transported
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ligands Hoechst 33342 and rhodamine 123 bound at distinct sites and that these sites 
were co-operatively linked. Additionally, studies of ATP hydrolysis have shown that the 
maximal rate of activity of drug (e.g.vinblastine) was decreased in the presence of a 
second drug (e g.verapamil) with no alteration in Km. This is suggestive of non­
competitive interaction between drugs and was interpreted to indicate distinct drug 
interaction sites on P-gp (93, 94).
Although investigation of drug effects on P-gp ATPase and transport activities suggested 
the presence of distinct drug binding sites they could not be taken as definitive proof. 
This is due to the fact that there are multiple stages in a transport and ATPase cycle 
making elucidation of the nature of drug:drug interactions difficult. Definitive proof for 
distinct drug binding sites could only result from direct measurement of drug binding. 
For this reason radioligand binding assays have been used to investigate the mechanisms 
contributing to the broad ligand specificity of P-gp. This may be achieved by looking at 
the effect of a drug on the dissociation rate of another (radiolabelled) drug. An alteration 
in the rate of dissociation of the radiolabelled drug-protein complex can only occur due 
to effects from an allosterically linked site(s). Using this kind of radioligand binding 
assay. Ferry et al. (29, 30) reported distinct sites of interaction for the transported drug 
[3H]-vinblastine and the 1,4 dihydropyridine nicardipine, which acts as a modulator of P- 
gp transport activity. In a similar type of study, the sites of interaction for the modulators 
verapamil and SR33397 were found to be distinct from the [3H]-vinblastine binding site 
(82). These studies were the first to directly show that there are distinct drug interaction 
sites on P-gp capable of communicating with each other through an allosteric 
mechanism. There is compelling evidence from both study of ATPase and transport 
activity and radioligand binding for the presence of distinct yet interacting drug binding
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sites on P-gp. This has been termed the multiple binding site model for P-gp transport 
and may explain the broad ligand specificity exhibited by P-gp (figure 1.11(c)).
The three models presented above all imply a direct role for P-gp in the MDR 
phenomenon. An alternative model has been proposed that assigns an indirect role for P- 
gp in altering the distribution and accumulation of chemotherapeutic drugs. The tenets 
of this model are based on observations that over-expression of MDR proteins such as P- 
gp alters plasma membrane potential (Avj/) and perturbs intracellular pH (ApH,). These 
Avy/pHj effects have been proposed to cause (i) reduced rates of influx of 
chemotherapeutic agents (ii) perturbations in die plasma membrane perhaps by affecting 
lipid distribution which in turn modulates drug diffusion (iii) alterations in the trans­
bilayer distribution of weakly basic drugs (iv) effects on signal transduction to reduce 
availability of cellular targets for cytotoxics (see (99-101) for reviews). Indeed, it has 
been demonstrated that that there is some perturbation of Avp and pH, in cells over­
expressing MDR proteins. However, this cannot form the sole basis of MDR exhibited 
by P-gp expressing cells for a number of reasons. Firstly, there is a substantial body of 
evidence to show that P-gp directly interacts with a wide diversity of compounds. 
Secondly, mutations of residues within the drug binding region(s) alter the drug 
specificity exhibited by P-gp. Mutations within some of the intracellular loops 
connecting the energy generating NBDs and the TMDs also affect resistance profiles. 
None of these findings may be reasonably supported by an indirect eff ect of P-gp in the 
MDR phenomenon.
Given the weight of evidence from wide-ranging studies, I would favour the multiple 
drug interaction sites model over the hydrophobic vacuum cleaner or flippase models. 
However, it is not clear whether the drug binding sites can be classified according to
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function i.e. sites from which transport occurs or sites that are regulatory only in activity. 
Are there sites at which both drugs that are normal substrates for transport and 
chemosensitisers that function to block P-gp activity interact? Knowledge of the classes 
of drug binding site on P-gp could then be used to design better strategies by which to 
inhibit P-gp extrusion of anticancer agents in chemotherapy. Elucidation of the classes 
of binding site on P-gp is a major focus of this thesis.
1.9 The kinetics of P-glycoprotein transport activity
P-gp is a membrane transporter that couples hydrolysis of ATP to the outward movement 
of ligand. There is a dearth of information concerning the kinetics of the P-gp transport 
process. How quickly are drugs transported by P-gp? Given that there is more than one 
drug binding site on P-gp, how many molecules of drug can be transported at any one 
time? The hydrolysis of ATP is coupled to drug translocation but it is still unclear as to 
the number of ATP molecules required per drug molecule effluxed.
The ability to determine the rate of P-gp mediated drug transport is dependent upon 
measures of initial rates of transport. Initial transport rates are driven by drug 
concentration and increase linearly over time, providing a direct measurement of the rate 
o f P-gp mediated efflux activity. The rate of transport can then be expressed as a 
function of drug concentration to yield values for Km of transport and maximal drug 
efflux rates. There are many technical problems that have thwarted efforts to measure 
the rate of drug transport by P-gp. This is borne out in the large discrepancies arising 
from transport assays of P-gp where vastly different values for drug turnover rates or the 
efficiency of coupling of ATP hydrolysis to drug translocation have been reported (130). 
The first major drawback relates to the largely hydrophobic nature of P-gp transport 
ligands. This feature allows these drugs to rapidly partition into the membrane bilayer
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resulting in rapid initial rates of drug movement that are not P-gp mediated and difficult 
to accurately determine. Secondly, hydrophobic drugs also tend to be ‘sticky* in nature 
and can bind to lipids and plastic-ware, which alters drug distribution in a manner 
unrelated to P-gp. This has precluded measurement of initial rates of P-gp mediated 
transport using radioligand binding assays regardless of the model system used (i.e. 
whole cells, membrane vesicles, purified reconstituted protein). Radioligand binding 
studies have been widely adopted to provide information concerning P-gp transport 
activity at steady-state. Transport activity at steady-state reflects P-gp activity when 
outward pumping by P-gp equals the rate of drug influx and therefore cannot be used to 
reliably determine kinetic parameters of the transport process.
Another important consideration in trying to measure transport kinetics of any protein is 
the model system. Many studies have been conducted in P-gp over-expressing whole 
cells. There are a number of problems associated with the use of whole cells in 
measuring drug transport kinetics as illustrated in figure 1.12(a). Passive influx and 
efflux processes (rates (1) and (3) respectively) can make it difficult to determine the P- 
gp component (rate (2)) of drug translocation. Intracellular distribution and metabolic 
modification of drug within the cell can also compound difficulties associated with such 
measurements (rate (4)). Experimentally, measurement of the P-gp component in whole 
cells is determined by either following the efflux of drug from preloaded cells, or looking 
at the uptake of drug into cells as depicted in figure 1.12(b). In using cells preloaded 
with drug, P-gp will be pumping drug down a drug concentration gradient and so passive 
efflux of drug will also contribute to efflux activity, making it difficult to determine 
precisely the P-gp contribution. Transport activity measured by looking at drug uptake 
relies on comparing intracellular accumulation in the presence or absence of inhibitors of
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P-gp transport. Both methods rely on approximations to determine the actual rate of 
transport due to the presence of P-gp alone.
Numerous studies have attempted to directly measure the rate of P-gp transport activity, 
the number of ATP molecules hydrolysed per molecule of drug transported and the
[D]i
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Figure 1.12 (a) Processes in whole cells that affect drag accumulation and kinetics. Passive influx 
and efflux denoted by rates (1) & (3) respectively. P-gp component of efflux is represented by (2). 
Rate (4) is due to compartmentalisation of drug. [D]c is concentration of drug in intracellular 
compartments. [D]ex and [Dji are extracellular and intracellular drug concentrations respectively, 
(b) Type of transport assays used to quantitate the P-gp component of transport Top half of cell, 
uptake of drug is measured by using reversal agents to block P-gp activity. Lower half of cell, P-gp 
efflux activity measured by preloading cells with drug prior to transport measurements.
number of drug molecules transported when the pump is operating at maximal activity. 
Widely varying results have been reported and there is no consensus regarding the above 
parameters for P-gp transport activity. For example, estimates of the coupling ratio of 
drug transport to ATP hydrolysis vary between 0.02-1.0 mol drug transported per mol 
ATP hydrolysed. Ambudkar et al. (3) looked at [3H]-vinblastine transport in NIH3T3 
cells transfected with human P-gp, and found that 3 molecules of ATP were hydrolysed 
for every molecule of vinblastine transported. Initial rates were measured by (a) looking
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at vinblastine uptake into P-gp expressing cells in the presence and absence of the 
modulator verapamil and (b) following efflux from cells preloaded with vinblastine. 
Turnover values for [3H]-vinblastine transport of 1.1s'1 and 1.4s'1 were determined from 
the above assays. Calculation of turnover number or kcat is dependent upon the system 
being at maximal activity (Vmax) and the number of protein molecules ([Rt]) must be 
known (kcat = Vmax/fRJ)- An estimate for the number of P-gp molecules in the plasma 
membrane of NIH3T3 cells was derived from measurement of the binding of a 
fluorescently-conjugated antibody (UIC2) to an extracellular epitope on P-gp. When 
determining the number of ATP molecules hydrolysed per molecule of vinblastine 
transported, the authors only considered the vinblastine stimulated portion of the ATPase 
activity as being directly involved in the translocation of vinblastine molecules. In 
contrast to the results of this study, Shapiro and Ling (129) report, using plasma 
membrane vesicles, a coupling ratio of 1 mole of rhodamine 123 transported per mole of 
ATP hydrolysed. This represents tighter coupling of rhodamine 123 transport to ATP 
hydrolysis than was reported for vinblastine and may be a reflection of (a) different 
model system used, membrane vesicles versus whole cells, (b) using a fluorescent 
compound where changes can be monitored over short time intervals (sub second) (c) 
differences in relating turnover for transport to turnover for hydrolysis.
In a different study conducted by the same authors, the fluorescent lipophilic compound 
Hoechst 33342 was used to measure the apparent rate of transport of purified 
reconstituted P-gp (125). They reported a rate where one molecule of Hoechst 33342 
was transported per minute per molecule of P-gp. This was in contrast to a turnover for 
ATPase activity, using the same system, of 50 molecules hydrolysed per minute per 
molecule of P-gp. This reflects very poor coupling of drug transport to ATP hydrolysis. 
The authors suggested that the slow rate of transport measured may be due to rapid re­
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binding of Hoechst 33342 to the membrane following efflux. They also found that the 
proteohposomes were leaky due to formation of Hoechst 33342 aggregates, therefore 
making it impossible to determine how much Hoechst 33342 was transported by P-gp. A 
combination of technical problems has probably led to an under-estimation of the rate of 
Hoechst 33342 transport in this study. Lu et al. (81) have used a derivative of the 
fluorescent compound rhodamine 123, tetramethylrosamine (TMR), to measure initial 
rates of efflux in purified reconstituted P-gp. Transport of TMR was ATP-dependent and 
followed Michaelis-Menten kinetics. The authors showed that the initial rate of TMR 
transport in proteohposomes was dependent upon the concentrations of TMR and ATP, 
and they report Km values of 0.3pM and 0.48mM for TMR and ATP respectively. The 
Km for ATP to fuel transport of TMR is similar to reported values for the Km of ATP 
hydrolysis. The fluorescent compound used in this study did not produce the high levels 
of background associated with the more lipophilic compound Hoechst 33342 due to 
rebinding to the lipid bilayer. Although the authors have been able to look directly at P- 
gp mediated transport of TMR, they have not been able to report on kcat for TMR 
transport or the coupling ratio describing molecules ATP hydrolysed per molecule drug 
transported. This is due to the inherent difficulty associated with attempts to calculate 
the absolute number of drug molecules effluxed from relative fluorescence units.
The use of simpler model systems, such as membrane vesicles or purified P-gp 
reconstituted into proteohposomes with defined lipid constituents, could circumvent 
some of the problems associated with direct measurement of P-gp mediated drug 
transport alluded to previously. For example, membrane vesicles and proteohposomes 
are devoid of intracellular components that might interfere with drug pharmacokinetics. 
However, studies conducted in membrane vesicles and proteohposomes with an inside- 
out orientation of P-gp are reliant on the formation of tightly sealed vesicles. This is
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because transport rates are obtained by measuring the movement of drug from the bilayer 
into the vesicle interior, as depicted in figure 1.13 (a) and (b). However, transport assays 
that involve quantitation of P-gp related transport kinetics by following accumulation 
into the interior of membrane vesicles or proteohposomes can also be fraught with 
difficulties.
(a) Radiolabelled drug (b) Fluorescent compounds
p - g p
<P 
<P
Figure 1.13 Model systems (membrane vesicles or proteoliposomes) used to measure kinetics of P- 
gp mediated drug transport (a) Assay where transport detected by measuring accumulation of 
radiolabèlled drug in vesicle/proteoliposome interior. (1) & (3) are passive influx and efflux 
respectively. (2) is drug influx due to P-gp. (b) Transport assays involving fluorescent ligands that 
are only fluorescent in the bilayer, measure reduction in fluorescence as ligand is moved to 
vesicle/proteoliposome interior. (1) & (3) represent passive influx and efflux. P-gp influx rate is 
represented by (2) & (2*) where (2’) arises from rebinding of drug from interior.
The interior of these systems is small and so high intracellular concentrations build up 
rapidly, leading to large passive efflux rates for drug (figure 1.13(a) and (b)). This is 
particularly problematic in fluorescence assays, which rely on high fluorescence in the 
bilayer and low levels in the aqueous interior. Rebinding of drug from the aqueous
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interior of vesicles or proteoliposomes with the bilayer will lead to high fluorescence and 
under-estimation of P-gp transport kinetics (figure 1.13(b)). Additionally, P-gp 
reconstituted into liposomes will be transporting down a concentration gradient. 
Therefore, the assay system will have to measure the P-gp component of transport above 
the passive influx processes that will exist.
There is still quite a deficit in our knowledge of the mechanism of P-gp mediated 
transport and disagreement concerning the results that have been obtained to date from 
transport assays. Development of improved methods to purify and functionally 
reconstitute the protein into lipids at lower lipidiprotein ratios may help reduce the 
problems of high background associated with assaying transport of hydrophobic P-gp 
ligands.
1.10 The catalytic cycle of P-gp
P-gp is similar to other active transporters in that its efflux and ATP hydrolytic activities 
are inextricably linked. Evidence for this has been derived using either membrane 
preparations or purified reconstituted P-gp that reveal P-gp mediated ATPase activity 
which is specifically stimulated by drugs that bind to the protein such as verapamil (1, 
111, 124, 144). These studies showed that MgATP was the physiological substrate for 
the hydrolytic activity of P-gp, although it was capable of hydrolysing other nucleotide 
triphosphates at a slower rate. Maximal drug-stimulated turnover rates for MgATP 
hydrolysis of 10-20s-1 have been reported with a Km value for MgATP in the range 0.15- 
1.4mM (117, 132). The ATPase activity was competitively inhibited by MgADP and the 
non-hydrolysable ATP analogue MgAMP-PNP with Kj values of 0.35-0.7mM (117). 
The ATPase activity of P-gp has a strict requirement for the presence of divalent cation 
and shows a particular preference for Mg2+ (1). Cations are thought to be necessary for
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the stable co-ordination of the y phosphate of the ATP molecule with an aspartate residue 
in the Walker B homology sequence within the catalytic site (145).
Although the ATPase activity of P-gp is stimulated by drug, P-gp displays a high level of 
intrinsic or ‘basal’ ATPase activity. This basal ATPase activity may indicate that the 
process of ATP hydrolysis is partially uncoupled from drug movement (69). 
Alternatively, the presence of an endogenous component within the plasma membrane or 
the lipid annulus surrounding purified P-gp has been postulated as the basis of this 
activity. This endogenous component may be a phosphohpid(s) as a range of 
phospholipids have been shown to stimulate P-gp ATPase activity dose-dependently 
(132). This study demonstrated that there were endogenous phospholipids associated 
with purified P-gp, and they consisted largely of phosphatidylethanolamine and 
phosphatidylserine and a small amount of phosphatidylcholine. This prompted study of 
the effect of the lipid environment on P-gp ATP hydrolytic activity. It is well established 
that the lipid environment is influential in affecting both basal ATPase activity and the 
extent of drug stimulation of ATPase activity (16, 27,102,105, 144).
Measures of P-gp related ATPase activity have revealed only one value of Km, even 
though there are two catalytic sites. This suggested that hydrolysis occurred from one 
site only. This was further investigated employing the technique of vanadate trapping 
which stabilises the protein in a stage of the catalytic cycle that immediately follows 
ATP hydrolysis but precedes dissociation of the resultant MgADP. The vanadate ion 
interacts with Mg.ADP with high affinity and dissociates slowly from the P- 
gp.Mg.ADP.Vi complex, allowing study of P-gp at this stage of the catalytic cycle (see 
figure 1.14). By using Mg-8-azido-[ot32P]-ATP to trap P-gp with vanadate, it was found 
that to achieve full inhibition there was only one molecule of nucleotide diphosphate
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trapped per molecule of P-gp, with no preference exhibited for either the N- or C- 
terminal NBD. This result suggested that not only are both NBD sites capable of 
hydrolysing MgATP, but they interact closely as trapping of nucleotide in one catalytic 
site prevented hydrolysis of nucleotide at the other (144). This finding was corroborated 
in a later study in which vanadate trapped protein was photochemically cleaved and 
trapped nucleotide found at one NBD only (54).
MgATP + Pgp Pgp.Mg.ATP
H20 PI
Pgp.Mg.ADP.Pi i Pgp.Mg.ADP ;ir
Pgp.Mg.ADP.VI
Mg.ADP + Pgp
Figure 1.14 Scheme depicting ATP hydrolysis and vanadate-inhibition of P-gp ATPase activity.
The functional requirement for two nucleotide binding domains on P-gp is still puzzling 
and a combination of approaches, using either introduced mutations or catalytic 
inhibitors, have been used to probe their role in the catalytic cycle of P-gp. Studies 
employing the covalent reagent 7-Chloro-4-Nitrobenzo-2-Oxa-1,3-Diazole (NBD-C1) 
showed that inhibition of ATP hydrolysis was complete when this compound covalently 
bound at a stoichiometry of 1 mol NBD-C1 mol*1 P-gp (2, 120). The inhibitory effect of 
NBD-C1 was reduced in the presence of ATP, indicating that this compound may be 
reacting at the catalytic site.
The strong interplay between the NBDs has also been demonstrated in mutational studies 
conducted by Loo & Clarke (76). They used a form of human P-gp from which the 
endogenous cysteines were removed following which single cysteine residues were 
systematically re-introduced into each NBD. Labelling of a cysteine residue within the
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Walker A motif of either NBD (cys-431 and cys-1074 respectively) was sufficient to 
inactivate ATPase activity. These studies demonstrate the strong interdependence that 
exists between the NBDs of P-gp and illustrate an absolute requirement for two intact 
catalytic units.
The evidence from (i) vanadate inhibition (ii) stoichiometries for inhibiton by NEM and 
NBD-C1 and (iii) mutational analyses all imply that nucleotide hydrolysis by P-gp occurs 
by an alternating cycle. However, it is still unclear as to why two NBDs are required for 
function. Given that the NBDs of P-gp seem to alternate in ATP hydrolysis, does this 
indicate that they do not display equivalency of function? It was of interest to look at 
binding of the physiological substrate Mg. ATP to the NBDs and determine whether both 
domains could bind nucleotide with different affinities. Attempts to measure binding 
have been difficult due to the relatively low affinity with which nucleotide binds at the 
catalytic site. This has posed technical problems in attempts to measure binding 
stoichiometries or the Kd for nucleotide binding using radioligand binding assays, 
because of the high concentrations of [32P]-ATP (mM) required to achieve saturable 
binding. In addition, trapping of bound complex is also difficult where binding affinities 
are low, due to rapid dissociation of bound complex. This problem was circumvented 
using a photoactivatable analogue of Mg.ATP, Mg-8-azido-[32P]-ATP, to perform 
photolabelling studies. It was previously shown that 8-azido-ATP is a good hydrolysis 
substrate for P-gp with Km values within the same range as those for Mg.ATP (144). Al- 
Shawi et al. (2) showed that Mg-8-azido-[32P]-ATP labelled P-gp with a stoichiometry 
approaching 2mol mol*1 P-gp. Trypsin digestion of labelled P-gp revealed that label was 
evenly distributed between the N- and C-terminal NBDs illustrating that both NBDs are 
capable of binding Mg-8-azido-[32P]-ATP and by extension Mg.ATP. However, it was 
not possible to determine the respective affinities of each NBD for Mg.ATP binding.
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The fact that ATP can bind to either NBD and the observation from vanadate trapping 
experiments that both NBDs appear to be capable of ATP hydrolysis, has been taken as 
evidence that the NBDs of P-gp are indistinguishable in function. However, a recent 
study suggests that the catalytic domains of P-gp are functionally distinct. Hrycyna et al. 
(55) investigated nucleotide binding to P-gp, by looking at labelling of catalytic sites 
with Mg-8-azido-[a-32P]-ATP under conditions where the protein can and cannot 
hydrolyse ATP. The C-terminal catalytic domain was preferentially labelled under 
hydrolysis conditions as shown in vanadate trapping experiments. On the other hand, the 
N-half was labelled with Mg-8-azido-[a-32P]-ATP whether hydrolysis was possible or 
not. P-gp proteins containing point mutations that affect Mg2+ binding within the Walker 
B motif of the N- (D555N) and C- (D1200N) NBDs, were examined for their ability to 
bind nucleotide. The extent of labelling of C-terminal mutant was comparable to wild 
type, but binding of Mg-8-azido-[a-32P]-ATP to mutant protein D555N was abrogated. 
This was taken as additional evidence for distinct functional roles of the two NBDs. It 
was suggested that binding of ATP to the N-terminal NBD may be necessary for 
hydrolysis of ATP to occur at the C-terminal catalytic site. This is the first study 
suggesting a non-equivalency in the role of the NBDs of P-gp.
There is evidence supporting distinct roles for the NBDs of other ABC proteins. The 
multidrug resistance associated protein (MRP1) also hydrolyses ATP effectively at the 
C-terminal NBD and displays preferential labelling of the N-terminal site (36, 53). 
Interestingly, the presence of Mg.ADP at NBD2 allosterically enhanced binding of 
Mg.ATP to the N-terminal site. A similar interplay between the NBDs was also reported 
for SUR1 (86) and TAP 1/2, the transporter associated with antigen presentation (40). 
Non-equivalency in the role of the NBDs has also been reported for CFTR in an elegant
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study conducted by Gadsby et al. (34). These authors demonstrated that hydrolysis of 
ATP at the N-site stimulated opening of the chloride channel whereas hydrolysis at the 
alternate NBD (C-site) brought about channel closure.
It is becoming clear that the NBDs of ABC proteins do possess distinct functional roles 
in catalysis and display strong interdependence in so doing. It is still unclear, 
particularly in the case of P-gp, what specific roles each individual NBD plays in drug 
transport. Do the NBDs transmit similar signals to the drug binding site during a 
transport cycle?
A T P
ADP
ADP.Pi
Figure 1.15 Proposed alternating catalytic sites cycle of ATP hydrolysis by P-glycoprotein. 
Rectangles represent the TMDs. Different conformations of the NBDs are represented by square, 
circle and hexagon (unfilled) Starting top left, N -site is em pty. B inding o f  ATP to N-site NBD allows 
ATP hydrolysis at the C-site that induces a change preventing hydrolysis at the N-site. The ADP.Pi 
bound C-site is in a state of ‘high chemical potential’ (hexagon). Relaxation of C-site occurs upon 
release of Pi and is coupled to drug (filled circle) movement from inside facing high affinity site to 
outward low affinity site. Drug and ADP dissociate to end the cycle (adapted from (117)).
As outlined in figure 1.15, an alternating catalytic sites model relating the catalytic 
activity of P-gp to drug transport, has been proposed by Senior et a l (119). The model
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of Senior and co-workers hypothesises that drug movement occurs post hydrolysis of 
ATP following release of Pi from the P-gp. ADP.Pi complex during the transport cycle. 
This, hypothesis is still accepted but has not been rigorously tested. One of the aims of 
this thesis is to look at drug binding during different distinct stages of the catalytic cycle 
to determine when alterations in drug binding site are induced and elucidate the type of 
change wrought on the drug binding site.
1.11 How are signals transmitted between domains of P-gp?
To achieve active, vectorial transport, P-gp must transduce and couple signal between the 
drug binding domain(s) in the membrane and the cytoplasmically located catalytic 
domains. The signal transduction route adopted (figure 1.16) is unknown but the 
mechanism involved is via conformational alterations in the protein. Many different 
studies have looked at both intra- and inter-domain communication on P-gp using a 
variety of experimental approaches.
TMTM
NBDNBD
Figure 1.16 Communication within the P-gp molecule involves inter- and intra-domain signalling 
the routes of which are unknown.
1.11.1 Signalling between TMDs and NBDs
47
Chapter 1 Introduction
From study of drug transport and ATPase activity of P-gp it is known that 
communication exists between the TMDs and NBDs. Binding of drug does not affect 
nucleotide binding but does either stimulate or inhibit ATP hydrolysis by a process 
which must involve long-range communication. Communication between the TMDs and 
NBDs was further investigated by Sharom and co-workers who employed an elegant 
assay to investigate how the drug binding sites located at the TMDs communicate with 
the catalytic sites within the NBDs. They demonstrated that the sulfhydryl modifying 
agent 2-(4-maleimidoanilino)naphthalene-6-sulfonic acid (MIANS) covalently labelled 
the Walker A cysteines of NBD 1 and 2 of P-gp purified and reconstituted from CHT330 
cells (74). The fluorescence of MIANS was quenched and the rate of labelling of P-gp 
by the fluorescent probe was reduced by the addition of a range of cytotoxic drugs and 
modulators of P-gp. The authors concluded that this was indicative of long-range 
communication between drug binding sites, located in the membrane domain, and the 
catalytic sites within the NBDs.
1.11.2 Intra-domain communication on P-gp
Not only is there conformational signalling between the domains on P-gp, but there is 
also evidence for intra-domain communication. As discussed in a previous section in 
this introduction (1.8.1) there is a growing consensus that P-gp contains multiple distinct 
drug binding sites. However, although the binding sites are distinct they are linked as 
shown in radioligand binding studies where binding of the cytotoxic [3H]-vinblastine, 
was allosterically modified by various modulatory compounds (29, 82). Such allosteric 
interaction is also indicative of domaimdomain signalling_within P-gp and will be 
explored further in chapters 4 and 6 of this thesis.
1.11.3 P-gp can exist in different conformations
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A number of biochemical and biophysical studies have provided evidence suggesting that 
P-gp does undergo changes in conformation, particularly with respect to its catalytic 
cycle. This has been interpreted from studies designed to monitor changes in secondary 
and tertiary structures in the presence of nucleotide and drugs. Acrylamide quenching of 
tryptophan residues in purified reconstituted P-gp was investigated in the presence of 
nucleotide or a range of cytotoxic agents (138).. This study revealed that there was 
differential accessibility of tryptophan residues to quenching agent, which was dependent 
upon the nucleotide added, with more modest changes observed in the presence of drug. 
The same authors, by measuring the kinetics of 2H/H exchange in the presence of 
MgATP and MgATP-verapamil, showed that there were major alterations in the tertiary 
structure of P-gp (137). Accessibility of the monoclonal antibody UIC2 to its 
extracellularly localised epitope, has also been used to monitor alterations in P-gp 
conformation. This antibody is conformationally sensitive and it was found that 
accessibility of UIC2 was decreased substantially due to binding of ATP. Binding of 
ATP conformationally reduced accessibility of the epitope for UIC2 and this effect was 
reversed in the presence of drugs such as cyclosporin A and vinblastine (87).
Similarly, study of proteolytic enzyme accessibility have been used to investigate the 
effect of different stages of the catalytic cycle on the conformation of P-gp. Wang et al. 
(154) investigated the proteolysis profiles of P-gp in the presence of Mg.ATP, Mg.AMP- 
PNP, Mg.ADP and Mg.ATP + vanadate. A total of four uonformational states of P-gp 
were detected which were proposed to represent conformational cycling of P-gp during 
the catalytic cycle. In a later study this work was extended to investigate the trypsin 
sensitivity of mutants bearing single or double mutations in Walker A lysines or Walker 
B aspartate residues respectively, under conditions of vanadate trapping (60). The 
proteolysis profiles observed for the double mutants (both Walker A lysines) and the
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single mutants (C-terminal Walker B aspartate) were significantly different to wild-type 
protein. This was due to the loss of ATP hydrolytic activity, but not ATP binding, in 
these mutants, as previously shown by Urbatsch et al, (145). However, the trypsin 
digestion profile observed for the single mutant bearing an N-terminal aspartate 
substitution resembled that observed in wild-type, suggestive of a difference between 
homologous Walker B aspartate residues in NBD 1 and 2. This result suggests that 
conformational cycling of P-gp during the catalytic cycle relies on the protein retaining 
full ATPase activity.
1.11.4 Functional relevance of conformational alterations in P-gp
Investigations highlighted in the preceding sections show that P-gp can adopt different 
conformations, particularly in response to the binding of nucleotides. How do the 
different conformations adopted by P-gp during the catalytic cycle affect drug binding? 
There have been few studies that have attempted to address this question directly, by 
looking at drug binding during the catalytic cycle. The binding of the photoaffinity 
prazosin analogue [125I]-IAAP and [3H]-azidopine with human P-gp, purified and 
reconstituted from insect cells, was significantly reduced in vanadate trapped protein 
(96). This abrogation in binding was only observed when protein was trapped under 
ATP hydrolysis conditions, indicating that ATP hydrolysis is required to induce a change 
in the drug binding sites. There was no effect of either ATP or ADP alone on drug 
binding properties. However, Ramachandra et al. did not directly investigate whether the 
abrogation in drug binding was due to altered affinity of [125I]-IAAP and [3H]-azidopine 
binding sites when the protein was vanadate trapped as only a single concentration of 
radioligand was used. The signal required to restore the drug binding site conformation 
during the catalytic cycle remains to be determined. Further investigation of 
conformationally driven alterations in drug binding site during the catalytic cycle will
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provide insights into how drug binding and nucleotide interaction at the NBDs are 
coupled to generate transport. This will form a major portion of the work presented in 
this thesis.
1.11.5 Region(s) involved in transduction of signal between TMDs and NBDs
The question of signalling within and between domains is central to our understanding of
the transport function of P-gp. However, what is not known are the regions on P-gp that 
are critical for signal transduction between the TMDs and the NBDs. There is some 
evidence suggesting a role for the intracellular loops that connect the TM helices in inter- 
domain signal transduction. In particular, a naturally occurring mutation in the first 
cytoplasmic loop (CL1) of P-gp from cells grown in high concentrations of colchicine, 
involving a glycinel85 to valine substitution, has been associated with altered 
specificities for ligands. This was demonstrated by an alteration in the degree of 
resistance conferred by the mutant P-gp to the cytotoxic drugs colchicine, etoposide and 
adriamycin compared to wild type protein. The change in resistance was related to the 
ability of drug to interact with protein as demonstrated by altered drug stimulation of P- 
gp mediated ATP hydrolysis (92). Direct proof for altered drug handling by the G185V 
mutant was shown by Safa et al. (110) who demonstrated that decreased resistance to 
vinblastine was associated with increased binding of a photoactive analogue of 
vinblastine. In the same study, cells expressing mutant protein were more resistant to 
colchicine but had lower levels of colchicine binding compared to wild-type protein. 
Furthermore, glycine->valine substitutions at two additional positions in CL1 have also 
resulted in altered substrate specificity in MDR1 P-gp (75). These authors also 
introduced glycine mutations at several other intracellular loops and found altered 
resistance to colchicine and adriamycin with no alteration in resistance to vinblastine.
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In a more recent study Kwan and Gros (70) used a random PCR mutagenesis method to 
introduce additional mutations into CL1 of mouse MDR3 P-gp (equivalent to human 
MDR1) and report a reduced ability of verapamil and valinomycin to stimulate ATPase 
activity in up to 70% of resultant mutants. This was also associated with loss of transport 
function in a smaller percentage of the mutants produced. In light of these studies it 
appears that CL1, and possibly other intracellular loops, do have a role to play in 
transmitting signals between the drug binding sites in the TMDs and the ATP hydrolysis 
sites at the NBDs. However, the nature of the change in drug specificities observed, as 
manifest by changes in drug stimulated ATPase activity or resistance profiles, is not 
known. It is not entirely clear whether altered drug resistance profiles or changes in drug 
stimulated ATPase activity is due to changes in (i) the binding affinity of drug or (ii) 
abrogation of the. mechanism that couples drug binding to hydrolysis to effect drug 
transport. It is not inconceivable that the intracellular loops of P-gp may be actively 
involved in TMD:NBD communication. Interestingly, it has been shown in many 
prokaryotic ABC proteins that the intracellular loop connecting TM segments IV and V 
has a very highly conserved sequence, called the EAA-loop, that is essential for ligand 
transport (116). An EAA-loop has only been found in one eukaryotic ABC protein (a 
yeast orthologue of human ADLP) where mutations introduced into this loop abrogated 
transport activity (73). Mutations introduced in CFTR into the intracellular loop 
connecting TM segments IV and V, equivalent to the EAA-loop, disrupted opening and 
closing of the channel which may be dependent upon communication between the TMDs 
and NBDs (156). This observation suggests that the intracellular loops of ABC proteins 
in general may be important to mediate signal transduction between the membrane and 
cytoplasmic domains to elicit transport and lends support to the studies outlined above 
proposing a role for the intracellular loops of P-gp in signalling between the TMDs and 
NBDs.
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1.11.6 Key residues in NBDs important for NBD:TMD signalling and drug 
specificity
Mutational analysis of the NBDs of P-gp has identified key residues that affect drug 
specificity and provides additional evidence that the NBDs can communicate with the 
TMDs. In studies of chimeric P-gp molecules where the NBD1 catalytic domain was 
replaced by the corresponding segments in NBD2, there was no loss of function except 
for a small segment (ERGA->DKGT (522-525)) located immediately upstream from the 
signature sequence and also at a single residue at position 578 (T—»C) immediately 
downstream from the Walker B motif (7). The mutations completely disrupted 
verapamil stimulation of ATPase activity, but demonstrated that the protein still retained 
drug binding activity. All of the mutants displayed comparable levels of [125I]-IAAP 
binding to wild type, that was displaced by a range of cytotoxic drugs and modulators 
(8). The mutations therefore seem to disrupt coupling of drug binding to hydrolysis of 
ATP. Another NBD mutation (K536R) has been shown to affect substrate specificity as 
manifested by enhanced resistance to colchicine. This mutation maps to a region 
upstream from the Walker B motif and immediately downstream from the ERGA/DKGT 
substitution mentioned above. The biochemical basis did not appear to involve 
abrogation of drug binding ability (51).
It has been postulated that the intracellular loops and the NBD residues highlighted in the 
above studies may be directly involved in transmission of signal between TMDs and 
NBDs. However, further study needs to be conducted in this regard to determine the 
location of putative signal transduction pathway(s) within the protein.
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1.12 Objectives of thesis
In the absence of detailed structural information we are still very much heavily reliant on 
studies of P-gp function in order to obtain sufficient information to put together a 
working model of its transport activity. The clinical problem of MDR posed by the over- 
expression of P-gp in tumours is directly related to its ability to transport chemically 
diverse and functionally unrelated cytotoxics. Reversal agents or modulatory compounds 
have been used to overcome P-gp transport activity in the hope of re-sensitising tumour 
cells to cytotoxic agents. Indeed, the range of modulatory agents used is equally diverse.
The suggestion that P-gp lacks ligand specificity can now be refuted based on the results 
of studies suggesting the presence of distinct sites of interaction for ligand. The 
mechanism by which transport of ligand is mediated remains to be elucidated. However, 
it is known that drug binding at the TMD domain elicits a signal that is transduced to the 
NBDs to stimulate hydrolysis of ATP necessary for drug efflux to occur. The 
mechanism by which binding of modulators inhibits transport is not certain. Studies to 
date suggest that some modulators function by inhibiting ATPase activity or ‘competing’ 
for transport. Signalling between the TMDs and NBDs is via conformational signalling. 
Communication between these domains is a two-way process as decreases in drug 
binding have been observed when protein is trapped by vanadate immediately post-ATP 
hydrolysis. The region(s) on the protein involved in transduction of signal has not been 
identified.
The focus of this thesis is to use a pharmacological approach to characterise drug 
interaction with P-gp. I will be specifically concerned with elucidating further the 
mechanism by which multiple drugs can interact with P-gp. How many classes of site 
are there? For instance, do modulatory compounds interact at a site(s) that performs a
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purely regulatory role and distinct from site(s) at which transport ligands may bind? 
Binding of drug at the TMDs does transduce a signal to the NBDs but is the signal 
transmitted dependent upon the molecule bound or the type of site occupied?
To address these questions I will use radioligand binding assays to directly characterise 
interaction of a range of cytotoxic drugs and modulatory agents with P-gp. The effect of 
drug interaction on P-gp activities such as ATPase and transport will be investigated in 
this initial characterisation. Then, using pairs of drugs, radioligand binding assays will 
be conducted to investigate the type of drug:drug interactions occurring on P-gp. This 
will yield information concerning whether drugs are interacting at die same site or not, 
particularly cytotoxic drugs and modulators. Studies of this kind have been lacking in 
the P-gp field to date.
A second major focus will be elucidation of how drug binding properties are altered as 
the protein undergoes a catalytic cycle and relating it to the transport cycle of P-gp. 
Again, radioligand binding assays are used to directly measure the binding parameters of 
the cytotoxic compound vinblastine at different discrete stages of the catalytic cycle. In 
terms of transport activity, binding sites for transported substances must cycle between 
low and high affinity conformations to facilitate transbilayer movement. I want to 
establish the stage in the cycle when the initial signal is transmitted from the NBDs to the 
vinblastine site to initiate transport. What is the nature of the change wrought on the 
vinblastine site and what triggers restoration of binding site to its pre-transport 
conformation?
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Based on the pharmacological investigations conducted in this thesis models depicting 
(a) an interconnecting network of ligand interaction sites and (b) a molecular mechanism 
for P-gp transport activity have been devised.
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Materials and Methods
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2.1 Introduction
In order to gain a clearer understanding of how drugs interact with P-gp it was necessary 
to develop a radioligand binding assay that would allow a direct and quantitative 
assessment of drug binding characteristics of this protein. Such an assay would provide 
important information concerning the potency of drug interaction, the binding site 
capacity on the protein, the type of site occupied by drug and the rate at which drug 
associates/dissociates. Although the range of compounds interacting with P-gp is 
extensive, they can be divided into two major classes a) transported ligands and b) 
modulators of the transport process. P-glycoprotein can be equated to a classic drug 
receptor and therefore is amenable to study using classical pharmacological techniques. 
Thus information can be obtained concerning the molecular pharmacology of drug 
interaction with P-gp in particular whether binding is to a single site or to multiple sites 
exhibiting high affinity for ligand. In addition, such studies may provide insight into the 
mode of modulator inhibition of transport function.
2.2 Drug Receptor Interaction
Simple occupation of receptor by ligand may be described by the Law of Mass Action. 
If P-gp is viewed as a receptor then binding of drug to P-gp can be described by the 
following;
[P ] +  [ D ] v = ^  [P D ]  (2.1)
K-l
where k+% and k_i are the rate constants for association and dissociation reactions 
respectively. [P] denotes binding site on P-gp, [D] is drug and [PD] is the P-gp-drug 
complex. According to the law of mass action, the forward reaction rate is given by
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k+i[P][D] and the reverse reaction by k_i[PD]. At equilibrium, the forward and reverse 
reaction rates are equal
By re-arrangement of this relationship the equilibrium dissociation constant for the 
reaction can be determined and it provides a measure of the affinity of ligand for its 
receptor
A relationship representing the fraction of sites on P-gp occupied by drug can be derived 
from equation 2.3 by making the following substitutions;
[Pt] denotes the total number of sites on P-gp available to ligand and can be represented
k.,[P][D] = k_,[PD] (2.2)
as;
[Pt] = [p ] + [PD] and substituting in 2.3;
(2.4)
thus the fraction of sites on P-gp that are occupied is represented by
[p d ] _ [d ]
(2.5)
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This equation derived from first principles is also known as the Langmuir adsorption 
isotherm, which was derived to model the binding of gas molecules to a surface (71) and 
can be used to describe binding of drug to receptor. This model assumes that binding is 
to a homogeneous class of non-interacting binding sites. The equation yields a hyperbolic 
curve relating fractional receptor occupancy ([PD]/[Pt]) to drug concentration. When 
this equation is plotted as a fimction of logio[D], a sigmoidal curve is produced with a 
slope factor equivalent to a Hill number of 1. The Langmuir isotherm model assumes 
that the Hill slope will always be unity. The slope of the binding curve provides an 
indication of whether drug is binding independently to one or more sites, or whether 
there is co-operativity occurring whereby binding of a drug molecule affects the binding 
of other drug molecules. If there is positive co-operativity of binding, the curve will 
have n>l, whereas negative co-operativity manifests as a shallow sigmoidal curve with 
n<l.
To model binding of ligand to two sites on a receptor, an equation that is the sum of two 
Langmuir equations can be used as shown below;
[ d J+k * [ d ] + k =
where Y is the fraction of sites on P-gp bound and Kdi and K# are the equilibrium 
dissociation constants for binding to two sites of differing affinity.
An alternative pharmacological model to the Langmuir isotherm may also be considered.
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[P] + [D] v = = ^  [PD]
K_1
[P] + [PD] 3 = ^  [PD2] (2.6)
Interaction of drug [D] with two sites on [P] can be described where an initial 
equihbrium may be established with association and dissociation rate constants of k+i 
and k_i respectively. The [PD] complex may then bind a further drug molecule with 
association and dissociation rate constants of k+2 and k_2 respectively. Adair used the 
pharmacological scenarios described in 2.6 to derive the following equation as outlined 
in appendix I;
on its receptor in the absence of co-operativity (Adair, 1925). When modelling 
radioligand-binding data obtained in this thesis, these different pharmacological 
scenarios were used to assess the type of drug interaction observed.
2.2.1 Model testing.
An iterative process using the sum of squares is used to determine how experimentally 
produced data points fit the model parameters. This involves squaring the differences 
between the actual data points (y) and the calculated data point (yc) (for each different 
parameter) until the smallest difference is obtained using the following model;
Y (2.7)
where Y is the fraction of sites bound.
This is the equation formulated by Adair, which describes binding of ligand to two sites
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SSq = ~ y 0) 2 (2-8)
The appropriateness of a particular model for a particular dataset can be tested by 
comparing data fitted with a more complex model to those fitted by a simpler model. 
This is achieved using the F statistic, which determines whether there is a significant 
difference between the complex model versus a simple model from the following 
equation;
((SSg(c) -  SSqjs)) (df, -  dfe ))
SSq(c)/dfc
where df refers to the degree of freedom of the model (number calculated from the 
difference between the number of data points and the number of fitting parameters in the 
model). If the value of F is not high enough to support a significant difference between 
these models, then the simpler model should be used to fit the data.
2.2.2 Standard saturation binding isotherms
Radioligand binding assays were conducted using P-gp containing CHrB30 plasma 
membrane vesicles in all cases. The binding of the cytotoxic drugs [3H]-vinblastine and 
[3H]-paclitaxel and the modulatory drug [3H]-XR9576 was characterised by measuring 
the amount bound as a function of radioligand concentration (i.e. saturation isotherm 
analysis).
Membrane vesicles were incubated in binding buffer (50mM Tris.HCl pH 7.4) with 
increasing concentrations of radiolabelled drug (added from 4X stock in binding buffer) 
in a total reaction volume of lOOpl The amount of membrane added to the reaction 
tubes varied depending upon the radioligand used. Tubes were set up in quadruplicate
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for each concentration of radioligand. The non-specific binding component (nsb) of the 
reaction was determined at each concentration of radioligand. A 100-fold excess of an 
unrelated non-radiolabelled drug, which also interacts with P-gp, was added to two of the 
four tubes. The remaining two tubes gave a measure of total radioligand bound to the 
membrane vesicles. Samples were incubated in the dark for 2-3 hours at room 
temperature, to ensure binding equilibrium was reached (refer to Chapter 3). Stock 
solutions of non-radiolabelled drugs were usually made up in DMSO. The final 
concentration of DMSO never exceeded 1% (v/v) in any of the reactions, as higher 
concentrations interfere with drug binding. Due to the high degree of hydrophobicity of 
the radiolabelled drugs used in this thesis, all 4X stocks were made up in borosilicate 
glass test-tubes to minimise loss of drug due to binding to the glassware from aqueous 
solutions.
Following the appropriate incubation period, unbound radiolabel was separated from 
bound complex, by rapid filtration. A custom-made filtration box comprising 48 wells 
was used and was connected to a vacuum pump (KJNF Neuberger, U.K. Ltd., type: 
PME0053 N035 AN18). Samples were passed under vacuum (600mbar) through single 
GF/F glass fibre filters, which were pre-soaked in wash buffer (20mM Tris-HCl, pH 7.4, 
20mM MgSC^) containing 0.1%(w/v) BSA, followed by washing with 2 X 3ml wash 
buffer. Glass-fibre GF/F filters were used based on a screen previously conducted in our 
laboratory of different filter types. This type of filter offered the highest retention of 
radiolabelled-P-gp complex with minimal adsorption of unbound radiolabel. Filters were 
briefly pre-soaked with BSA to further reduce retention of unbound ligand.
The amount of radioactivity trapped on the filters was measured using liquid scintillation 
counting. The amount of radiolabel added to each tube was also measured by
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scintillation counting by aliquoting the appropriate volume directly into scintillation 
vials. The results were displayed in disintegrations per minute (dpm) and using the 
specific activity of the radioligand, the dpm measured were converted to determine a) the 
molar amount of radioligand added to the assay tubes and b) the amount of drug bound to 
trapped membrane vesicles. Specific binding of radiolabel to P-gp was quantitated by 
subtracting the amount bound in the presence of an excess of unlabelled ligand, from the 
total amount bound (absence of unlabelled ligand). Specific binding (pmol mg'1 
membrane protein) was plotted as a function of free radioligand concentration (nM) 
using the Langmuir binding isotherm, as described in section 2.2 from which parameters 
such as binding capacity (Bmax) and Kd were obtained.
2.2.3 Homologous displacement of binding to extend saturation isotherm binding
Measuring binding parameters of a drug over a wider concentration range is often not 
possible using radiolabelled drugs, due to limits imposed by the stock concentration and 
the specific activity of radioligand. Strategies have been devised where this problem can 
be circumvented by combining two different types of binding assay (106). This can be 
achieved by performing a saturation binding assay over a range of radiolabelled drug 
concentrations and then extending the range by diluting the highest radioligand 
concentration, with increasing amounts of unlabelled ligand. It is possible to extend the 
range of ligand concentration over which binding is measured several fold. This 
approach was adopted to look at [3H]-vinblastine binding to P-gp as follows.
Membranes (15pg) were incubated with increasing concentrations of [3H]-vinblastine up 
to lOOnM in the presence and absence of an excess of nicardipine (3pM) (which was 
sufficient to measure the n.s.b. component of binding). To measure binding over higher 
concentrations of vinblastine, membranes (15pg) were incubated with lOOnM [3H]-
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vinblastine arid increasing amounts of unlabelled vinblastine (up to 3000nM vinblastine) 
in the presence or absence of 3pM nicardipine. Unlabelled vinblastine was added from 
100X DMSO stocks as Ipl aliquot in a total reaction volume of lOOpl Samples were 
incubated in the dark for 2-3 hours to reach equilibrium.
Bound ligand was separated from unbound by rapid filtration, and filter-entrapped 
radioactivity measured by liquid scintillation counting. The amount of ligand bound at 
the lower concentration range was calculated as outlined above for saturation binding. 
The amount of vinblastine bound in the homologous displacement assay was calculated 
by using the diluted specific activity of [JH]-vinblastine at each added concentration of 
unlabelled vinblastine. The amount of bound dpm measured was then transformed to 
pmol vinblastine bound per mg membrane protein. The binding measured in the 
presence of nicardipine was subtracted from both the saturation binding data and the 
homologous displacement data to give specific vinblastine bound. Both data sets were 
combined and plotted as a fimction of ligand concentration.
2.2.4 Heterologous displacement of binding
Heterologous displacement of binding involves displacement of radioligand by an 
unlabelled drug distinct froin the radioligand. These assays involved labelling of 
membranes with a single concentration of radioligand and using a range of 
concentrations of unlabelled drug to displace radiolabelling.
Membranes were incubated with either none or increasing concentrations of unlabelled 
competing drug and a fixed concentration of radiolabelled drug in binding buffer for 2-3 
hours. Details concerning the amount of protein or concentration of radiolabelled drug 
employed, with respect to the various radioligands used in this thesis, are outlined in
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Chapter 3. Bound ligand was separated from unbound by rapid filtration and filter- 
retained radioactivity measured by scintillation counting. Specific dpm were plotted as a 
fimction o f the logarithm of displacing agent concentration and the effect of antagonist 
analysed using the dose-response relationship described by DeLean et al. (24)
where Y is amount bound, a = initial binding, b = maximal binding, c = EC50 
concentration (log M), d = slope factor and x = drug concentration (log M). EC50 denotes 
the concentration of antagonist that displaces 50% of the bound radioligand, and provides 
an estimate of the potency of the antagonism.
However, EC50 or IC50 values are not constants and are dependent upon the concentration 
of ligand displaced. A useful transformation of this parameter was devised by Cheng & 
Prusoff whereby IC50 values can be expressed as inhibition or antagonist affinity 
constants (Kj) using the equation below (19);
where Kj is antagonist affinity constant, IC50 is concentration of antagonist to displace 
50% of bound radioligand, [L] = concentration of radioligand bound, Kd = equilibrium 
dissociation constant of radioligand. Estimates of K; will only be valid where slopes of 
displacement curves are equal to or constrained to 1.
2.3 Drug-Receptor binding kinetics
In all studies of receptor-ligand interaction, knowledge of the kinetics of binding is
essential. Investigation of the binding kinetics of drug with receptor provides
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information concerning the onset and duration of drug action at a receptor. The rate of 
formation of drug receptor complex over time (d[PD]/dt) is dependent upon the 
difference between the rate at which drug associates with receptor and dissociation of 
drug receptor complex represented as follows;
d[PD] 
dT
The following function was derived from 2.12 as described in appendix II
= k 1[p][D ]-k ,[P D ] (2.12)
l
[ r o ]  . - k  obs ‘= 1 - 6  008 (2.13)
[ P D ] „
where [P D ]eq is the amount of drug receptor complex at equihbrium; kobs is the 
association rate for formation of [PD ]/[PD ]eq over time. But kobs is a function of the drug 
concentration used and the dissociation and association rate constants as described 
below;
kobs = k, [D] + A_, (2.14)
To determine the association rate constant, Kobs measured at different concentrations of 
radiohgand is plotted as a function of ligand concentration. The slope of the linear 
relationship (equation 2.14) yields a value for ki the association rate constant 
(concentration"1, time"1).
2.3.1 Association kinetics of radioligand binding
The rate of onset of both [3H]-vinblastine and [3H]-XR9576 with P-gp was measured in 
CHrB30 membranes. Membrane vesicles (2pg for [3H]-XR9576 and 10pg for [3H]- 
vinblastine) were incubated with a fixed concentration of tritiated drug (within the range 
5-75nM) for fixed time intervals up to 2 hours. Binding reactions were set up in
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quadruplicate by adding radiolabelled drug (75 pi in binding buffer) to borosilicate glass 
test-tubes. The association reaction was begun with the addition of membrane protein 
(25pi) to the reaction tubes at timed intervals, in the presence or absence of an excess 
concentration of nicardipine (3pM). Reaction was stopped by rapidly filtering all of the 
samples together under vacuum, as previously described. Filter-entrapped radioactivity 
was measured and the amount of specifically labelled protein calculated. The association 
rate constant was determined from the binding data as described in the previous section.
2.3.2 Dissociation kinetics for drug-receptor complex
The rate of offset or the dissociation rate constant (k_i) of either [JH]-vinblastine or [3H]- 
XR9567 was measured by labelling CHrB30 membranes (lOpg and 2pg respectively) 
with a fixed concentration of labelled drug (ususally Kd concentration) to equilibrium (2- 
3 hours at room temperature). The association reaction was stopped at timed intervals by 
adding a large excess of unlabelled drug vinblastine or XR9576 respectively (100-fold) 
from concentrated DMSO stocks. Dissociation of [3H]-XR9567 was measured by adding 
unlabelled XR9576 (3pM) over the following time intervals, 0, 2, 4, 6, 8, 10, 15, 20, 30, 
40, 50, 60 minutes to the [3H]-XR9576-P-gp equihbrium complex. Dissociation of [3H]- 
vinblastine was measured by adding unlabelled vinblastine (3pM ) at intervals over 40 
minutes (0, 2, 4, 6, 8, 10, 15, 20, 25, 30, 40). Different time courses were followed to 
accommodate differences in the off rate of the two radioligands. Samples were filtered 
sequentially at the end of the time-course.
In order to look at the effect of a second unrelated drug on the dissociation kinetics of 
radioligand as determined using the method outlined above, the assay was modified as 
follows. For example, dissociation of [3H]-vinblastine was measured by adding excess 
unlabelled vinblastine, in the presence of an excess concentration of a second unrelated
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drug, to the radioligand-P-gp complex for timed intervals. The concentrations of drug 
used in such experiments are detailed in Chapter 4.
2.4 Competitive & Non-competitive antagonism
Studies of antagonism of radiohgand binding yield important information concerning (i) 
sites of interaction of drugs on P-gp, (ii) the effect of drug on the binding of other ligands 
and (iii) provide a measure of antagonist affinity. In general, antagonists may be 
classified into two broad groups namely, competitive and non-competitive. Competitive 
antagonism describes the binding of competing drug to the same site as the ‘agonist’. 
This kind of competition manifests as a parallel shift to the right in the binding dose- 
response curves where increasing concentration of ‘agonist’ overcomes the effect of the 
competing drug to obtain maximal binding again. However, non-competitive drug 
interaction is due to binding of drug at an alternative site on P-gp. This inhibition of 
binding often manifests as a reduction in maximal binding and does not always cause a 
shift in the dose-response curve. In conducting studies to delineate the type of 
interaction occurring between drugs on a protein, it is important to use a range of 
antagonist concentrations in order to be able to fully assess the nature of the antagonism. 
A mathematical equation to predict competitive effects of antagonist on interaction of 
agonist was first devised by Gaddum (33). If drug interacts with protein in a competitive 
manner then the following products will be produced;
[D] + [A] + [P] [AP] + [DP] (2 l1 5 )
As detailed in Appendix m, fractional saturation in the presence of antagonist is given
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where [D*] > [d ] and represents the concentration of drug required to produce the same 
fractional saturation in the presence of antagonist.
Schild derived a useful equation based on the Gaddum model (equation 2.16), allowing a 
convenient means of estimating antagonist affinity (K a )  through linear regression,of a 
series of dose ratios obtained over a range of antagonist concentrations (5):
log (DR -1 )  = 7! log [>4] -  log K a (2.17)
DR refers to the ratio of equiactive concentrations of agonist, (usually defined as 
producing 50% occupation of receptor), in the presence and absence of antagonist. If the 
agonist-antagonist interaction is truly competitive, the above relationship will be linear 
over a wide concentration range with a slope of n=l. The x-intercept will then provide 
an estimate of Ka when the slope is equal to or constrained to 1. This type of analysis 
has been termed Schild analysis (see Kenakin, 1997). It is a powerful tool in 
pharmacology to differentiate between competitive and non-competitive interactions. 
This is particularly important as some non-competitive antagonists do produce parallel 
shifts in agonist dose-response curves but when Schild analysis is applied, fail to produce 
a linear curve with slope equal to unity.
Non-competitive drug interactions can also be investigated by following the effect of 
antagonist on the dissociation kinetics of agonist. If the rate of dissociation of an agonist 
is increased or decreased in the presence of antagonist, this is indicative of a non­
competitive interaction according to the law of mass action. Such an effect can only be 
exerted through an allosteric interaction between the sites of interaction of the agonist 
and antagonist. Therefore interactions of drugs with P-gp were examined using
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equilibrium binding or Schild Analysis in conjunction with kinetic analyses as detailed in 
Chapter 4.
2.5 Cell Culture
Drug resistant Chinese hamster ovary cells (CHOs) that over-expressed P-gp (CtfBSO) 
were used as the source of P-gp in this thesis. The cells were routinely grown at 37°C, 
5% CO], in a-minimal essential medium (a-MEM) including 10% foetal bovine serum 
and supplemented with 30pg ml'1 colchicine to maintain selection of resistant cells. The 
CHrB30 cells were originally derived from AuxBl cells by step-wise selection in 
colchicine, as described in detail elsewhere (62). The parental AuxBl cells were grown 
under the same conditions as CHT330 cells but without inclusion of colchicine in the 
media. All of the cells used in this thesis were grown at the ICRF tissue culture facility 
at Clare Hall except those used in steady-state drug accumulation assays.
2.5.1 Plasma membrane vesicle preparation
Plasma membrane vesicles were prepared by disruption of CHrB30 cell membranes using 
nitrogen cavitation at a pressure between 1000-1500psi for 3 cycles of 15 minutes at 4°C. 
Protease inhibitors (leupeptin, 0.1 mg ml"1, pepstatin A, O.lmg ml'1, benzanudine, ImM) 
were included in the disruption buffer (lOmM Tris, 250mM sucrose, 0.2mM CaCl], pH 
7.4). Membrane vesicles were collected from the lysed cell suspension following 
sucrose density centrifugation for 30 minutes at 30,000g on a 35% (w/v) sucrose cushion. 
Membranes at 0-35% sucrose interface were collected and pelleted at 100,000g over 45 
minutes at 4°C. Pellets were resuspended at a protein concentration of approximately 
20mg ml'1 in buffer (lOmM Tris, pH 7.4, 250mM sucrose) containing protease inhibitors 
listed above and stored at -80°C for up to six months.
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2.5.2 Purification of P-gp from CHrB30 membrane vesicles.
Anion exchange chromatography was used to enrich P-gp from CHrB30 membrane 
vesicles to 60% purity and the purification method is outlined in detail in Callaghan et 
al, (16). In brief, P-gp containing membranes (protein content 5mg ml'1) were 
solubilised in l%(w/v) dodecyl-maltoside with 0.4% (w/v) crude lipid mixture 
(asolectin) in a low ionic strength buffer containing lOmM pipes, pH6.9, ImM EDTA, 
0.02% NaN] (w/v), 18%(v/v) glycerol. The soluble protein was passed down a 5ml bed 
volume anion-exchange column (Econo-pac High Q). All chromatography buffers 
contained 0.1%(w/v) dodecylmaltoside to maintain protein solubility. Protein was eluted 
with a continuous linear gradient of NaCl. P-gp containing fractions were identified by 
SDS-PAGE and concentrated to approximately Img ml'1 protein, using 50kDa 
membranes in an Amicon stirred cell concentrator.
2.5.3 Reconstitution of P-glycoprotein
2.5.3.1 Liposome preparation
The phospholipids phosphatidylcholine (PC) and phosphatidylethanolamine (PE) were 
used as the lipid system for the reconstitution of purified P-gp. PC and PE in the ratio 
9:1 (w/w) were dried from chloroform stocks under Nz onto glass test tubes. A trace 
amount of [3H]-PC (0.1 pCi/l Omg lipid) was added to the lipid film to help detect lipids 
in analyses. The lipid films were suspended at lOmg ml'1 in buffer A containing 150mM 
NaCl, ImM EDTA, 50mM Tris.HCl, pH7.4 by vortexing. The lipid suspensions were 
subjected to five freeze-thaw cycles to create larger liposomes that were predominantly 
multilamellar. These multilamellar vesicles were extruded through 200nm filters to 
produce unilamellar liposomes (see (16)).
2.5.3.2 Reconstitution procedure using SM-2 BioBeads
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P-gp purified by anion-exchange chromatography is contained within 
protein/dodecylmaltoside (0.1%(w/v) detergent) micelles. Dodecylmaltoside (DDM) 
was the detergent of choice for the purification of functionally active P-gp (16). 
However, it was not possible to effectively reconstitute P-gp at low lipid/protein ratios 
using DDM. As described in Rothnie et al. (105) decylmaltoside (DM) was used to 
effectively reconstitute P-gp. Liposomes saturated with decylmaltoside were added to 
the solubilised protein at a ratio of 3:1 to ensure that (i) (DM) is the major detergent 
species present and (ii) the concentration of DDM is brought below its critical micellar 
concentration thereby facilitating its removal. The detergent/lipid/protein mixture is left 
to equilibrate on ice for a 40 minute period. Reconstitution is achieved by removal of 
detergent and the technique employed was detergent adsorption to SM-2 BioBeads. Bio- 
Bead additions (40mg ml'1) were repeated at 40 minute intervals.
The efficiency of reconstitution was assessed by following the relative migration of 
protein and lipid through sucrose density gradients. Proteoliposomes (lOpg) were 
diluted to a volume of 200pl and mixed with equal volume of 60% sucrose (w/v) in 
buffer A containing 0.05% (w/v) Triton-X-100. This was sequentially overlayed with 
400pl each of 20, 10, 5 and 0% (w/v) sucrose solutions in buffer A. Samples were 
centrifuged at 150,000 X g for 8-10 hours at 4°C to reach equilibrium. Following 
centrifugation, 200pl fractions were taken throughout the gradient. Protein was 
precipitated from 150pl of each fraction using trichloroacetic acid. Pellets were 
resuspended in 20pl of solution containing 4% (w/v) SDS, 0.2M Tris.HCl pH 10, 0.15M 
NaOH and 5pi 5X Laemmli sample buffer (10%(w/v) SDS, 0.25%(w/v) DIT, 1.5M 
Tris.HCl pH 6.8, 18% glycerol, 0.5M EDTA, 0.01% (w/v) bromophenol blue). Samples 
were subjected to 8% SDS polyacrylamide electrophoresis (SDS-PAGE). Protein was 
located by silver-staining, using Rapid Ag Stain Kit (ICN) according to the
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manufacturer’s protocol. The location of phospholipid in the gradient was detected by 
taking 50pl of each fraction and subjecting to liquid scintillation counting.
2.6 Measurement of P-gp mediated ATPase activity of CHrB30 membranes
P-gp-mediated ATPase activity was measured by following inorganic phosphate (Pi) 
release using a modification of a colorimetric assay developed by Chiffiet (20). In brief, 
a microtitre plate assay has been developed to measure activity in the presence and 
absence of drugs that either stimulate or inhibit ATP hydrolysis. Membrane vesicles 
(Ipg) were incubated in ATPase buffer (150mM NH4CI, 50mM Tris, pH 7.4, 5mM 
MgSC>4, 0.02% NaN3) with either (i) 2mM Na2ATP in the presence or absence of 
increasing concentrations of drug (see results Chapter 3) or (ii) a range of ATP 
concentrations (0-3mM) in the presence or absence of a single concentration of drug that 
produces a maximal effect on P-gp ATPase activity in a total volume of 50pl. Drugs 
were added as Ipl aliquots from concentrated DMSO stocks. Reactions were allowed to 
proceed at 37°C for 25 minutes (it had been previously determined in this laboratory that 
activity is linear up to 40 minutes at 37°C). Non-P-gp related ATPase activity of 
CHrB30 membranes was accounted for by measuring activity in the presence of 200pM 
sodium vanadate. Sodium vanadate inhibits activity of P-type ATPase proteins including 
P-gp. The contribution of other ATPase proteins present in the membrane vesicles used, 
was also eliminated by omitting Ca2+, Na+ and K+ ions from the ATPase buffer.
Hydrolysis was stopped with the addition of 40pl 12%(w/v) SDS solution to each well. 
To detect Pi released in the hydrolysis reaction, lOOpl 1% (w/v) ammonium molybdate 
solution was added to form a complex with Pi. Samples were incubated at room 
temperature for 5  minutes to allow formation of phospho-molybdate complex. Samples 
were further incubated at 37°C for 15 minutes with lOOpl 2%(w/v) sodium
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citrate/arsenite/acetic acid solution to stabilise colour formation. Absorbance was read at 
X = 750nm using a plate reader (Spectra Max 250, Molecular Devices). A standard curve 
was set up of known amounts of Pi (0.1-10nmoles) to quantitate nmoles Pi released in 
assays.
P-gp associated ATPase activity in CHrB30 membrane vesicles was determined by 
subtracting nmoles of Pi released in the presence of 200pM sodium vanadate from all 
values, to eliminate contributions from non-vanadate-sensitive ATPase proteins as 
previously described (1). The vanadate-sensitive ATPase activity was expressed as 
nmoles Pi released minute'1 mg'1 membrane protein and was plotted as a function of drug 
or ATP concentration according to the experiment performed. In general, when 
experiments were conducted investigating the effect of a single concentration of drug on 
the kinetics of ATP hydrolysis i.e. Vmax and Km for ATP, results were plotted using the 
Michaelis-Menten equation below;
y  = 2jmx[^L 2.16
K m +[S]
where Y is ATPase activity (nmol m inting'1 membrane protein), Vmax is maximal 
activity (nmol min^mg'1 membrane protein), [S] is ATP concentration (mM), Km is the 
concentration of ATP which produces 50% maximal activity. In experiments designed to 
look at the ability and potency of drug to affect the ATPase activity of P-gp, data were 
plotted as fold change in basal activity as a function of drug concentration using the 
general dose-response equation (equation 2.10). Fold change in basal activity was 
calculated by expressing activity measured in the presence of drug as a fraction of that 
measured without drug present.
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2.6.1 Vanadate-trapping of P-gp
As mentioned in the preceding section, sodium vanadate is a potent inhibitor of P-gp 
mediated ATPase activity. The mechanism of this inhibition is due to the ability of the 
vanadate ion to mimic Pi. Following hydrolysis of ATP, formation of nucleotide 
diphosphate/Pi complex results. This complex is transient and when Pi dissociates, 
vanadate can interact with the remaining bound ADP molecule to form a stable transition 
complex with P-gp. This feature of vanadate has been exploited to “conformationally 
restrict” P-gp and other ATPases to enable structural and functional studies.
Sodium orthovanadate stock solutions (lOOmM) were made up in water and adjusted to 
pH 10 and subsequently boiled for 2-5 minutes to eliminate the presence of polymeric 
species prior to each use as described by Goodno (39). Trapping studies were conducted 
by first incubating CHrB30 membrane vesicles (4pg p i'1) with 2mM hla^ATP or 8- 
azidoATP, 0.3mM NaVOg, 50pM verapamil and ATPase buffer, in a total volume of 
400pl over 25 minute period at 37°C. Verapamil was included in the reaction as it 
stimulates ATP hydrolysis and thus increases the rate of trapping by vanadate. Reactions 
were stopped by placing samples on ice. Components that were not used up by the 
reaction were removed by centrifuging 120pl aliquots through 1ml sephadex G-50 gel 
filtration spin columns at 300g for 4 minutes at 4°C as described in Urbatsch and Senior 
(147). Spin columns were pretreated with ATPase buffer prior to use. Where trapped 
samples were used in radiohgand binding studies to measure the ability of drug to 
interact with trapped P-gp molecules, vanadate (300pM) was included in the spin­
column equilibration buffer to prevent dissociation of Vi over the course of the binding 
experiment.
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Some trapping experiments were conducted using 2mM 8-azidoATP as it was desirable 
to have P-gp molecules with ADP covalently bound (refer to Chapter 5). Identical 
trapping conditions were used except that 20%(v/v) glycerol was included in the ATPase 
buffer and the azido nucleotide was cross-linked to the protein following the trapping 
reaction. Cross-linking was achieved by placing samples on ice at a distance of 5cm 
from the U.V. lamp (Blak Ray, Model B 100 AP; from UPL, Upland, CA91786, USA) 
and exposed to U.V. light for 4 minutes. Unbound reaction components were removed 
using spin columns.
Removal of bound vanadate was achieved by incubating trapped protein at 37°C for up to 
2 hours.
2.6.2 Photoaffinity labelling of reconstituted P-gp with 8-azido[cc-32P]ATP
Proteoliposomes (8pg) were incubated with 2pM 8-azido[a-32P]ATP (2-10Ci mmol"1) in 
ATPase buffer including 20% (v/v) glycerol, in the presence of increasing concentrations 
of unlabelled ATP (0.01-lmM). Reactions were made up in a final volume of 70pl and 
incubated for 15 minutes at 37°C. Labelling was stopped by placing the samples on ice. 
Bound nucleotide was cross-linked to the protein by U.V.-irradiating samples (100W) for 
4 minutes on ice at a distance of 5cm. Unbound nucleotide was removed by 
trichloroacetic acid precipitation of P-gp, followed by electrophoresis on 8% SDS-PAGE 
gels. The relative labelling efficiency of the samples was measured by autoradiography 
of the gels.
2.7 Steady-state drug accumulation assay
AuxBl and CHrB30 cells were grown to confluent monolayers in 12-well (24mm) tissue 
culture dishes. Monolayers were washed with phosphate-buffered saline (PBS) and then
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incubated in 1ml transport buffer (lOOmM NaCl, lOmM Tris, 25mM NaHCOs, 5mM 
KC1, 2mM CaCl], ImM MgCb and 7mM glucose). Competing agents were added in the 
concentration range 10*9 to 10"5M from DMSO stocks giving a final solvent 
concentration of 0.2%(v/v). The steady-state accumulation of either vinblastine or 
paclitaxel was started with the addition of 0.1 pCi radiolabelled drug and up to lOOnM 
unlabelled drug respectively. Samples were incubated over a 1 hour period at 37°C 
under 5% C 02, to reach steady-state. This period of time has previously been shown to 
be sufficient to achieve steady-state accumulation of drug in Chinese Hamster Ovary 
cells (KCallaghan personal communication). Monolayers were washed with 2 X 2ml 
ice-cold PBS. Cells were harvested with 0.4ml of 0.4M NaOH, and the cell extract 
neutralised with 0.8ml of 0.25M ammonium acetate (pH6.6). Radioactivity was 
measured using liquid scintillation counting and normalised for cell protein content. The 
general dose-response equation was used to plot [3H]-vinblastine or [3H]-paclitaxel 
accumulated (pmol mg'1 cell protein) as a function of modulator concentration. The 
amount of [3H]-XR9576 accumulated (pmol mg'1 cell protein) was plotted as a function 
of [3H]-XR9576 concentration using the same equation.
Experiments investigating accumulation of [3H]-XR9576 in AuxBl and CHrB30 cells 
were essentially as described above. This was achieved by incubating cells with a range 
of radiolabelled XR9576 concentrations (l-300nM) in the presence and absence of IpM 
GF120918.
2.8 Protein Assay
Protein content of all samples used in this thesis was measured using a DC Brad assay kit 
(BioRad, U.K.) that was based on the Lowry method for assaying protein concentration. 
Samples were diluted where necessary, and made up to 20pl with H2O. A range of BSA
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concentrations (in 20|il) were used to produce a linear standard curve (l-20pg). The 
assay was carried out according to the manufacturer’s protocol.
2.9 Curve-fitting and statistical Analyses
All of the curve-fitting was carried out using Graphpad prism 2.0 (Graph?ad Software, 
San Diego, CA).
All statistical analyses were conducted on sample means, using the parametric Students t 
test. P value below 0.05 was deemed significant.
2.10 Materials 
Radiochemicals
[3H]-vinblastine sulphate (12-18Ci mmol'1), L-3-Phosphatidyl[N-methyl-3H]choline, 
1,2-dipalmitoyl (40-85Ci mmol'1) Amersham Pharmacia Biotech (Amersham, UK), 
[3H]-paclitaxel (2.5-6 Cimmol'1) Campro Scientific (Veenendaal, Netherlands), 
[3H]-XR9576 (32 Ci mmol'1) gift from Xenova Ltd. (Slough, UK),
8-azido[a-32P]ATP (2-10Ci mmol-1) ICN Pharmaceuticals BY, (Netherlands).
Drugs
Vinblastine sulphate, nicardipine hydrochloride, paclitaxel, verapamil hydrochloride, 
colchicine were purchased from Sigma, (Poole, U.K).
XR9576, XR9051 and GF120918 were synthesised and donated by Xenova Ltd. (Slough, 
UK).
Lipids
Egg phosphatidylcholine (PC), bovine liver phosphatidylethanolamine (PE), cholesterol 
were obtained from Sigma (Poole, U.K.). Soya-bcan asolectin (50% pure) was obtained 
from Fluka (U.K.).
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General chemicals
Adenosine 5’-triphosphate (ATP) disodium salt, adenosine 5’-diphosphate (ADP) 
disodium salt, adenosine 5 ’ -monophosphate (AMP) disodium salt, 5’- 
adenylimidodiphosphate (AMP-PNP) lithium salt, sodium orthovanadate, N- 
ethylmaleimide (NEM), 7-chloro-4-nitrobenz-2-oxa-l,3-diazole (NBD-C1), sodium azide 
(NaN]), Tris-HCl, magnesium chloride, magnesium sulphate, sodium dodecylsulphate, 
sodium citrate, ammonium molybdate, sodium arsenite, phosphorous standard solution, 
benzamidine hydrochloride, ethylenediaminetetraacetic acid (EDTA), bovine serum 
albumin (BSA), PIPES (Piperazine-N,N’-bis[2-ethanesulfonic acid] 1,4- 
Piperazinediethanesulfonic acid), DL-Dithiothreitol (dl-D T T ),sodium hydroxide, 
bromophenol blue (sodium salt), potassium chloride, calcium chloride, sodium 
bicarbonate, ammonium acetate, were all obtained from Sigma (Poole, U.K.).
Glycerol (Analar), dimethylsulphoxide (DMSO), BDH (U.K.)
8-azidoATP, ICN Pharmaceuticals BY (Netherlands).
Adenosine 5’-0-(3-thiotriphosphate) (ATP-y-S), decyl- and dodecyl-P-maltoside, 
leupeptin hemisulphate, pepstatin A, Calbiochem (UK).
Maleimidylanilino-naphthalene-6-sulfonate (MIANS), Molecular Probes (Netherlands). 
Ready Protein™ Scintillation fluid, Beckman (High Wycombe, U.K.)
Rapid-Ag Stain Kit, ICN (Thame, U.K.)
Detergent compatible protein assay k it , Bio Rad (U.K.)
Alpha Minimum Essential Medium (a-MEM), Foetal Bovine Serum, Gibco-BrL (U.K.) 
Unless otherwise stated, all of the chemicals used were of the highest grade possible.
Materials
GF/F glass-fiber filters, Whatman (U.K.); Bio-spin disposable chromatography columns, 
Econo-pac High Q anion-exchange column, BioRad (Hemel Hempstead, U.K.); 
Sephadex™ G-50 Fine, Amersham Pharmacia Biotech (Sweden); Poly-Q mini 
scintillation vials, Beckman (High Wycombe, U.K.); borosilicate glass tubes, Samco 
(U.K.);
Instruments
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LS6500 multipurpose scintillation counter, Beckman (High Wycombe, U.K.); Micro-titre 
Plate Reader, Spectra Max 250, Molecular Devices; U2010 spectrophotometer, Hitachi.
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Pharmacology of drug interaction with P- 
glycoprotein and its effect on ATPase 
function and drug efflux activities
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3.1 Introduction
I have used a pharmacological approach to address the question of how P-gp can interact 
with diverse and often chemically distinct compounds. To achieve this, radioligand 
binding assays have been developed to allow direct measurement of drug binding to P- 
gp. These types of studies can provide quantitative information concerning the 
characteristics of drug binding, the sites of interaction and the affinity of drug for P-gp. 
Studies of this kind have been sadly lacking in the area of P-gp research.
Compounds that interact with P-gp can be classified as either transport ligands, as is the 
case for many cytotoxic drugs or, modulatory ligands, compounds that inhibit activity of 
the protein, but are not themselves transported. In this chapter the interaction of a range 
of transport and modulatory ligands with P-gp has been characterised in terms of their 
effect on P-gp drug efflux and ATP hydrolytic activities. The manner by which drug 
affects these activities of P-gp was characterised by directly assessing binding of the 
cytotoxic drugs [3H]-vinblastine and [3H]-paclitaxel and the modulator [3H]-XR9567 
with the protein. The ability of other unlabelled ligands to affect binding of radiolabelled 
drug provided the first direct measure of drug:drug interactions on P-gp. By fully 
characterising and comparing the interaction of agents that serve as transport substrates 
for P-gp, and those that are inhibitory in function, light may be shed on the mechanism of 
drug interaction with P-gp and also on the mechanism underlying inhibition of transport 
activity.
3.2 Drug efflux activity of P-gp
P-gp functions as a drug efflux pump preventing the intracellular accumulation of 
compounds such as many cytotoxic agents used in the chemotherapeutic treatment of 
cancer. I have characterised P-gp transport activity by looking at the accumulation
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deficit o f cytotoxic drug in P-gp over-expressing CHrB30 cells as compared to the 
parental non-P-gp expressing AuxBl cells. The effect of the modulatory compounds 
XR9576 and GF120918 on the efflux activity of P-gp has also been investigated. These 
drugs are third generation reversal agents as discussed in Chapter 1 section 1.3.2 and 
have been designed to specifically target P-gp.
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Figure 3.1 Steady-state accumulation of cytotoxic drug in AuxBl cells versus CH'BSOs. 
Accumulation of [’H]-vinblastine (0.1 pM) and -paclitaxel (1 pM) measured over 60 minute 
period at 37°C. Mean accumulation + s.e.m. from at least three independent experiments are shown.
The ability of P-gp to mediate transport of [3H]-vinblastine (0.1 pM) and [3H]-paclitaxel 
(IpM) was investigated by measuring steady-state accumulation of these cytotoxics in P- 
gp positive CH^B30 cells and the AuxBl controls. CHrB30 cells reached a steady-state 
accumulation for [3H]-vinblastine of 5 ± 2 pmol mg'1 (n>3) and 7.4 + 1.1 pmol mg'1 
(n>3) for [3H]-paclitaxel. This is in contrast to steady-state concentrations of 40 ±_5 
pmol mg'1 (n>3) and 43 + 3 pmol mg'1 (n>3) reached in the parental AuxBl cells, for 
[3H]-vinblastine and [3H]-paclitaxel respectively (figure 3.1). The presence of P-gp in
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CHrB30 cells reduces the accumulation of cytotoxic 5-8 fold as compared to control 
cells.
The effect of the modulators XR9576 and GF120918 on the accumulation deficit was 
investigated and compared to steady-state accumulation observed in the non-P-gp 
expressing control cells. This was achieved by measuring accumulation of a single 
concentration of [3H]-vinblastine and [3H]-paclitaxel in the presence and absence of a 
range of concentrations of modulator (lO -^lO™4 M). The accumulation of [3H]- 
vinblastine was increased dose-dependently to levels observed in the drug-sensitive 
parental cells in the presence of both XR9576 and GFT20918 (figure 3.2 (b)). Maximal 
accumulation of [3H]-vinblastine of 44 ± 2 pmol mg*1 (n>3) cell protein was achieved in 
the presence of XR9576 and the EC50 value to increase accumulation was 487 ± 50nM. 
The presence of GF120918 reversed the accumulation deficit for [3H]-vinblastine to a 
similar extent as XR9576, with maximal accumulation at steady-state of 53 ± 2  pmol mg' 
1 (n>3). The EC50 value for the GF120918 effect on [3H]-vinblastine accumulation was 
512 ± 25nM. Therefore both of these modulators displayed similar efficacy to reverse P- 
gp mediated transport of [3H]-vinblastine.
The accumulation deficit seen for [3H]-paclitaxel in CHrB30 cells was also reversed in 
the presence of XR9576 to 69 + 2.4 pmol mg*1 (n>3) (EC50 = 25.4 + 6.9nM) and by 
GF120918 to 56.4 ± 1.7 pmol mg'1 (n>3) (EC50 = 109 ± 21nM) (figure 3.2 (a)). 
However, XR9576 and GF120918 each displayed greater potency in reversing the 
accumulation deficit of [3H]-paclitaxel compared with their efficacy to restore 
accumulation of [3H]-vinblastine. This may be due to the fact that 10 times more [3H]- 
paclitaxel was used in accumulation assays than [3H]-vinblastine reflecting poorer
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Figure 3.2 Effect of modulator on the steady-state accumulation of (a) [^H]-paclitaxel (IpM) and (b) 
[3H]-vinblastine (0.1 pM) in CH B30 cells at 37°C as described in methods, (c) Cellular accumulation 
of [3H]-vinblastine (0.1 pM) in drug-senstidve AuxBl cells in presence of XR9576 over the 
concentration range indicated. All values represent mean + s.e.m. of at least three independent 
experiments, (a) and (b) published in Martin et al., (84).
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affinity of [3H]-paclitaxel for transport by P-gp. XR9576 displayed 4-fold higher 
potency than GF 120918 (P< 0.05) to restore accumulation of [3H]-paclitaxel in CHrB30 
cells. This contrasts with the indistinguishable EC50 values for each of these compounds 
to affect accumulation of [3H]-vinblastine.
The mechanism(s) by which modulatory compounds inhibit the drug efflux activity of P- 
gp is not known, although there are a number of possibilities. Inhibition could occur at 
the level of ATP hydrolysis, which is required to fuel transport, or through a direct 
competition for the transport process. As I had a radiolabelled version of [3H]-XR9576 
the latter possibility was investigated first. The accumulation of [3HJ-XR9576 in P-gp 
expressing CHrB30 and the control AuxBl cells was measured over a range of 
concentrations (2-300nM). As shown in figure 3.3(a) there was no difference between 
the cell lines in the level of [3H]-XR9576 accumulated at any of the concentrations used. 
When [3H]-XR9576 accumulation was measured in CHrB30 cells in the presence of a 
high concentration of GF 120918 (IpM), there was no effect of modulator on the levels 
of [3H]-XR9576 accumulated (figure 3.3(b)). This is in contrast to the ability of 
GF 120918 to affect the accumulation of the transported drugs vinblastine and paclitaxel, 
and suggests that P-gp is not involved. Finally, accumulation of [3H]-XR9576 was linear 
over the entire concentration range used, in the presence and absence of GF120918. The 
lack of saturation in the levels of [3H]-XR9576 accumulated within the cell, indicates 
that it was achieved by passive diffusion, rather than an active transport process. Taken 
together, these three lines of evidence suggest that XR9576 is not a transport substrate 
for P-gp. The mechanism underlying its ability to block drug efflux activity of P-gp 
most likely does not involve direct competition for transport with the transport ligands 
vinblastine and paclitaxel.
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Figure 3 3  Cellular accumulation profiles for [3H]-XR9576 in CHrB30 and AuxBl cells, (a) The 
relative accumulation of various concentrations of [3H]-XR9576 in drug sensitive AuxBl and drug- 
resistant CH'BSO cells measured at 37°C over 60 minutes, (b) Effect of GF120918 (IpM) on the 
accumulation of [3H]-XR9576 in CH'BSO cells. All values represent the mean + s.e.m. of at least 
three independent experiments. Published in Martin et al., (84).
3.3 Effect of drug on P-gp ATPase function in CH B30 membrane vesicles
This section is concerned with characterising the consequence of drug interaction at the
TMDs on P-gp related ATPase activity. P-gp transport activity cannot occur in the
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absence of ATP hydrolysis. Therefore binding of drug at the TMDs must signal to the 
NBDs to generate transport. The ability of cytotoxic drugs and modulatory compounds to 
affect P-gp related ATPase activity has been investigated. In fact, inhibition of ATPase 
activity may be a mechanism employed by some modulators to reduce P-gp mediated 
transport especially since it was shown in section 3.2 that XR9576 does not inhibit P-gp 
transport activity via direct competition for transport. As discussed in the introduction to 
this thesis (Chapter 1 section 1.10) P-gp mediated ATPase activity has been detected in 
membrane vesicles from drug resistant CITB30 cells. ATP hydrolytic activity has been 
previously measured in CHrB30 membranes in the absence of added drug and is 
described as ‘basal’ activity. The basal activity can be stimulated or inhibited in the 
presence of added drug. The ATPase activity measured in CHrB30 membranes in the 
absence of drug may be due to endogenous lipid component in the membrane, but may 
also be due to contributions from non-P-gp ATPases. Although the buffer used in the 
ATPase assay is devoid of constituents that may be used by other ATPase proteins (no 
Ca2+, or K"1)  and contains NaNs to inhibit V-type ATPases, it may not be sufficient to 
block all non-P-gp ATPase activity. Therefore, ATPase activity was measured in the 
presence of 200pM vanadate, which inhibits all P-type ATPase proteins including P-gp. 
The vanadate inhibited portion of the basal ATPase activity is described as the vanadate- 
sensitive portion. ATPase activity detected in the presence of vanadate represents the 
proportion of the basal activity that is insensitive to vanadate and is attributable to non P- 
type ATPases. The contribution of non-P-gp ATPase activity to basal activity is 
corrected for by subtracting the vanadate-insensitive fraction.
The effect of drug binding on the ATPase activity in CHrB30 membrane vesicles has 
been investigated as shown in figure 3.4 (a) & (b). It was surprising to find that the 
cytotoxic drugs paclitaxel and vinblastine, which were shown to be transported by P-gp
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in the preceding section (3.2), exerted little effect on P-gp mediated ATPase activity in 
the membrane vesicles used. There was only a modest increase in the basal activity (1.33 
fold) in the presence of paclitaxel (EC50 = 0.45 + 0.2pM) (n>3) (figure 3.4 (a)). There 
was no detectable alteration in basal ATPase activity of CHrB30 membranes at any 
concentration of vinblastine used (data not shown). This lack of measurable effect of 
vinblastine has also been reported by other groups (132) and may be due to the high 
basal ATPase activity.
The modulatory compounds investigated had opposing effects on basal ATPase activity. 
There was a 1.8- and 2.2-fold increase in P-gp related ATPase activity above basal in the 
presence of verapamil (EC50 = 0.6 + 0.13pM) (n>3) and nicardipine (EC50 = 0.3 + 
O.OpM) (n>3) respectively (figure 3.4 (a)). In contrast to the results observed with 
verapamil and nicardipine, the modulators XR9576, GF 120918 and XR9051 all caused 
60-70% inhibition of the P-gp related basal ATPase activity of CHrB30 membranes. The 
IC50 values or potencies of this inhibition were 43 ± 9nM, 44 ± 5nM and 0.7 ± 0.09pM 
respectively (n>3 in all cases) (figure 3.4(b)). The effect of vanadate on the basal 
activity of P-gp is also included in figure 3.4 (b). The extent of the vanadate induced 
inhibition of activity was approximately 85% of total basal activity measured and had a 
potency value or IC50 = 0.4 ± 0 . 0 2  pM (n>3). This indicates that at least 15% of the 
activity measured in CHrB30 membrane vesicles is not attributable to P-gp. However, 
the modulatory compounds mentioned above inhibited 60-70% of basal ATPase activity 
suggesting that not all of the vanadate sensitive portion of basal ATPase activity 
measured can be attributed to P-gp.
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Figure 3.4 The effect of cytotoxic and modulatory compounds on the ATPase activity in CHrB30 
membrane vesicles, (a) & (b) Membrane vesicles (Ipg) were incubated with a range of drug 
concentrations (10 * to 10^ M) and 2mM ATP for 25 minutes at 370C. Mean value ± s.e.m. from at 
least three independent experiments are plotted. Values for Vm» and EC# were derived as 
described in methods, (b) published in Martin et al., (84).
The fact that the modulators XR9576, XR9051 and GF 120918, which are thought to 
specifically target P-gp, inhibited 60-70% of total basal ATPase activity provides 
evidence that they are specific for P-gp. The partial inhibition by these agents also
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indicates that up to 25% of the vanadate-sensitive fraction of the total basal activity of 
CHTB30 membranes may be attributable to non-P-gp ATPases. The data also indicate 
that inhibition of P-gp mediated transport by XR9576, XR9051 and GF120918 (reported 
in section 3.2) is through inhibition of ATP hydrolysis. It was not possible to determine 
the mechanism through which the modulators verapamil and nicardipine inhibit drug 
transport. It may be through competition for transport, but in the absence of tritiated 
versions of these compounds, it has not been possible to pursue this possibility.
In subsequent sections of this chapter, radioligand binding assays were devised to further 
characterise the nature of drug interaction with P-gp, and to investigate how the protein 
deals with the presence of multiple ligands.
3.4 Characterisation of the binding of [^H]-vinblastine to CHrB30 membrane 
vesicles
3.4.1 Saturation binding isotherm
A rapid filtration radioligand binding assay was used to characterise the interaction of 
[3H]-vinblastine sulphate with CHrB30 membrane vesicles which was based on a method 
developed by Ferry et al. (30). As outlined in Chapter 2 (2.2.3) when designing a 
radioligand binding assay a number of criteria must be adhered to. The ligand used must 
display selectivity for the target, it is important to measure specific interaction with P-gp 
and eliminate contributions due to non-specific drug interactions.
It is therefore essential that the concentration of free ligand in the binding system is not 
depleted so that it does not become rate-limiting. This can be avoided by using the 
lowest possible concentration of receptor. The first experiment was designed to look at 
[3H]-vinblastine binding to CHrB30 membrane vesicles using 8pg membrane protein 
over a range of radioligand concentrations (l-120nM). The specificity of [3H]-
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vinblastine binding for P-gp has previously been demonstrated by the lack of binding of 
vinblastine to membranes from the parental AuxBl cells (RXallaghan, personal 
communication) and the fact that there was no transport of vinblastine in AuxBl cells as 
shown in section 3.2. The degree of non-specific binding (nsb) occurring at each 
concentration of radiolabelled drug was determined by adding an excess of an unrelated 
drug, which also displays selectivity and high affinity for P-gp. Specific [3H]-vinblastine 
binding was determined by subtracting binding measured in the presence of lOpM 
unlabelled verapamil from total [3H]-vinblastine bound. Figure 3.5 is a representative 
plot depicting specific, total and nsb [3H]-vinblastine binding to P-gp containing 
membrane vesicles as a function of free [3H]-vinblastine concentration. Specific binding 
was fitted using the Langmuir adsorption isotherm. From this equation the maximal 
[3HÎ-vinblastine bound or Bmax, was estimated at 95pmol mg'1 membrane protein and the 
dissociation constant, Kd, a measure of binding affinity, was 20nM. There was a linear 
relationship between the degree of non-specific binding occurring and the concentration 
of free radioligand. The nsb component of [3H]-vinblastine binding to CHrB30 
membranes never exceeded 25% of total binding measured, and total binding was <15% 
of radioligand added. Therefore, specific binding of [3H]-vinblastine to CFfB30 
membranes comprised at least 75% of the total radiolabel bound. The effect of receptor 
concentration on [3H]-vinblastine (50nM) binding was determined by varying the amount 
of C H % 0  membranes added (5-40pg). Figure 3.6 shows specific [3H]-vinblastine 
binding as a function of the amount of membrane protein.
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Figure 3.5 Saturation binding isotherm for binding of [3H]-vinblastine to CHT*30 membrane vesicles. 
Membranes (8pg) were incubated with [^H]-vinblastine (l-120nM) over 2 hour period at 22°C. Non­
specific binding was determined in the presence of lOpM unlabelled verapamil. A representative 
saturation binding isotherm is shown illustrating total, specific and nsb -vinblastine binding as a 
function of free radioligand concentration. Values for maximal binding capacity (Bmax) and potency of 
interaction (Kd) were derived as described in methods.
The specific binding of [3H]-vinblastine was linear up to 20pg, illustrating that there is 
no excessive depletion of the free ligand occurring within this range of membrane 
protein. As illustrated in the inset to figure 3.6, when the amount of receptor added was 
in excess of 20pg, total binding measured represented > 20% depletion of added 
radioligand. This reduction in the concentration of free radioligand caused a loss of 
linearity of binding, at higher amounts of receptor. All future binding experiments with 
[3H]-vinblastine were conducted with < 15pg CHrB30 membrane vesicles.
By conducting a series of [3H]-vinblastine binding assays the mean value for the Bmax of 
binding was 93 + 10 pmol mg'1 membrane protein with IQ = 21 + 5nM (n=4).
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Figure 3.6 Effect of protein concentration on specific [3H]-vinblastine binding to CHrB30 
membrane vesicles. Membrane vesicles (5-40pg) were incubated with [^H]-vinblastine (50nM) for 2 
hours at 22°C. Non-specific binding was determined in the presence of lOpM unlabellcd verapamil. 
Inset % depletion of radioligand added as a function of membrane protein.
3.4.2 Kinetics of [3H]-vinblastine interaction with CHrB30 membrane vesicles
The previous section has been concerned with measuring the binding of [3H]-vinblastine 
to P-gp containing membrane vesicles at equilibrium. The kinetics of drug-P-gp 
interaction were also studied in order to provide information concerning the onset and 
duration of drug action. The off-rate for [3H]-vinblastine from its binding site was 
determined by labelling CH^B30 membrane vesicles with 20-3OnM [3H]-vinblastine until 
equilibrium was attained, following which the association reaction for [3H]-vinblastine 
was blocked by the addition of 100-fold excess unlabelled vinblastine. The unlabelled 
vinblastine competed with [3H]-vinblastine for binding to P-gp, and the reduction in 
[3H]-vinblastine binding observed provides a measure of vinblastine dissociation. In 
figure 3.7 the natural logarithm of the proportion of [3H]-vinblastine remaining as a 
function of time is shown. The linear logarithmic plot demonstrates that dissociation of
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[3H]-vinblastme from its binding site is monophasic suggesting that the dissociation is 
from a single class of site. The dissociation rate constant (k_i) was obtained from the 
slope of the relationship and a mean value for k_i of 0.027 + 0.001 min '1 was obtained 
from at least three independent experiments (refer to table 3.1).
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Figure 3.7 Measurement of the dissociation rate constant for [^H]-vinblastine binding to CHD30 
membrane vesicles. CHrB30 membrane vesicles (8|ig) were incubated with [^-vinblastine (20- 
30nM) and allowed to bind to equilibrium over 2hrs at 22°C. Association was blocked by adding 
3pM unlabelled vinblastine and dissociation of [^H]-vinblastine measured over 40 minutes at 22°C. 
Bt is binding remaining at time t and Beq represents amount bound at equilibrium prior to 
dissociation. Dissociation rate constant determined as described in methods. Data plotted represent 
the mean + s.e.m. of at least three independent experiments.
The rate of onset or the association rate for the formation of the P-gp-[3H]-vinblastine 
complex, was measured by allowing a range of concentrations of [3H]-vinblastine to 
associate with P-gp for various periods of time. The amount of [3H]-vinblastine 
specifically bound (nM), was plotted as a function of time as shown in figure 3.8. Using 
equation 2.13, a value for Kobs was obtained for the data shown in figure 3.8 that defines 
the rate of association of [3H]-vinblastine with P-gp. However, Kobs is defined by the 
following relationship K obs = kx [L] + k_x (equation 2.14) and is therefore a function of
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the sum of the association and dissociation rate constants and the concentration of ligand 
used. Therefore, values for Kobs were measured at different concentrations of [3H]- 
vinblastine to determine the association rate constant for [3H]-vinblastine binding using 
the above relationship. The experimentally determined value for k_i (see above) was 
used to determine the association rate constant, for [3H]-vinblastine binding. A mean 
value for k% of 0.00048 ± 0.00013 (nM-1 min'1) (n>4) was obtained for [3H]-vinblastine 
binding (summarised in table 3.1)
•a
it
i 1a
3
2
1
0
50 75 100 125 150
time (minutes)
Figure 3.8 To determine the K*b: for the binding of -vinblastine to CHD30 membrane vesicles. 
Membrane vesicles (8pg) were incubated with -vinblastine (17nM) over the time period shown. 
Data was plotted using an exponential function and value for derived as described in methods.
3.5 Radioligand binding assay to measure the binding of [^-paclitaxel to P-gp 
containing membrane vesicles.
Paclitaxel is a natural product cytotoxic drug and has been shown to be transported by P- 
gp resistant cells (section 3.2). A radioligand binding assay based on that used to 
measure [3H]-vinblastine binding was established to directly assess the affinity of [3H]- 
paclitaxel binding to P-gp. Membrane vesicles (20pg) were incubated with a broad 
range of [3H]-paclitaxel concentrations (10-600nM) and the nsb component was
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measured in the presence of an excess of unlabelled vinblastine (lOjiM). Higher 
amounts of membrane vesicles were used in the binding assays for [3H]-pachtaxel 
compared to assays of [3H]-vinblastine, in order to reproducibly obtain high levels of 
binding. The specific binding of [3H]-pachtaxel was saturable with respect to free 
radioligand concentration, as illustrated in figure 3.9. The Bmax for [3H]-pachtaxel 
binding was 25 pmol mg"1 membrane protein with a Kd value of 85nM, as determined 
using the Langmuir adsorption isotherm. There was no specific binding of radioligand to 
membranes produced from the parental AuxBl cell line, suggesting that binding 
measured in CH'BSO membranes was due to the presence of P-gp (data not shown). 
What is apparent from figure 3.9 is that the nsb binding component of [3H]-paclitaxel 
constitutes more than 50% of the total binding to CHrB30 membranes. However, there 
was no significant depletion of free radioligand concentration (< 5%) by total binding of 
ligand to membrane vesicles.
The effect of varying the amount of receptor (P-gp containing membranes) added to the 
binding assay was investigated to see if this had any effect on the amount of specific 
[3H]-paclitaxel binding measured. As shown in figure 3.10 specific binding of [3H]- 
paclitaxel was linear with up to lOOpg membrane protein indicating that binding can be 
measured over a wide range of protein concentration without affecting the reaction 
kinetics. By conducting a series of radioligand binding assays the specific binding of 
[3H]-paclitaxel to CHrB30 membranes was characterised by a mean value for Bmax of 
binding of 26 ± 4 pmol mg"1 (n=3) and Kd of 102 + 17nM (n=3). This agrees with the 
studies of Woodhouse (155) who report values for Bmax and Kd for binding of [3H]-
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Figure 3.9 Saturation binding isotherm for ["hE]-paclitaxel interaction with CH B30 membrane 
vesicles. Membranes (20pg) were incubated with [^H]-paclitaxel (l-600nM) for 2 hours at room 
temperature. Non-specific binding was measured in the presence of lOpM unlabelled vinblastine. A 
representative binding isotherm is shown with total, specific and non specific binding as a function of 
free radioligand. Values for Bm» and Kd were derived as described in methods. .
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Figure 3.10 Effect of amount of CH'BSO membrane protein on [3H]-paclitaxel binding. [3H]- 
paclitaxel (lOOnM) was incubated with membrane vesicles (l-100pg) for two hours at 22°C. Non­
specific binding was measured in the presence of lOpM unlabelled vinblastine.
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paclitaxel of 48 + 5 pmol mg'1 and 81 + 25nM respectively. The binding of [3H]- 
paclitaxel to P-gp displays 3-4-fold lower affinity than [3H]-vinblastine binding. 
Unfortunately, it was not possible to extend the radioligand binding studies to investigate 
the binding kinetics of [3H]-paclitaxel because of the relatively low levels of specific 
[3H]-paclitaxel binding measured in CHrB30 membranes (see figure 3.9).
3.6 Radioligand binding assay to assess interaction of [^-XRPSTb with P-gp 
containing CBFBSO membrane vesicles.
XR9576 is an anthranilic acid derivative and was generated from a chemical screening
programme to identify novel but selective modulators of P-gp action as reviewed in the 
introduction to this thesis (1.3.2). It has been established in sections 3.2 and 3.3 that 
XR9576 can potently inhibit transport and ATPase activities of P-gp. However, there 
was little knowledge concerning the affinity of its interaction with P-gp. A radioligand 
binding assay was developed to directly and quantitatively measure the interaction of 
XR9576 with P-gp containing membrane vesicles.
Initially, membrane vesicles (lOpg) were incubated with a broad range of [3H]-XR9576 
concentrations (l-60nM) and the non-specific binding component measured in the 
presence of IpM GF120918 at each concentration of radioligand. Specific, total and 
non-specific binding of [3H]-XR9576 were plotted as a function of free [3H]-XR9576 
concentration and curve-fitting performed using the Langmuir adsorption isotherm 
(figure 3.11).
It was possible to measure specific binding of [3H]-XR9567 to CHrB30 membrane 
vesicles whilst there was no binding of this compound to membranes from the parental 
drug sensitive AuxBl cells (data not shown). Upon examination of all of the 
components of [3H]-XR9576 binding to CHrB30 membranes, it was found that there
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Figure 3.11 Interaction of [*H]-XR9576 with CH B30 membrane vesicles. Membranes.(lOpg) were 
incubated with a range of concentrations of [3H]-XR9576 (l-60nM) for three hours at 22°C. Non­
specific binding was determined in the presence of IpM unlabelled GF120918. Binding is plotted as 
a function of free radioligand concentration. Values for and Ky were derived as described in 
methods. Inset: nsb component of binding is shown as a function of free radioligand concentration.
was a loss in linearity of the non-specific binding component at concentrations of 
radioligand > 7-1 OnM, as shown in the inset to figure 3.11. There was also significant 
depletion of radioligand (up to 60%) for concentrations up to lOnM. Such a reduction in 
the concentration of free drug available will alter the kinetics of drug-receptor 
interaction. The loss in linearity of the nsb component and the reduction in the amount 
of free radiolabel available for binding, suggested that the amount of receptor in the 
assay system may be excessive. Therefore, the effect of varying the amount of 
membrane protein on [3H]-XR9576 binding was investigated as shown in figure 3.12.
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Figure 3.12 Effect of protein concentration on the specific binding of [^H]-XR9576. Membrane 
vesicles (l-20pg) were incubated with 50nM [3H]-XR9576 for three hours at 22°C. Specific binding 
is plotted as a function of protein.
Specific binding was linear up to lOpg of membrane protein added, and all future 
binding experiments with [3H]-XR9576 were conducted using 2pg of membrane protein.
[3H]-XR9576 binding was then measured using 2p,g membrane protein per assay tube in 
the concentration range 0.5-50nM. Using the Langmuir adsorption isotherm, the Bmax for 
[3H]-XR9576 binding was calculated to be 350pmol mg*1 and the K<i value for binding 
was 3nM using the representative data shown in figure 3.13. The nsb component was 
linear and did not exceed 10% of total [3H] XR9576 bound. By conducting a series of 
radioligand binding studies, mean values for Bmax and Kd of 275 ±15  pmol mg*1 and 5.1 
+ 0.9 nM (n=7) respectively were determined for binding of [3H]-XR9576 to CHrB30 
membranes. The low value for Kd indicated that this modulator interacts with P-gp with 
high affinity displaying 4-fold and 20-fold higher affinity of binding than [3H]- 
vinblastine and [3H]-paclitaxel respectively.
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Figure 3.13 Saturation binding isotherm for ^H]-XR9576 binding to CH B30 membrane vesicles. 
Membrane vesicles (2pg) were labelled with [3Bn-XR9576 (0.5-50nM) for three hours at 22°C. Non­
specific binding was determined in the presence of IpM unlabelled GF120918. Specific, total and 
non-specific components of binding are shown. 8 ^» and Kd were obtained as described in methods.
3.6.1 Kinetics of [3H]-XR9576 binding to CHrB30 membrane vesicles
Dissociation of the [3H]-XR9576-P-gp complex was followed over time to assess the
duration of action of this modulator with P-gp. Membrane vesicles (2pg) were allowed 
to equilibrate with 12nM [3H]-XR9576 in the dark for at least three hours. The 
association reaction was stopped by the addition of IpM  unlabelled XR9576 and a 
monophasic linear plot relating fraction of [3H]-XR9576-P-gp complex remaining over 
time was produced (figure 3.14). The dissociation rate constant (k.i) of 0.0166 ± 0.0004 
min'1 was derived from the slope of this relationship. This corresponds to a half-life of 
42 minutes for [3H]-XR9576 dissociation as compared to Xm = 26 minutes for [3H]- 
vmblastme.
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Figure 3.14 Measurement of the dissociation rate constant for binding of [3H]-XR9576 to CHT130 
membrane vesicles. Membrane vesicles (2pg) were incubated with [3H]-XR9576 (12nM) and allowed 
to bind to equilibrium over 3 hrs at room temperature. The association reaction was blocked by the 
addition of IpM unlabelled XR9576 at timed intervals. Bt is binding remaining at time t and Beq 
represents amount bound at equilibrium prior to dissociation. Dissociation rate constant (k_i) was 
derived as described in methods. Data are the mean + s.e.m. of at least three independent 
experiments.
The rate of formation of the [3H]-XR9576-P-gp complex was measured by allowing 
varying concentrations of [3H]-XR9576 (7-60nM) to associate with membrane vesicles 
(2p,g) over time. The rate constant, or Kobs, for association of each concentration of [3H]r 
XR9576 with P-gp, was derived from plots of specific [3H]-XR9576 bound (nM) as a 
function of time (an example is shown in figure 3.15). Equation 2.13 was used to derive 
a value for Kobs- The value for Kobs is dependent upon the concentration of radioligand 
and is not strictly a measure of the association rate constant (Iq). The lq for [3H]- 
XR9576 association with CHrB30 membranes was derived from equation 2.14, where 
Kobs is expressed as a function of ligand concentration and the on and off rate for ligand 
interaction.
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Figure 3.15 Measurement of Kobs for [3H]-XR9576 association with CH B30 membrane vesicles. 
Membrane vesicles (2pg) were incubated with [3H]-XR9576 (40nM) at 22°C over the time period 
indicated. Value for Kobs was derived as described in methods.
The experimentally derived value for k_i (see above) was used to determine k%. The rate 
constant for [3H]-XR9576 association was 0.00421 + 0.00043 nM'1 min'1 (mean value + 
s.e.m. from at least 7 independent experiments) see table 3.1. This is approximately 10- 
fold greater than the rate measured for [3H]-vinblastine association. From these kinetic 
studies it was found that the modulator XR9576 displays a faster rate of onset, and longer 
duration of interaction with P-gp, by comparison with the cytotoxic agent vinblastine. 
Interestingly, the Kd for interaction of drug with its receptor is a function of k_i/ki. Using 
the values for k_i and ki measured in [3H]-XR9576 and [3H]-vinblastine kinetic assays, 
Kd values of 3.9 and 56nM respectively were obtained for these radioligands. These 
correlate well with the values obtained in equilibrium binding assays reported earlier in 
this chapter.
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Table 3.1 Kinetics of [3H]-XR9576 and [^H]-vinblastine binding to P-gp in CHrB30 
membranes.
Ligand Association rate 
constant
Dissociation rate 
constant
ki (nM-1 min'1) k_i (min'1)
[^-vinblastine 0.00048 ±0.00013 0.027 ±0.001
(n = 3) (n = 3)
[3H]-XR9576 0.00421 +0.00043 0.0166 ±0.0004
(n = 7) (n = 4)
P <0.05 <0.05
The association (ki) and dissociation (k_i) rate constants for binding of [3H]-XR9576 and [3H]- 
vinblastine to CH'BSO membrane vesicles were measured at room temperature as described in 
methods. All values represent means + s.e.m. for the number of observations indicated. P values 
obtained from Student’s t test comparing [3H]-XR9576 with [?H]-vinblastine (Published in Martin et 
a l, (84))
3.7 Displacement equilibrium binding assays to investigate relative affinities of 
ligand interaction with P-gp
As stated in the introduction to this thesis a distinctive feature of P-gp function is its
broad substrate specificity, whereby it interacts with a myriad of chemically and
functionally distinct compounds. This feature was evident during the course of refining
and establishing radioligand binding assays to investigate the binding parameters of the
anticancer drugs [3H]-vinblastine and [3H]-paclitaxel and the resistance modulator [3H]-
XR9576. In this section, I shall present data on the ability of a range of P-gp ligands to
displace binding of radiolabelled drug. This provides evidence for (i) a direct interaction
of drug with P-gp (ii) an indication of the potency of drug interaction particularly where
drugs are not available in radiolabelled form. Radioligand binding assays of this type are
a first step towards direct investigation of drug:drug interactions on P-gp.
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The assays involve labelling of CHrB30 membrane vesicles with a single concentration * 
of radiolabelled drug in the presence of increasing concentrations of ‘antagonist’ 
(generally 10'9 to 3.10'4M). The amount of radioligand chosen was usually the Kd 
concentration. Essentially, an important criterion was to ensure that a concentration was 
chosen whereby the level of specific binding was sufficient to provide adequate 
displaceable counts, so that drug effects could be detected. Membrane vesicles (2pg, 
8pg, 20pg respectively) were bound to equilibrium with [3H]-XR9576 (12nM), [3H]- 
vinblastine (30nM) and [3H]-paclitaxel (lOOnM) respectively, in the presence of 
displacing drug for a 2-3 hour period at room temperature. The fraction of specific 
radioligand bound as a function of ‘antagonist’ concentration was plotted using the 
general dose-response equation (2.10). Displacement equilibrium binding curves were 
obtained for each radioligand as shown in figure 3.16(a-c). Information concerning the 
extent of radioligand displaced and the IC50 of the displacing agent were obtained from 
these curves. The IC50 for displacing agent is a measure of the ability of drug to displace 
50% of specific binding observed in the absence of antagonist, and also provides an 
index of the potency of displacing agent. However, this value is not a constant and is 
dependent upon the concentration of radioligand used in the binding assay. The IC50 can 
be converted to a K* value or inhibition constant using the Cheng-Prusoff transformation 
as described in methods (chapter 2 section 2.2.4). The value of Kj for antagonist may be 
equated to the antagonist affinity constant only if  the interaction with antagonist and 
radioligand is competitive in nature. Data obtained from displacement curves are 
summarised in table 3.2.
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Figure 3.16 Drug displacement of equilibrium binding of [^-paclitaxel, [3H]-XR9576 and [3H]- 
vinblastine to CHrB30 membrane vesicles, (a) Membrane vesicles (2 0 [ig) were labelled with [3H]- 
paclitaxel (lOOnM) in the presence of displacing agent (10'16M to 10' 5 M) for 2hrs at room 
temperature, (b) [3H]-XR9576 (12nM) was used to label CHrB30 membrane vesicles (2pg) to 
equilibrium for 3 hrs at 22°C in the presence of displacing agent over the concentration range 
indicated, (c) Membrane vesicles (8 pg) were labelled with fH]-vinblastine (20-30nM) for 2 hrs at 
room temperature in the presence of increasing concentrations of displacing agent as shown. All 
values represent the mean + s.e.m. of at least four independent experiments.
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Most of the drugs examined were able to displace at least 85% of the specifically boutid 
radioligand. The transport substrate paclitaxel could only displace 18% of bound [3H]- 
XR9576 with an estimated Kj value of 1640 + 270nM. However, these values are 
estimates only as higher concentrations of paclitaxel could not be used to extend the 
displacement curve due to precipitation of solutions of paclitaxel at concentrations in 
excess of ImM. Nonetheless, this value deviates significantly from the experimentally 
derived Kd for [3H]-paclitaxel binding of lOOnM. The fractional displacement and 
different affinities suggest that these drugs are not interacting at the same site on P-gp. 
The Kj (1250 ± 510nM) obtained for displacement of [3H]-XR9576 binding by 
vinblastine which is also a transport ligand for P-gp, also differed from its measured Kd 
(25nM) and vinblastine was also only able to exert fractional displacement of XR9576 
binding (70%). However, as was the case with paclitaxel, these values are estimated 
values due to limitations on the concentration of vinblastine used in the [3H]-XR9576 
displacement assays.
The P-gp modulators XR9576, XR9051 and GF120918 were all able to displace at least 
90% of bound [3H]-vinblastine, [3H]-paclitaxel and [3H]-XR9576 and the Kj values for 
this antagonism were all in the low nM range (<20nM), indicating that these agents have 
high affinity interaction with P-gp. Such high affinity interaction has facilitated the use 
of these modulators in clinical trials for MDR reversal (see introduction 1.3.2). The 1,4,- 
dihydropyridine nicardipine, which is also modulatory in function, displaced most of the 
bound [3H]-paclitaxel and [3H]-vinblastine with Kj value in the low nM range. However, 
the potency with which nicardipine displaced the binding of [3H]-XR9576 was shown by 
a Kj value of 885 + 52nM. It is difficult to reconcile the different values for Kj observed 
for nicardipine with competitive interaction with displaced drug, as the Kd for binding of 
nicardipine with P-gp is not known. However, differences observed in the value for Kj to
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displace radiolabelled drug may be indicative of non-competitive interactions between 
different pairs of drugs for binding to P-gp.
Table 3.2 The relative affinities of drug interaction with P-gp in CHrB30 
membrane vesicles.
pH]-XR9576 [3BQ-paclitaxel [3H]-vinblastine
Displacing
agent
Fraction
displaced
IC50
(nM)
K,
(nM)
Fraction
displaced
IC50
(nM)
K,
(nM)
Fraction
displaced
IC50
(nM)
K.
(nM)
Vinblastine 0.7+0.1 7120+281 1250+510 0.77+0.13 28.5+6.4 199+7.5 — — —
Paclitaxel 0.18±0.02 5310+110 1640±270 — — — 0.9+0.05 486+59 335+6
Nicardipine 0.88+0.05 5120+88 885+52 0.92+0.04 HO+4O 10.8+1.4 0.99+0.01 Î72+2Î 82+9
XR9576 — — — 0.86+0.07 7.1+0.6 4.2+Î.4 1 .0 4.4+O.9 2 .6+0 .8
GF120918 0.93+0.02 8.5+0.75 Î.5+O.2 O.94+O.O3 7.Î+4.3 2.5+O.2 0.99+0.07 5.4+O.7 1.4+0.4
XR9051 0.91+0.03 29+ÎO 11+4.2 O.86+O.O4 2 Î+2 .8 10.6+1.4 1 3.6+O.6 Î.8+O.3
Displacement drug equilibrium binding studies were used to look at the ability of various substrates 
and modulators to displace the binding of [3H]-XR9576 (12nM), [^J-paclitaxel (lOOnM) and 
vinblastine (20-30nM) from CH B30 membrane vesicles. ICso values for antagonist activity were 
obtained from displacement binding curves (see figure 3.16). K, values were derived from the IC50 
values as described in methods. The extent of [^ET]-ligand displacement has also been shown. The 
data represent the means + s.e.m. of 3-5 independent experiments. (Published in Martin et al., (84))
3.8 Summary
1. P-gp over-expressing CHrB30 cells transport the cytotoxic drugs vinblastine and 
paclitaxel as shown by the accumulation deficit of these drugs in a whole cell 
assay.
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2. The transport of vinblastine and paclitaxel by P-gp was inhibited in the presence 
of the modulatory compounds XR9576 and GF120918, in the sub-micromolar 
range. This is in contrast to the relatively low efficacy of the modulatory 
compound verapamil, which is only able to effectively block vinblastine transport 
at micromolar concentrations (Martin et al., (82)).
3. The mechanism by which XR9576 modulated the transport activity of P-gp was 
shown to be due to inhibition of ATP hydrolysis.
4. Steady-state accumulation assays showed that XR9576 is not a transport ligand 
for P-gp.
5. Radioligand binding assays provided a direct measurement of ligand interaction 
with P-gp. The affinity of the cytotoxic agents [3H]-vinblastine and [3H]- 
paclitaxel to bind to P-gp was described by Kd values of 21 + 3.2nM (n=4) and 
102 + 17nM (n=3) respectively. The third generation reversal agent [3H]- 
XR9576 displayed higher affinity binding for P-gp with a Kd for binding of 5 + 
0.9nM (n=7). The amount of drug specifically bound to P-gp containing 
membranes also varied. The Bmax for [3H]-XR9576 binding was 275 + 15pmol 
mg'1 (n=7) membrane protein. This is higher than the values for Bmax obtained 
for binding of [3HJ-vmblastme and [3H]-paclitaxel, 93 ± lOpmol m g 1 (n=4) and 
26 + 4 pmol mg"1 (n=3) respectively.
6. Study of the binding kinetics of [3H]-vinblastine and [3H]-XR9576 showed that 
XR9576 has a faster rate of onset (10-fold) and slower rate of dissociation than
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vinblastine, and this is probably reflected in the higher affinity of XR9576 for P- 
gp, since IQ is a function of off and on rates for binding.
7. The displacement equihbrium binding studies have provided an initial insight into 
drug:drug interactions on P-gp. The results of these studies reveal that binding of 
drug X can affect the binding of drug Y, but the nature of this effect was not 
determined. However, discrepancies observed in K; values indicates that not all 
drug:drug interactions with P-gp are competitive.
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Chapter 4 Communication between drug binding sites on P-gp
4.1 Introduction
The preceding chapter was concerned with characterising the interaction of drug with P- 
gp in terms of binding kinetics, the affinity and capacity of drug interaction sites and the 
ability of ligands to displace drug binding. The consequence of drug interaction on P-gp 
function was investigated by examining the drug efflux and ATP hydrolytic activities. 
As outlined in chapter 1 (section 1.8.1) the apparent lack of ligand specificity displayed 
by P-gp arises because of the presence of multiple drug binding sites. However, there is 
no information concerning the number of sites, their location within the TMDs or the 
nature of the communication that may exist between binding sites. Are there distinct 
sites for drugs that are transported by P-gp and those that are purely inhibitory? The 
focus of this chapter is to investigate drug interactions with and between drugs on P-gp in 
order to address some of these issues.
4.2 Effects of XR9576, XR9051, GF120918 and nicardipine on the equilibrium and 
kinetic binding of [^H]-vinblastine.
The first stage of our investigation into drug:drug interactions on P-gp was to conduct a 
more indepth analysis of [3H]-vinblastine binding in the presence of known inhibitors of 
P-gp transport activity. As mentioned earlier, drugs that interact with P-gp can be 
broadly classified as either modulators of, or ligands for, the transport activity of P-gp. 
Previous studies have shown that XR9576, XR9051 and GF 120918 can inhibit P-gp 
transport function through a mechanism other than direct competition for transport (22, 
57, 84). The other inhibitor used was the 1,4,-dihydropyridine nicardipine, but it is not 
known whether it is transported by P-gp or not.
To fully assess interaction between [3H]-vinblastine and modulatory compounds on P-gp, 
complete saturation isotherms for [3H]-vinblastine binding were measured in the
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presence of several different concentrations of added modulator (10 * to 10"^M). 
Equilibrium binding isotherms for [3H]-vinblastine were plotted for each concentration 
of modulator added and the individual Bmax values determined. In figure 4.1 a 
representative plot is shown illustrating saturating [3H]-vinblastine binding dose- 
response curves at different concentrations of nicardipine (only three concentrations are 
shown for clarity). The reduction in the Bmax for [3H]-vinblastine binding was dependent 
upon the concentration of modulator used. In fact there was a dose-dependent decrease 
in the Bmax for [3H]-vinblastine binding in the presence of each modulator. In order to 
determine the potency of modulator to elicit a reduction in the
Nicardipine 
log (M)
75-
.5 ■ -6.52
w  ™-gif
I I 25"
-6.5-9.5 -8.5 -7.5
log [3H]-vinblastine (M)
Figure 4.1 Effect of nicardipine on the binding of [3H]-vinbIastine. Dose-response curves for 
vinblastine (l-100nM) binding to CH^B30 membrane vesicles (8 pg) were measured in the presence oj ' 
different concentrations of nicardipine. Values for Bm» and Kd were determined from dose-responsc 
equation as described in methods.
Bmax for [3H]-vinblastine binding, secondary plots of the type of data shown in figure 4.1 
were produced. The value for Bmax of [3H]-vinblastine binding determined in the 
presence of modulator was expressed as a fraction of that in the absence of modulator,
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and plotted as a function of modulator concentration (figure 4.2 (a)-(d)). Figure 4.2(a) 
demonstrates that nicardipine reduced the Bmax for [3H]-vinblastine binding to less than 
5% of that observed in the absence of nicardipine with EC50 = 459nM + 12nM (n=3). 
The modulators XR9576 (EC50 = 11.8 + 0.3nM (n=3)), XR9051 (EC50 = 19.2 ± 0.4nM 
(n=3)) and GF120918 (EC50 = 11.2 + 0.2nM (n=3)) had a similar effect on Bmax but 
displayed higher potency of action than nicardipine. The affinity or the Kd for [3H]- 
vinblastine binding was not altered in the presence of any of the modulatory compounds 
investigated. The fact that binding of modulator resulted in a reduction in the Bmax for 
[3H]-vinblastine binding, but had no effect on the Kd of binding, is indicative that these 
agents are interacting non-competitively. Therefore, it can be concluded that the reversal 
agents tested are interacting at a site(s) distinct from the site of interaction for [3H]- 
vinblastine. The most likely method by which modulator can diminish vinblastine 
binding is via an allosteric effect. To corroborate the existence of an allosteric 
interaction between binding sites, the effect of modulator on the dissociation kinetics of 
[3H]-vinblastine was investigated.
As discussed in methods the rate of dissociation of a drug from its binding site can only 
be altered by a second unrelated drug through an allosteric mechanism. Therefore, the 
dissociation kinetics of [3H]-vinblastine was measured in the presence and absence of up 
to a 100-fold excess of modulatory compound (chapter2, 2.3.2). The effect of 
nicardipine on the rate of dissociation of [3H]-vinblastine is illustrated in figure 4.3 (a). 
A logarithmic plot of the amount of [3H]-vinblastine remaining bound at time t (Bt), as a
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fraction of amount bound at equilibrium (Bcq), was plotted as a function of time. 
Monophasic plots for vinblastine dissociation were produced and the dissociation rate 
constant derived from the slope of the relationships in figure 4.3(a). The presence of 
nicardipine elicited a dose-dependent increase in the rate of dissociation of [3H]- 
vinblastine from its binding site. This reduced accessibility of [3H]-vinblastine to its site 
is indicative of a negative heterotropic effect induced by binding of nicardipine. To 
quantitate the allosteric potency of modulator, the mean value for k_i measured at each 
concentration of modulator was plotted as a function of modulator concentration (figure 
4.3(b)). By conducting non-linear regression of the data in figure 4.3 (b), (i) the potency 
or EC50 for nicardipine to increase k_i and (ii) the maximal k_% in the presence of 
nicardipine were derived. The maximal value for k_i of [3H]-vinblastine binding in the 
presence of nicardipine was compared to the value for k_i measured in the presence of 
unlabelled vinblastine, to quantify fold increase in the dissociation rate constant due to 
modulator. The dissociation rate constant for [3H]-vinblastine binding, as determined by 
following dissociation in the presence of 3pM unlabelled vinblastine, was 0.093 minute'1. 
From figure 4.3(b) the dissociation rate constant was found to be maximally increased to 
0.452 min"1 in the presence of nicardipine, representing a 4.9-fold increase in the rate of 
dissociation of [3H]-vinblastine from its binding site. The potency of the allosteric effect 
of nicardipine was described by an EC50 value of 1.2 pM. This value is similar to the 
efficacy of nicardipine (0.459 + 0.012pM) to reduce the Bmax for [3H]-vinblastine 
demonstrated earlier. Indeed all of the modulatory agents investigated caused a dose- 
dependent increase in the dissociation rate constant for [3H]-vinblastine binding. The 
allosteric potencies for modulator and the maximal change in the dissociation rate 
constant for [3H]-vinblastine were determined as described for nicardipine and are 
summarised in table 4.1.
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Figure 4.3 Effect of modulator on the dissociation rate constant for [^H]-vinblastine binding, (a) 
Dissociation rate constant for [^H]-vinblastine binding was measured in the absence and presence of 
increasing concentrations of nicardipine. A representative plot is shown depicting the logarithm of 
the fraction of [^ H] -vinblastine-Pgp complex remaining as a function of time. Dissociation rate 
constants (k_i) were determined from the slope of the relationship, (b) The allosteric potency to 
affect f3!!]-vinblastine dissociation rate was determined by plotting k_i values as a function of 
nicardipine concentration. Values represent the mean + s.e.m. of at least four independent 
experiments.
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The third generation modulators XR9576, GF 120918 and XR9051 all increased the 
dissociation rate constant for [3H]-vinblastine binding several fold as shown. However, 
the efficacy of these agents to increase the k_i for [3H]-vinblastine were up to 40-fold less 
than their EC50 values to reduce the Bmax for [3H]-vinblastine binding. This most likely 
reflects a difference in the experiments conducted. In order to follow dissociation 
kinetics of [3H]-vinblastine, unlabelled vinblastine must be added in a large molar excess 
to compete effectively with radiolabelled drug to stop the association reaction. In order 
to ascertain the effect of a second unrelated drug on the dissociation rate, it too needs to 
be in a large molar excess.
Table 4.1 Effect of modulators on the dissociation kinetics of [^-vinblastine.
Drug
(n>3)
Maximal rate (k_i) 
(min.1)
Fold change Potency
(UM)
Vinblastine 0.093 N/A N/A
XR9576 0.493 5.3 0.46
GF120918 0.293 3.2 0.17
Nicardipine 0.452 4.9 1.2
XR9051 0.370 4 0.29
The effect of drug on the dissociation rate constant (k_i) for [^H]-vinblastine binding was measured 
as described in methods. The dissociation rate constants were determined at a number of drug 
concentrations and the maximal rate constant was estimated from non-linear regression of the 
general dose response equation. The potency of each drug to increase the dissociation rate constant 
is shown as an EC50 value.
In summary, two different assays have been used to look at how modulatory drugs 
interact with the transport ligand vinblastine on P-gp. It was found that each modulator 
was able to abrogate Bmax for [3H]-vinblastine binding in the absence of any alteration in 
the affinity (Kd) of binding. This finding strongly suggested that the modulatory agents 
used were interacting at a site distinct from the vinblastine site. The mechanism by
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which they affected vinblastine binding was thought to involve conformational alteration 
of the vinblastine drug binding site. The effect of modulator on the dissociation rate 
constant for vinblastine was used to corroborate such an allosteric interaction. All of the 
modulators caused between a 3- to 5-fold increase in the k_i for vinblastine, providing 
definitive proof that the modulatory compounds were interacting at a distinct but 
allosterically linked site(s) from that of vinblastine.
4.3 [3H]-vinblastine binding parameters assessed in the presence of Paclitaxel, 
Hoechst 33342 and Rhodamine 123
In the preceding section it was shown that a range of different classes of modulatory 
agent interacted with the [3H]-vinblastine site non-competitively, suggesting distinct sites 
of action for vinblastine and modulator. How then do compounds that are substrates for 
transport by P-gp interact with the vinblastine binding site? Is there a common site on P- 
gp for transport? The drugs paclitaxel, Hoechst 33342 and Rhodamine 123, have 
previously been shown to be transported by P-gp, and are not used as modulators of P-gp 
function. It is on this basis that they are referred to as transport ligands for P-gp in order 
to distinguish them from compounds that play a purely modulatory role.
To assess how drugs that are transport ligands for P-gp interact with each other for 
binding to P-gp, a series of [3H]-vinblastine equilibrium binding assays were carried out 
in the presence of different concentrations of transport ligand, and the effect on the Bmax 
and Kd of binding was determined. From the saturation isotherms obtained, the Bmax for 
[3H]-vinblastine binding at different concentrations of added drug was determined. As in 
section 4.2, this information was used to construct secondary plots of the binding data to 
relate fractional alteration in the Bmax for [3H]-vinblastine binding as a function of
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Figure 4.4 Effect of transport ligands on [3H]-viblastine binding in CH^B30 membrane vesicles. 
The effects of (a) paclitaxel, (b) rhodamine 123 and (c) Hoechst 33342 on the Bm» for [^ H]- 
vinblàstine binding were determined. Data are presented as the fractional reduction in Bm,, as a 
function of antagonist concentration. Values represent the mean + s.e.m. of at least three 
independent experiments.
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transport ligand concentration. As shown in figure 4.4 (a to c), all of the transport 
substrates investigated abrogated the Bmax for [3H]-vinblastine binding in a similar dose- 
dependent fashion to the modulatory compounds. The potency or EC50 value of drug to 
reduce the maximal binding capacity for [3H]-vinblastine was similar for all three of the 
transport ligands examined (paclitaxel EC50 = 4.8 + 0.1 pM (n=3); rhodamine 123 EC50 = 
9.0 + 0.4pM (n=3); Hoechst 33342 EC50 = 1.26 ± 0.01 pM (n=3)). On close examination 
of the relationship depicting the reduction in the Bmax for [3H]-vinblastine as a function of 
Hoechst 33342 concentration (figure 4.4(c), a slope factor of 3 for this relationship was 
measured. This deviation in the slope of the dose-response curve from a value of one 
suggests that vinblastine and Hoechst 33342 are interacting co-operatively with P-gp. It 
may indicate that Hoechst 33342 is interacting at more than one site. This is in contrast 
to a slope factor of 1 which best described the relationships for paclitaxel and 
rhodamine 123 (F test , PO.Ol). There was no observed effect of any of the transport 
ligands on the affinity (Kd) of [3H]-vinblastine binding. Since there was a reduction in 
the maximal binding capacity for [3H]-vinblastine by transport ligand in the absence of 
an alteration in the Kd for binding, it was concluded that paclitaxel, Rhodamine 123 and 
Hoechst 33342 are interacting non-competitively with the vinblastine binding site.
Non-competitive interactions between drugs must involve allosteric mechanisms. The 
nature of the non-competitive interaction observed between the transport ligands and the 
vinblastine site was investigated by looking at the effect of drug on the dissociation 
kinetics of [3H]-vinblastine. As in the previous section, the dissociation rate constant (k_ 
1) for vinblastine was measured following addition of 3pM unlabelled vinblastine to pre­
equilibrated P-gp-[3H]-vinblastine complexes. The measured dissociation rate constant 
for [3H]-vinblastine was 0.093 min'1 as shown in table 4.2. The effect of increasing
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concentrations of paclitaxel, rhodamine 123 or Hoechst 33342 (10"* to 10~5M) on this rate 
was investigated.
Dose-response curves relating changes in k-i to concentration of transport ligand were 
produced (data not shown). From non-linear regression analysis of dose-response curves 
the potency (EC50) and the maximal effect of drug on the dissociation kinetics of [3H]- 
vinblastine were determined (table 4.2). There was a 3.4-fold increase in the dissociation 
rate constant for [3H]-vinblastine in the presence of Hoechst 33342 with an EC50 value of 
18p,M. In contrast, paclitaxel was only able to cause a modest increase in k_i (1.2-fold) 
and there was no measurable effect of rhodamine 123 on die [3H]-vinblastine 
dissociation rate constant. Therefore, it can be concluded that Hoechst 33342 is able to 
reduce the Bmax for [3H]-vinblastine binding via an allosteric mechanism that promotes 
dissociation of the P-gp-[3H]-vinblastine complex. The lack of effect seen with 
paclitaxel and rhodamine 123 may simply be due to the poorer
Table 4.2 Effect of transport ligands on the dissociation kinetics of [3H]-
vinblastineII Maximal rate (k_i) 
(min*1)
Fold change Potency
(uM)
Vinblastine 0.093 N/A N/A
Paclitaxel 0.114 1.2 0.024
Hoechst 33342 0.317 3.4 18
Rhodamine 123 0.095 1.0 N/A
Effect of drug on the dissociation rate constant for [^-vinblastine was determined as described in 
methods. The k_i for [^H]-vinblastine was determined at a number of drug concentrations. Maximal 
change in k_i and the potency of drug allosteric effect (EC50) were estimated from non-linear 
regression of dose-response equations, n refers to number of independent experiments conducted to 
obtain parameters shown in table.
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allosteric efficacy of these drugs by comparison with the modulators investigated in the 
previous section. Due to problems with drug solubility it was not possible to use higher 
concentrations of either paclitaxel or rhodamine 123 to test this possibility. However, it 
is clear from the experiments conducted thus far that P-gp does not contain a single site 
from which transport is mediated.
4.4 Investigation of [^H]-XR9567 binding parameters in the presence of transport 
ligands
The preceding sections have demonstrated that some modulator compounds interact at a 
site(s) distinct from the site of interaction of the transport ligand [3H]-vinblastine. In 
addition, the binding of vinblastine is modulated in the presence of MDR reversal agents 
through a negative allosteric mechanism. It has also been shown in the previous section 
that not all transport ligands interact at a common site. In this section experiments have 
been conducted to investigate:
a) , the mechanism by which transport ligands affect modulator binding, and
b) whether modulatory compounds, some of which may not be transported, share a 
common site of interaction?
In chapter 3 (3.6), a radioligand binding assay was developed to quantitatively 
characterise the interaction of the third generation modulator [3H]-XR9576 with P-gp. It 
was found that this modulator binds P-gp containing CHrB30 membranes with high 
affinity (2-4nM). I have also demonstrated (refer to chapter 3, (3.7)) that the transport 
ligands vinblastine and paclitaxel could displace binding of [3H]-XR9576 by 70% and 
18% respectively. However, the type of antagonism produced could not be determined 
in these experiments. It has been shown in this chapter that vinblastine and XR9576 
interact non-competitively and that XR9576 can communicate with the vinblastine
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binding site via an allosteric mechanism. Is there two-way communication between 
these sites, that is can binding of vinblastine elicit an allosteric effect on the XR9576 
binding site? It was also of interest to investigate how other transport ligands such as 
rhodamine 123, Hoechst 33342 and paclitaxel interact with [3H]-XR9576, particularly as 
it has been established that they interact at site(s) distinct from the vinblastine site.
•
To address these issues, the effect of the transport ligands vinblastine, Hoechst 33342, 
rhodamine 123 and paclitaxel on the complete binding isotherms for [3H]-XR9576 were 
investigated. Saturation isotherms for [3H]-XR9576 were measured in the presence of 
different concentrations of transport ligand as described in methods. There was no 
reduction of the Bmax for [3H]-XR9576 binding to CHrB30 membrane vesicles in the 
presence o f either vinblastine or Hoechst 33342 at any of the concentrations used. 
However, there was a dose-dependent shift in the saturation isotherms for [3H]-XR9576 
binding in the presence of different concentrations of vinblastine and Hoechst 33342 (10" 
6-10^ M). Data for Hoechst 33342 are shown in figure 4.5(a) and for vinblastine in 
figure 4.6(a). The observed reduction in the apparent affinity of [3H]-XR9576 binding in 
the absence of any diminution of Bmax, was suggestive of competitive interaction 
between either vinblastine or Hoechst 33342, with [3H]-XR9576. However, I had 
previously shown that XR9576 non-competitively affects [3H]-vinblastine binding. 
Therefore the alterations in the apparent Kd for [3H]-XR9576 binding observed with both 
vinblastine and Hoechst 33342, required further investigation to determine whether it 
was due to competitive interaction.
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Figure 4.5 Effect of Hoechst 33342 on the binding parameters of [3H]-XR9576. (a) [3H]-XR9576 
saturation binding isotherms measured in the presence of different concentrations of unlabelled 
Hoechst 33342 (a representative plot is shown), (b) Schild plots were derived from saturation 
isotherms to describe the interaction of Hoechst 33342 with [3H]-XR9576 binding. The shift in the 
apparent Kd for [3H]-XR9576 binding in the presence of Hoechst 33342 was used to derive a dose 
ratio (DR). The DR was plotted as a function of unlabelled antagonist The slope of this relationship 
and the x-axis intercept are used to delineate the type of interaction occurring between compounds 
on P-gp. Each value represents the mean + s.e.m. from four independent experiments. Published in 
Martin et al., (83).
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Competitive interactions involve specific quantifiable changes in the apparent Kd which 
can be assessed using Schild analysis. The shift in Kd apparent at each concentration of 
antagonist was expressed as a ratio of Kd measured in the absence of antagonist to 
produce a dose ratio (DR). The logarithm of the dose ratio is plotted as a function of 
logarithmic antagonist concentration. According to Schild, if  there is a competitive 
interaction occurring the relationship between dose ratio and antagonist concentration 
will be linear, and the slope of that relationship must equal 1. Figure 4.5(b) is a Schild 
plot of the data shown in figure 4.5 (a) where dose ratio or alteration in Kd for [3H]- 
XR9576 binding was related to concentration of Hoechst 33342. The slope of this 
relationship was 1.14 + 0.2 (n=3) and was not significantly different from 1 (F test, P> 
0.05). This result strongly suggests that Hoechst 33342 competitively interacts with 
[3H]-XR9576 for binding to P-gp. The antagonist affinity constant (Kb) obtained from 
the Schild plot was 5.3 + 0.076pM (n=3). Where competitive interactions exist the value 
for Kb of antagonist equals the Kd for binding of antagonist. The value for the affinity of 
Hoechst 33342 obtained from Schild analysis, agrees with the previously reported 
affinity of Hoechst 33342 to interact with P-gp, as reported by Shapiro and Ling (122).
The effect of Hoechst 33342 on the rate of dissociation of the [3H]-XR9576-P-gp 
complex was also investigated. There was no effect of Hoechst 33342 measured over a 
range of concentrations (up to a 1000-fold molar excess) on the dissociation rate constant 
for [3H]-XR9576. This result supports the findings from Schild analysis, and thus it was 
concluded that the transport substrate Hoechst 33342 and the modulator XR9576 interact 
at the same site on P-gp. This important result provides direct evidence that the same 
binding site on P-gp can elicit either a transport role or act as a regulator of activity, 
depending upon the drug bound.
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Figure 4.6 Effect of vinblastine on the binding of [3H]-XR9576. (a) [3H]-XR9576 saturation 
binding isotherms measured in the presence of different concentrations of unlabelled vinblastine (a 
representative plot is shown), (b) Schild plot relating dose ratio as a function of vinblastine 
concentration. The slope of this relationship and the x-axis intercept are used to delineate the type of 
interaction occurring between compounds on P-gp. Each value represents the mean ± s.e.m. from 
four independent experiments. Published in part in Martin et al., (83).
A Schild plot relating alterations in the apparent Kd for [3H]-XR9576 due to vinblastine, 
is shown in figure 4.6(b). The resultant relationship yielded a slope of 0.52 + 0.05 and a 
value for Kb = 6.56 ±  0.56pM (n=4). Since the slope was significantly different from 1.0
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(P < 0.01), this strongly indicated that vinblastine and [3H]-XR9576 are interacting non- 
competitively on P-gp. The fact that the value for Kb (antagonist affinity constant) 
deviated from the measured Kd for vinblastine binding by more than 300-fold, is further 
evidence for non-competitive interaction. This finding agrees with the results obtained in 
section 4.2 and also substantiates the power of Schild analysis to prove the existence of 
competitive antagonism.
Unfortunately there was no effect of the transport substrates rhodamine 123 and 
paclitaxel on any of the binding parameters for [3H]-XR9576 binding at any 
concentration used which is probably due to the relatively low affinity of these agents to 
bind P-gp (data not shown).
4.5 Is there a common site of interaction for modulators on P-gp?
The modulators XR9576, XR9051, GF120918 and nicardipine have been shown to non- 
competitively interact with the [3H]-vinblastine site by reducing the maximal binding 
capacity via an allosteric mechanism. Is this effect on the vinblastine binding site 
mediated from a common site of interaction for modulatory agents on P-gp, or from 
separate and pharmacologically distinct sites? To address this question, a series of 
complete [3H]-XR9576 binding curves were produced in the presence of unlabelled 
modulator (XR9051 10"8 to 10"6 M; GF120918 10"8 to 10"6 M; Nicardipine 10"7to 10"4 M) 
to elucidate the type of interaction occurring between [3H]-XR9576 and other 
modulatory compounds on P-gp. XR9051 elicited a dose-dependent alteration in the 
affinity of [3H]-XR9576 binding, as evidenced by a rightward shift in [3H]-XR9576 
binding curves (see figure 4.7(a)). Representative binding curves obtained in the
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Figure 4.7 Effect of XR9051 on the binding of ["^J-XRPSVô to CH'BSO membranes, (a) [3H]-XR9576 
binding curves conducted in the presence of different concentrations of unlabelled XR9051 (a 
representative plot is shown), (b) Schild plot was derived from type of data shown in (a) relating 
change in affinity (DR) as a function of antagonist concentration. The slope of this relationship and 
the jc-axis intercept are used to determine the type of interaction occurring between compounds. 
Each value is the mean+s.e.m. of at least three independent experiments. Published in part, in 
Martin et al., (83).
presence of antagonist are shown for clarity. A shift in the binding curve with no 
diminution in Bmax is indicative of a competitive interaction, but not proof às such, as 
was the case with the effect of vinblastine on the saturation binding curves for [3H]-
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XR9576 in section 4.4. To unequivocally determine the existence of competitive 
interaction, Schild plots relating the change in the apparent Kd for [3H]-XR9576 binding 
as a function of antagonist concentration, were produced (figure 4.7(b)). The Schild plot 
describing the interaction between XR9051 and [3H]-XR9576 on P-gp yielded a slope 
value of 0.981 + 0.075 (n=3) that was not significantly different from 1.0 (F test, P > 
0.05). The value for Kb, a measure of antagonist affinity, was 89.3 + 9.3nM (n=3). This 
value for Kb, agrees with the previously reported potency of XR9051 binding to P-gp 
(22) and is similar to its IC50 value to displace [3H]-XR9576 binding (chapter 3, 3.7). 
This result shows that XR9051 and [3H]-XR9576 have a common site of interaction on 
P-gp, which is not surprising, given their structural similarity (refer to figure 1.3 chapter
1,1.3.2).
The effect of unlabelled XR9051 on the dissociation rate constant (k_%) for [3H]-XR9576 
binding was also investigated as another means of identifying how XR9051 and XR9576 
interact with each other for binding to P-gp. As illustrated in previous sections, the 
dissociation rate constant for drug can only be altered by a second unrelated drug via an 
allosteric interaction that only arises from binding at a distinct site. The presence of 
XR9051 did not have any effect, even at concentrations up to 1000-fold excess, upon the 
dissociation kinetics of [3H]-XR9576 (data not shown). This provides further support for 
the findings of the Schild analysis demonstrating a competitive interaction between these 
two agents on P-gp.
The saturation binding curves for [3H]-XR9576 binding obtained in the presence of 
different concentrations of the 1,4-dihydropyridine nicardipine also display a rightward 
shift as shown by the representative plots in figure 4.8(a).
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Figure 4.8 Investigating the binding parameters of [3H]-XR9576 in the presence of nicardipine,
(a) effect of different concentrations of nicardipine on binding curves for [3H]-XR9576 
(representative plot shown), (b) Schild plot derived from binding data relating alteration in Kd to 
antagonist concentration. The type of interaction occurring between drugs is determined by the 
slope and jc-axis intercept of this relationship. Each value is the mean + s.e.m. of at least three 
independent experiments. Published in Martin et al., (83).
To determine whether the displacement of binding curves by nicardipine was due to a 
competitive interaction, Schild analysis of the binding data was conducted. A Schild plot 
depicting alterations in the affinity of [3H]-XR9576 binding due to the presence of
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increasing concentrations of nicardipine, is shown in figure 4.8(b). The slope of this 
relationship did not deviate significantly from 1.0 (0.945 + 0.066) (F test, PO.05). 
However, the affinity constant (Kb) for nicardipine derived from the %-axis intercept of 
this relationship was higher than expected (Kb = 4.89 + 0.34pM), given its 10-fold 
greater potency (see section 4.2) to modulate [3H]-vinblastine binding. This suggested 
that the interaction occurring between nicardipine and [3H]-XR9576 on P-gp may not be 
competitive in nature. To determine whether this was the case, the effect of nicardipine 
on the dissociation kinetics for [3H]-XR9576 binding was examined. There was a 2.1- 
fold increase in the dissociation rate constant for [3H]-XR9576 in the presence of 1000- 
fold molar excess of unlabelled nicardipine (see table 4.3). This alteration in the 
dissociation rate constant of a drug by another drug can only be exerted via an allosteric 
mechanism. When considered in combination with the aberrant value for Kb observed, it 
provides proof for non-competitive interaction.
In contrast to the effects of XR9051 and nicardipine on the binding of [3H]-XR9576, 
inclusion of different concentrations of the acridonecarboxamide GF 120918 in binding 
assays of [3H]-XR9567 elicited a reduction in the Bmax for binding. The degree by which 
the maximal binding capacity was reduced was dependent upon the concentration of 
GF120918 present. A secondary plot depicting fractional reduction in the Bmax as a 
function of GF 120918 concentration is shown in figure 4.9. There was a 75% reduction 
in the Bmax for [3H]-XR9576 binding in the presence of GF 120918. The potency (EC50) 
of this antagonistic effect was derived from non-linear regression of the dose-response 
curve in figure 4.9. GF120918 reduced the binding of [3H]-XR9576 with an EC50 value 
of 85.9 ± 0.9nM (n=3). There was no measurable alteration in the Kd of binding. A 
reduction in Bmax in the absence of any changes in the Kd is indicative of non-competitive 
interactions.
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Figure 4.9 Effect of GF120918 on Bm,, for [3H]-XR9567 binding to P-gp. Data presented are 
fractional reduction in Bm,% for [3H]-XR9576 obtained from binding dose-response curves produced 
at different concentrations of GF120918. All values are the mean ± s.e.m. from at least three 
independent experiments. Published in Martin et al., (83).
To corroborate that XR9576 and GF120918 interact non-competitively on P-gp, the 
effect of increasing concentrations of GF120918 on the dissociation rate constant for 
[3H]-XR9576 was investigated. There was a dose-dependent increase in the dissociation 
rate constant for [3H]-XR9576 in the presence of GF120918 (increased maximally 1.4- 
fold) as shown in table 4.3. This finding provided unequivocal evidence that XR9576 
and GF120918 interact at distinct, but allosterically linked sites. The results obtained in 
this section indicate that there is not a common site on P-gp at which modulatory 
compounds bind, as GF 120918 and nicardipine interact at a site(s) distinct from the 
XR9567 site. Due to the unavailability of radiolabelled versions of GF120918 or 
nicardipine, it was not possible to determine whether these modulators share a common 
site on P-gp or not.
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Table 4.3 Effect of modulatory compounds on dissociation kinetics [3H]-XR9576
II Maximal k_i(min1) Fold change EC50(UM)
XR9576 0.023 N/A N/A
GF120918 0.0315 1.4 0.08
Nicardipine 0.049 2.1 1.7
Effect of drug on the dissociation rate constant for [3H]-XR9576 was determined as described in 
methods. The k_i for [3H]-XR9576 was determined at a number of drug concentrations. Maximal 
change in k_, and the potency of drug allosteric effect (EC50) were estimated from non-linear 
regression of dose-response equations.
4.6 Summary
A number of radioligand binding studies have been conducted to investigate competitive 
and non-competitive interactions between drugs on P-gp. These studies have identified 
four distinct classes of drug interaction site on P-gp. Two distinct sites of interaction for 
transport ligands were found. A third site was identified capable of binding either 
modulator or transport ligand, and a fourth was found that appears to be purely 
modulatory in role. Not only are there distinct sites of drug interaction on P-gp, but these 
sites interact via an allosteric communication network. A model depicting a multiple 
inter-connecting binding site network on P-gp has been proposed based on these 
findings, and will be discussed at length in chapter 6.
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5.1 Introduction
As P-glycoprotein is a primary active transporter, the binding of drug at the 
transmembrane domains must be intimately linked, or coupled, to its catalytic activity at 
the cytoplasmic nucleotide binding domains. Presumably, to achieve transmembrane 
translocation, the drug binding sites must cycle between high and low affinity 
conformations in response to signals from the NBDs. However, the stages of the 
catalytic cycle involved in inducing such alterations in drug binding site affinity have not 
been fully delineated. The purpose of the studies reported in this chapter is to examine 
drug binding parameters during discrete stages of the catalytic cycle to determine (i) 
when the initial signal is transmitted to instigate a transport event and (ii) the point in the 
cycle at which transport is completed and the binding site has returned to its “pre­
transport” conformation.
(i)
Mg. ATP ♦ Pgp
(II)
Pgp.Mg.ATP
Mg ADR I
(IV ) Pgp.Mg.A0P
Pi
Pgp.Mg.A0P.Pi
(in)
Pgp.Mg.ADP.Vi
(ina)
Figure 5.1 Discrete stages in the catalytic cycle of P-gp
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A catalytic cycle refers to the events involved in the hydrolysis of a single molecule of 
ATP and a scheme depicting discrete stages of a catalytic cycle of P-gp is shown in 
figure 5.1, as proposed by Senior et a l  (117), and discussed in section 1.10 of this thesis. 
Catalysis can only occur at a single NBD at any one time, as it has been previously 
shown that the NBDs of P-gp do not hydrolyse ATP simultaneously (146). The NBDs of 
P-gp are proposed to alternate in ATP hydrolysis, exhibiting strong co-operativity as both 
NBDs must be intact to permit even a single round of hydrolysis. How drug interacts 
with the protein as it undergoes a catalytic cycle has not been fully elucidated. In this 
chapter, I want to investigate the ability of drug to bind at all of the stages outlined in 
figure 5.1. Radioligand binding studies will be used to directly measure the binding 
parameters of the transport ligand vinblastine and the modulatory compound XR9576. 
This will provide information regarding signalling between the NBDs and two different 
classes of drug binding site, at different steps in the catalytic cycle.
In order to examine specific stages of a catalytic cycle, a number of experimental tools 
will be used as outlined in the scheme presented in figure 5.2. To look at drug binding to 
P-gp at an early or pre-hydrolysis stage (stage II) a technique is required to investigate 
the ATP bound form of the protein. The molecules ATP-y-S and AMP-PNP, which are 
non-hydrolysable analogues of ATP, have been chosen to mimic binding of intact ATP 
by P-gp. It is not technically possible to directly assess the type of signal transmitted to 
the drug binding sites at the next stage of the cycle (m/ma in figure 5.2), which follows 
ATP hydrolysis but precedes dissociation of Pi. This is due to the instability of the P- 
gp.Mg.ADP.Pi complex (147). To circumvent this problem the technique of vanadate 
trapping can be used to mimic stage HI (refer to stage M a of figures 5.1 and 5.2). The 
vanadate ion has higher affinity than Pi for the P-gp.Mg.ADP complex, which is 
reflected in a much slower rate of dissociation and thereby functions to 'stabilise' the
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protein in the Mg.ADP. Vi bound form. Finally, it was of interest to investigate whether 
conformational changes are wrought on drug binding sites following dissociation of Pi. 
To investigate this stage, it was important to be able to measure drug binding to P-gp 
with bound nucleotide diphosphate, but without Pi (see stage IV of figures 5.1 and 5.2).
Pre-hydrolysis
P-gp.MgATP
Stage II
AMP-PNP
or
ATP-y-S
Stages of Catalytic cycle
Hydrolysis
-M P-gp.MgADP.Pi
Stagein/nia
P-gp.MgADP.Vi
Vanadate trapping
Release of Pi
► P-gpMgADP
Stage IV
Mg.azido-ADP
Figure 5.2 Scheme outlining the stages in the catalytic cycle to be investigated. The experimental 
tools used to isolate each stage are shown in red.
However, this is difficult due to the inherently low affinity of ADP to bind P-gp. To 
achieve this, P-gp was vanadate-trapped using 8-azido-ATP, an azido analogue of P-gp, 
which has previously been shown to be hydrolysed by P-gp (1). Following vanadate 
trapping, the samples are irradiated with U.V. light to covalently cross-link 8.azido.ADP 
to P-gp. Vanadate was removed as described in Chapter 2, 2.6.1.
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5.2 The effect of nucleotide analogues and vanadate trapping on ATPase activity in 
CHrB30 membranes
Prior to proceeding with investigation of drug binding during the catalytic cycle using the 
tools outlined above, the effect of these agents on the ability of P-gp to hydrolyse ATP 
was investigated. Measurement of ATPase activity is a convenient means by which to 
assess the effectiveness of the compounds used to interact with and affect the activity of 
P-gp. The ability of the non-hydrolysable ATP analogues ATP-y-S and AMP-PNP to 
interact with P-gp was assessed by measuring basal ATPase activity in the presence of a 
range of concentrations of these nucleotides (0.0ImM to lOmM). The ATPase activity 
of P-gp was inhibited in the presence of ATP-y-S with a potency of IC50 = 0.31 + 
O.OlmM (n>3). It was not possible to determine the effect of AMP-PNP on the ATPase 
activity of P-gp using a Pi release assay due to the high free Pi content of the 
commercially available AMP-PNP.
The effect of vanadate on basal ATPase activity in CHrB30 membranes has been 
reported on in Chapter 3, 3.3. Vanadate could inhibit up to 85% of basal activity 
measured at a single concentration of ATP in CHT330 membranes with IC50 = 0.7 + 
0.09pM (n>3). CHrB30 membranes were incubated with ATP and 300pM vanadate, a 
concentration that is significantly greater than its IC50 value above, and was thus 
sufficient to achieve full inhibition of activity. Trapped protein nucleotide complex was 
separated from unincorporated nucleotide and vanadate using gel filtration 
chromatography. Isolated trapped protein was examined to ascertain (i) whether protein 
was sufficiently trapped with vanadate to inhibit activity, (ii) if  activity was recoverable, 
(iii) the conditions required to achieve recovery of activity. The Vmax of basal ATPase 
activity in vanadate trapped protein, prior to separating unbound components, was 
reduced from 177 + 30 nmol min'1 mg"1 membrane protein to 29 + 4 nmol min'1 mg'1 
(n=3). This represents an 85% reduction in the Vmax for ATP hydrolysis. Activity
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remaining in CHrB30 membranes may be due to contributions from non-P-gp ATPases. 
The reversibility of the vanadate effect was investigated by looking at conditions 
required to dissociate bound vanadate ion. Following separation of unbound reaction 
components, recovery of ATPase activity was monitored by incubating trapped protein
recovered
control trapped no ATP ImM ATP
Figure 53 CHrB30 membrane vesicles were incubated with 2mM ATP and 300pM vanadate at 37°C 
for 25 minutes. Unbound nucleotide and vanadate were removed by sephadex G50 centrifuge 
columns and recovery of ATPase measured by incubating at 37°C in the presence or absence of 
ImM ATP. Data are the mean + s.e.m. from at least three independent experiments.
at 37°C in buffer with or without ImM ATP and devoid of vanadate, for up to 2 hours. 
As shown in figure 5.3, there was full recovery of ATPase activity after incubation at 
37°C, and recovery was complete by 120 minutes post-incubation. The presence of ATP 
did not influence the extent to which activity could be recovered, indicating that ATP 
hydrolysis is not required to restore activity post-vanadate trapping. This is in agreement 
with the previously published study of Urbatsch et al., (144). Trapping of P-gp with 
vanadate produces a stable catalytic cycle intermediate, which is more long-lived at
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22°C, thus enabling study of the characteristics of drug binding at this step (m /m a) of 
the cycle.
As stated in the previous section, in order to isolate stage IV of the catalytic cycle (see 
figures 5.1 and 5.2), an azido nucleotide diphosphate (8-azido-ADP) will be covalently 
cross-linked to the protein using U.V. light. However, it was important to determine (i) 
the efficiency with which the azido-nucleotide diphosphate was crosslinked to the protein 
and (ii) that there was no effect of the cross-linking procedure on the activity of P-gp. 
This was achieved by looking at the ability of verapamil to stimulate basal ATPase 
activity of 8-azido-ADP bound P-gp.
V7777A control
U .V .control 
■ ■  azido-ADP
Figure 5.4 GHrB30 membrane vesicles (Ipg) that were either untreated, exposed to U.V. light or 
U,V, cross-linked with 8-azidoADP were incubated with 0-2.5mM Na7ATP in the presence of 50pM 
verapamil over a 20 minute period at 37°C. Dose-response curves plotting drug stimulated ATPase 
activity as a function of ATP concentration were produced from which values for V ^  of activity 
were derived. Values presented represent mean Vma, + s.e.m. from at least three independent 
experiments. * Significant reduction in activity versus untreated control (Student’s t test P < 0.01)
There was significant reduction in the level of drug-stimulated ATPase activity measured 
in CHrB30 membranes treated with azido-nucleotide and U.V. cross-linking, as 
compared to untreated membranes (P< 0.01) (figure 5.4). There was a small decrease
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(10%) in the ATPase activity of CHrB30 membranes exposed to cross-linking conditions, 
but this was not statistically significant (P>0.05). This suggests that inhibition of 
ATPase activity was due to the presence of azido-nucleotide covalently bound at the 
catalytic site, and not by a detrimental effect of the cross-linking procedure on verapamil 
binding or ATP hydrolysis.
The effect of the sulphydryl-reactive agents NBD-C1, NEM and MIANS on basal 
ATPase activity of CHrB30 membranes was also investigated. These compounds can 
covalently label cysteine residues located within the Walker A motif of each nucleotide 
binding domain. I wanted to examine the ATPase activity of P-gp in the presence of
Table 5.1 Potencies of ‘catalytic’ inhibitors to affect the ATPase activity of P-gp.
compound Inhibition o f ATPase activity 
IC50 (pM)
NBD-C1 17.8 ±3.6
NEM 3.2 ±0.6
MIANS 1.9 ±0.3
ATP-y-S 311 ±99
Vanadate 0.7 ±0.1
The potencies ( I C 5 0 )  of vanadate, covalent inhibitors and nucleotide analogues on the ATP hydrolytic 
activity of P-gp were measured using 2mM ATP at 37*C with Ipg CH'BSO membrane vesicles. 
Values represent the mean+s.e.m. of at least three independent experiments. (Published in Martin et 
al., (85).
molecules, other than nucleotide analogues, which bind within the catalytic pockets of P- 
gp. All three sulfhydryl-reactive compounds caused a dose-dependent decrease in basal 
ATPase activity as shown in table 5.1. MIANS (IC50 = 1.9 + 0.3pM) (n=3) and NEM 
(IC50 = 3.2 ± 0.6pM) (n=3) abolished activity with similar potency, whilst NBD-C1
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displayed slightly lower potency to inhibit activity (IC50 = 17.8 ± 3.6pM) (n=3). The 
effect of these agents on drug binding will be investigated in the next section.
Having developed various procedures to inhibit P-gp activity and ‘freeze’ it at specific 
stages of the catalytic cycle, the ability of drug to interact at discrete steps of this cycle 
was investigated.
53 Drug binding in the presence of nucleotide.
Signalling between the TMDs and NBDs underlies transport activity of P-gp. Numerous 
studies using a variety of assays, including measurements of ATPase activity, have 
demonstrated that drug binding sites are capable of communicating with the NBDs. 
There is little information concerning the reverse, i.e. the effect of events at the catalytic 
sites on drug binding. In this section, I have directly measured drug binding in the 
presence of different nucleotides, as a first step towards elucidating the effect of signals 
originating at the NBDs on the ability of drug to bind at the TMDs. The relative effects 
of the nucleotides ATP-y-S, AMP-PNP, ADP and AMP (O.Ol-lOmM) on the binding of 
[3H]-vinblastine and [3H]-XR9576 were measured. As shown in figure 5.5, the binding 
of [3H]-vinblastine (15-20nM) was reduced by 60% in a dose-dependent fashion in the 
presence of ATP-y-S (IC50 = 0.14 ± 0.05mM) (n>3). The presence of AMP-PNP 
displaced 70% of bound [3H]-vinblastine and the potency to reduce binding was reflected 
in an IC50 value of 0.37 + 0.09mM (n>3). Binding of [3H]-vinblastine measured in the 
presence of increasing concentrations of ADP displayed less than 30% displacement of 
bound drug, whilst there was a modest (<10%) reduction of binding in the presence of 
AMP. In contrast to the nucleotide-induced changes in [3H]-vinblastine binding, there 
was no effect of any of the nucleotides used on the binding of the modulatory compound 
[3H]-XR9576 (data not shown). This initial investigation of the effect of nucleotide on
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the ability of drug to interact with P-gp shows that binding of nucleotide, particularly 
nucleotide triphosphate, transmits a signal to the TMDs that alters the vinblastine drug 
binding site. However, the lack of effect seen with [3H]-XR9576 indicates that perhaps 
not all binding sites are coupled to binding of nucleotide. The specificity of the effect 
seen with nucleotide on [3H]-vinblastine binding was investigated further by
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Figure 5.5 Nucleotide displacement of [Tl]-vinblastine binding. CHrB30 membrane vesicles (8 pg) 
were incubated with [^ H] -vinblastine (15-20nM) in the presence of nucleotides (0.01-5mM). The 
amount bound was expressed as a fraction of the total specific binding obtained in the absence of 
nucleotide and plotted as a function of nucleotide concentration. The extent of displacement and the 
IC50 values were obtained from general dose-response curves. Data presented are the mean +_s.e.m. 
from three to five independent experiments. (Published in Martin et al., (85).
looking at the ability of the sulphydryl-reactive compounds MIANS, NEM and NBD-C1 
to alter drug binding. There was no reduction of [3H]-vinblastine binding in the presence 
of these agents (data not shown). This demonstrates that signalling from the NBDs to the 
TMDs is specifically dependent upon the molecule bound in the catalytic pocket. This 
initial investigation of drug binding in the presence of nucleotide has provided the first 
direct evidence that the drug binding site receives specific communication from the
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NBDs. The fact that binding of the transport ligand [3H]-vinblastine was effectively 
displaced by non-hydrolysable analogues of ATP suggests that binding of ATP provides 
a signal early in the catalytic cycle to alter [3H]-vinblastine binding. The nature of the 
change induced on the vinblastine binding site in the presence of non-hydrolysable ATP 
analogues could not be ascertained from the displacement equilibrium binding assays 
conducted. Therefore, to characterise the effect of ATP binding on the vinblastine site, 
full saturation binding isotherms for [3H]-vinblastine were conducted in the presence of 
different concentrations of ATP-y-S or AMP-PNP. These assays are more informative 
than displacement binding experiments as they provide information concerning the effect 
of nucleotide on the affinity and extent of drug binding by P-gp.
Full saturation binding assays for [3H]-vinblastine and [3H]-XR9576 were conducted in 
the presence of different concentrations of either ATP-y-S (0-5mM) or AMP-PNP (0- 
3mM). Investigation of the effect of AMP-PNP on [3H]-XR9576 saturation binding 
curves was not possible due to lack of continued availability of this radiochemical. The 
Bmax for [3H]-vinblastine binding measured at each concentration of nucleotide was used 
to produce a secondary plot (as shown in figure 5.6) relating effects on Bmax to nucleotide 
concentration. As shown in figure 5.6 (a), there was a dose-dependent decrease in the 
Bmax for [3H]-vinblastine binding in the presence of ATP-y-S to 40% of that observed in 
the absence of nucleotide. The potency of ATP-y-S to alter [3H]- vinblastine binding was 
described by an IC50 value of 0.14 + 0.05mM (n=3). AMP-PNP, on the other hand, 
caused more than 90% reduction in the Bmax for [3H]-vinblastine binding and a maximal 
effect was seen at 2-3mM. The IC50 value (0.2mM) to inhibit binding was similar to that 
determined for ATP-y-S, and these values are within the range of values reported for the 
Km of ATP hydrolysis (see chapter 1, section 1.10).
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Figure 5.6 (a) Effect of ATP-y-S on the binding capacity of [^-vinblastine and [3H]-XR9576. 
Saturation isotherms for [^[-vinblastine (l-100nM) and [3H]-XR9576 (0.1-40nM) were conducted in 
the presence and absence of different concentrations of nucleotide. A secondary plot relating Bmax at 
each concentration of nucleotide is shown and data fitted using the general dose-response equation. 
Data are mean+s.e.m. from 3 to 5 independent experiments, (b) Effect of AMP-PNP on 8^ .% for 
[^-vinblastine binding. Saturation isotherms were conducted in the presence of different 
concentrations of AMP-PNP (0-3mM). A secondary plot showing Bm,, as a function of nucleotide 
concentration is shown. Data represent single observations from full isotherms at each 
concentration of nucleotide used. Note data in (a) published in Martin et al., (85).
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By using two different non-hydrolysable analogues of ATP, it was shown that binding of 
ATP in the absence of hydrolysis causes a reduction in the Bmax for [3H]-vinblastine 
binding. However, the difference in the extent to which binding is reduced by these 
nucleotide analogues may be due to the fact that ATP-y-S is very slowly hydrolysed at 
22°C and AMP-PNP is not. This slow hydrolysis was confirmed by conducting a 
coupled enzyme assay as described in Al-Shawi et al. (1), data not shown. Therefore, 
AMP-PNP was used in all subsequent investigations of nucleotide effects on drug 
binding. Nonetheless, the decrease in the Bmax for [3H]-vinblastine due to binding of 
ATP analogues suggests that vinblastine cannot readily access its binding site, and is 
indicative of conformational alteration of the high affinity site.
In contrast, there was no effect of ATP-y-S on the binding of [3H]-XR9576 (figure 
5.6(a)) which confirmed the result seen from displacement binding assays conducted 
earlier. The lack of effect of nucleotide on the binding of [3H]-XR9576, which is a 
modulatory compound and not transported by P-gp, (shown in chapter 3, 3.2.) may 
suggest either (i) binding of nucleotide transmits a different signal to different sites or (ii) 
the signal transmitted by nucleotide is dependent upon the drug bound.
5.3.1 Further characterisation of nucleotide-induced alteration of [^-vinblastine  
binding
5.3.1.1 Modification of radioligand binding assay to detect changes in affinity
The results in the previous section have shown that the binding site for the transport 
ligand vinblastine is altered at a stage of the catalytic cycle (stage II in figure 5.1) that 
occurs prior to nucleotide hydrolysis. The alteration in the binding site was manifest as a 
reduction in the Bmax and indicates an altered affinity of the protein for vinblastine. The 
reduced binding capacity could be due to either a complete conformational shift in the 
high affinity drug binding site to a low affinity conformation, or complete occlusion of
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the high affinity drug binding site. It has not been possible to directly measure 
vinblastine binding to the low affinity site due to the technical limitations of the existing 
radioligand binding assay. The highest concentration of [3H]-vinblastine used in 
radioligand binding assays is 150nM and is clearly not high enough to measure low 
affinity binding. To circumvent this problem, the radioligand binding assay for [3H]- 
vinblastine was modified to enable measurements to be made over a range of 
concentrations up to 3jiM vinblastine, which is 150-fold higher than its measured IQ for 
binding. This was achieved by performing homologous displacement binding (refer to 
chapter 2, section 2.2.4) and was based on methods described by Rovati (106)i
This type of analysis could also provide detailed information relating to whether there 
was a single class of site for vinblastine, or two classes of site that alternated between 
high and low affinity conformations. This was of particular interest as it had been 
suggested from study of the effect of vinblastine binding on (a) the fluorescence of 
MIANS bound at the NBDs and (b) accessibility of UIC2 for its extracellularly located 
epitope, that there were two vinblastine binding sites on P-gp. Two models were chosen 
to test these possible pharmacological scenarios on the experimentally produced [3H]- 
vinblastine binding data. As shown in figure 5.7 (a), theoretical binding data that was 
best-fitted by the dose response equation (equation 2.10), indicated binding to a single 
class of binding site, whilst data best described by the Adair equation (equation 2.7) or 
the sum of two Langmuir equations (equation 2.7a) was indicative of drug interaction at 
two sites of different affinity (figure 5.7 (b) and (c)). If vinblastine interacted at a single 
class of site, a reduction in affinity would be represented as a parallel shift to the right in 
the binding curve (figure 5.7 (a)). In contrast, if  vinblastine interacted with two sites, one 
of which was altered during the catalytic cycle, the binding curve would become biphasic 
as illustrated in figure 5.7(b) & (c).
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Figure 5.7 Theoretical binding curves were generated to demonstrate the characteristics of binding 
to a single site or to two sites of different affinity, (a) Dose-response curves as first described by 
Gaddum, simulating fraction of ligand bound to a single site over a range of ligand concentrations 
having arbitrary affinity (K,,) between 1 and 1000. (b) & (c) Fraction bound to two independent 
sites determined over a range of ligand concentrations where the ratio of affinity of two sites (IWkdi) 
is increased from 1-up to 10000. This data was modelled using the Adair equation (b) or the sum of 
two Langmuir isotherms (c) as described in methods.
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The experimentally produced [3H]-vinblastine binding data, measured in the absence of 
nucleotide, was plotted as a function of vinblastine concentration and fitted by both 
equation 2.7 and 2.10.
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Figure 5.8 Binding of [3H]-vinblastine in the presence of AMP-PNP. CHrB30 membrane vesicles 
(15pg) were labelled with l-100nM -vinblastine and ligand range extended by supplementing 
lOOnM fH] vinblastine with unlabelled vinblastine (up to 3pM). Non-specific binding was measured 
in the presence of lOpM nicardipine. Representative semi-logarithmic plots depicting specific 
binding (fraction of saturable binding) as a function of vinblastine concentration (M). Values for 
Bmax and Ky determined from dose-response equation as described in methods.
The goodness of fit was determined using the F-test and equation 2.7, which describes 
binding to a single class of binding site, best fitted the data produced (F-test, P<0.05) 
(figure 5.8 refer to ‘control’ data). [3H]-vinblastine binding to P-gp in the absence of 
nucleotide was described with a single Kd of 59 + 7nM (n=7) and a binding capacity 
(Bmax) of 62 ± 2 pmol mg'1 membrane protein (figure 5.8 & table 5.3).
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5.3.1.2 Homologous displacement of vinblastine binding in the presence of 
AMP-PNP
In the previous section, an abrogation in the Bmax for [ H]-vinblastine was observed at 2- 
3mM AMP-PNP. However, this was only measured over concentrations of vinblastine 
up to 150nM. By using an extended range of vinblastine concentrations, it was apparent 
that the binding was not abrogated, as a parallel shift to the right in the vinblastine 
isotherm was detected in the presence of AMP-PNP. Vinblastine binding in the presence 
of nucleotide was described by a Kd value of 856 + 165nM (n=3) (table 5.3), which 
represents a 20-fold decrease in the affinity of binding. There was no diminution in the 
binding capacity. The more simple dose-response curve provided the best fit for the 
binding data as compared to the Adair equation (F-test, PO.05), illustrating that 
vinblastine binding was still to a single class of site. This strongly suggested that the 
binding of nucleotide, prior to a hydrolytic event, conformationally alters the vinblastine 
site from high to low affinity. This also demonstrated that there were not multiple sites 
for vinblastine present that were alternating in affinity. Subsequent steps in the catalytic 
cycle were examined next in order to determine when the binding site re-adopts a high 
affinity conformation again.
5.4 The binding of drug to CHrB30 membranes at post-hydrolytic stages of the 
catalytic cycle
5.4.1 The ability of drug to bind to ‘vanadate trapped’ P-gp
As outlined in section 5.1 of this chapter, the technique of vanadate trapping can be used 
to mimic stage HI of the catalytic cycle (figure 5.1). This step immediately follows 
hydrolysis of ATP, but precedes dissociation of the P-gp.MgADP Pi complex from the 
catalytic site. As mentioned earlier, the vanadate ion mimics Pi and can stabilise the 
protein in the ‘transition state’ conformation (stage Ida, figure 5.1) that precedes 
dissociation of the products of hydrolysis from the catalytic site. It has been established
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that the binding site for [3H]-vinblastine is conformationally altered by binding of 
nucleotide. Does this alteration persist post-hydrolysis of nucleotide? In contrast, the 
binding site for [3H]-XR9576 is ‘resistant’ to nucleotide induced alterations in 
conformation. Can the energy of nucleotide hydrolysis provide a signal that will 
conformationally alter this drug binding site? To address these issues the ability of [3H]- 
vinblastine and [3H]-XR9576 to bind vanadate trapped protein was investigated.
An initial characterisation of drug binding was conducted by performing saturation 
binding isotherms on vanadate-trapped protein. There was a significant effect of 
vanadate trapping on the equilibrium binding of [3H]-vinblastine and [3H]-XR9576 as 
shown in the representative saturation isotherms in figure 5.9 (a) & (b). The vanadate- 
trapped P-gp displayed a markedly reduced binding capacity (Bmax) for [3H]-vinblastine 
(15.2 + 2.1 pmol mg*1 membrane protein) (n>3) as compared to the non-trapped state 
(58.7 + 8.3 pmol mg*1) (n>3) with no apparent effect on the affinity of ligand binding. 
This reduction in the binding capacity of [3H]-vinblastine was completely reversed upon 
removal of unbound vanadate and subsequent incubation of treated membranes at 37°C 
for up to 120 minutes (71.7 ± 16.1 pmol mg'1) (n>3). This complete recovery 
demonstrates that the low affinity binding is occurring because the protein is in a 
transition state complex, rather than a detrimental effect of the treatment on P-gp activity. 
The addition of nucleotide or drug to the ‘recovery’ sample was not required to restore 
[3Hj-vinblastine binding.
In a similar fashion, there was a reduced ability of vanadate-trapped P-gp to bind [3H]- 
XR9576, as manifest by a reduced value for Bmax (63.9 ± 6.8 pmol mg"1) (n>3) as 
compared to untreated P-gp (211 + 37 pmol mg'1) (n>3), with no apparent alteration in
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Figure 5.9 The effect of vanadate-trapping on the equilibrium binding of (a) [^Hj-vinblastine and
(b) [3H]-XR9576 to CH B30 membrane vesicles. Plasma membrane vesicles were treated with 
300pM vanadate and allowed to recover at 37°C for 2 hours prior to radioligand binding. The 
equilibrium binding of [^H]-vinblastine (l-100nM) and [3H]-XR9576 (0.1-40nM) was measured by a 
rapid filtration method following 2-3 hour incubation at 22°C. Representative saturation isotherms 
are shown for each radioligand. Values for Em,, and Ky were obtained from the hyperbolic 
relationships and are summarised elsewhere (table 5.2).
the Kd of the binding reaction. Binding of [3H]-XR9576 to P-gp was fully restored 
following recovery of trapped protein, illustrating that the effect of vanadate treatment 
was reversible, as was the case for [3H]-vinblastine binding (data summarised in table
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5.2). The reduced ability of [3H]-XR9576 to bind to trapped protein contrasts with the 
lack of effect of nucleotide binding on the binding site for XR9576. This indicates that 
binding of nucleotide and hydrolysis of nucleotide elicit different conformational 
outcomes with respect to the binding site for XR9576. However, it cannot be determined 
whether the different signalling to the XR9576 site is due to the nature of this site or the 
specific drug bound.
Table 5.2 Effect of vanadate trapping on the binding of -vinblastine and 
[3H]-XR9576
[3H]-vinblastine [3H]-XR9576
n > 3  B mM (pmol mg'1) K d  (nM) B mM (pmol mg"1) K d  (nM)
control 58.7±8.3 16.1±2.2 211+37 4.6±0.5
trapped Î5.2+2.Î 23.6±5.4 63.9±6.8 1.5±0.1
recovered_______ 71.5±16.1 23.O+4.7-_________179±35_________ 7.2+2. l
Equilibrium binding of [^H]-vinblastine (1-lOOnM) and [^H]-XR9576 (0.1-40nM) was conducted at 
22°C for 2-3hrs on CEfB30 membranes that had undergone the treatments indicated. The mean 
values + s.e.m. for Bm», and Kd from at least three independent experiments are presented. 
(Published in Martin et al., (85).
These results show that the initial alterations wrought on the vinblastine binding site by 
nucleotide binding persist post-hydrolysis when protein is trapped in the MgADP.Vi 
bound conformation. However, the alterations in binding site have presented as a 
reduction in the Bmax for binding over the low concentration range of [^H]-vinblastine 
used (l-150nM). Homologous displacement equilibrium binding over a wider 
concentration range of radiolabel was conducted to quantitate the change in affinity, and 
to determine whether binding was still to a homogeneous population of sites. When 
binding of vinblastine to MgADP.Vi bound P-gp was measured over a broad range of 
concentrations, it was found that binding was still to a single class of low affinity site.
156
Chapter 5 Drug binding at discrete stages of the catalytic cycle of P-gp
Binding data was best fitted by the dose-response equation for a single site (F-test, P < 
0.05) and a value for Kd of 337 + 60nM (n=3) was determined (representative plot shown 
in figure 5.10). This value for Kd was ‘intermediate’ between that observed for control 
and nucleotide bound P-gp. It could not be shown whether this represents the same low 
affinity conformation obtained in the presence of nucleotide.
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Figure 5.10 Effect of vanadate-trapping on binding parameters of [^H]-vinblastine. CETBSO 
membrane vesicles (15pg) were labelled with 1-100nM [3H]-vinblastine and ligand range extended by 
supplementing 100nM [^H]-vinblastine with unlabelled vinblastine up to 3pM. Non-specific binding 
was measured in the presence of lOpM unlabelled nicardipine. Representative logarithmic plot is 
shown. Bmax and K<, for binding determined as described in methods.
However, it can be concluded that the [3H]-vinblastine binding sites on vanadate-trapped 
P-gp constitute a homogeneous population of low affinity sites. This experiment was not 
conducted with [3H]-XR9576 as there was not a radiolabelled version of this compound 
available at the time.
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5.5 Restoration of the high-affinity drug binding site conformation during the 
catalytic cycle
Characterisation of the binding of [3H]-vinblastine to vanadate trapped P-gp revealed that 
at stage HI of the catalytic cycle (figure 5.1) the vinblastine binding site is still in a low 
affinity conformation for substrate. This demonstrated that hydrolysis of nucleotide did 
not trigger restoration of the high affinity conformation. The next stage of the cycle 
involves dissociation of Pi from the MgADP.Pi-Pgp complex (see stage IV, figure 5.1). 
The effect of dissociation of Pi from the post-hydrolytic nucleotide complex was 
investigated to determine whether this provides the signal necessary to ‘reset’ the binding 
site again (stage IV, figure 5.1). The MgADP bound form of P-gp was mimicked by 
vanadate trapping P-gp with Mg-8-azido-ATP, following which the resultant azido-ADP 
was cross-linked to the protein and bound vanadate dissociated following gel filtration 
chromatography.
The binding of vinblastine to azido-nucleotide diphosphate bound P-gp was measured 
over a broad concentration range of vinblastine using the homologous displacement 
assay. Vinblastine binding was best described by the dose-response equation for binding 
to a single class of site. The Kd value of 81 ± 39nM (n=5) showed that the vinblastine 
binding site had been restored to a high affinity conformation. As shown in table 5.3, the 
value for Kd post-dissociation of Pi/Vi was not significantly different to the Kd for 
binding to protein under basal conditions (P>0.05). However, it was significantly lower 
than Kd observed under nucleotide binding or vanadate-trapping conditions. This result 
suggests that the release of Pi from the post-hydrolytic nucleotide diphosphate complex 
transmits a signal to the TMDs that restores high affinity binding of vinblastine.
;
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Table 5.3 The effect of distinct stages of the catalytic cycle on the affinity of
[3H]-vinblastine binding
'
Stage in 
' catalytic 
cycle
I n n ia IV V
control AMP-PNP ATP + Vanadate ADP ADP + AMP-PNP
K<i (nM) 59+7 856±165 337+6O 81±39 85+Î3
n 7 3 3 5 3
P <0.001 <0.01 NS NS
Radioligand binding assays were conducted over a wide range of ligand concentration (0-3000nM) to 
compare the binding characteristics of [3H]-vinblastine in the absence of nucleotide with pre- and 
post-nucleotide hydrolysis stages of the catalytic cycle. Dose-response curves were generated from 
which a single value for Kd (nM) was determined for each condition investigated, as described in 
methods. Mean values for Ky ± s.e.m. are presented. P values relate changes to untreated control 
(Student’s t test). NS are non-staüstically significant
5.6 Role of non-catalytically active NBD in catalytic cycle
The investigations conducted thus far have identified stages in the catalytic cycle at 
which drug binding site parameters are altered. I have shown that a single round of 
catalysis is sufficient to cycle the binding site for the transport ligand vinblastine between 
high and low affinity conformations. This suggests that hydrolysis of a single molecule 
of ATP may be sufficient to support a single transport event. As discussed in chapter 1, 
1.10, the NBDs of P-gp are proposed to alternate in hydrolysis, with only one NBD 
actively participating in a single round of the catalytic cycle (146, 147). This was borne 
out in vanadate trapping experiments conducted by Urbatsch et al. who showed trapping 
of one mol of nucleotide diphosphate per mol of P-gp. However, given the strong 
interplay that has been demonstrated to exist between the NBDs of P-gp, is there a role 
for the non-active NBD in signal transmission to the TMDs during catalysis and 
transport?
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The nucleotide occupancy of the NBDs as the protein undergoes a cycle of catalysis is „ 
not known. I wanted to establish whether the non-active NBD was occupied during a 
catalytic cycle. This was achieved by comparing binding of ATP to untreated control 
membranes and those that were subjected to vanadate trapping. A displacement binding 
assay in which a range of concentrations of unlabelled ATP (0.01-ImM) was used to 
prevent photolabelling with a single concentration of 8-azido[a-32P]ATP (2pM) was used 
to measure the affinity of ATP binding. Displacement assays were conducted, as it was 
not possible to use concentrations of 8-azido[a-32P]ATP high enough to produce a 
saturation binding isotherm for ATP binding. Photo-affinity labelling experiments were 
carried out with P-gp purified and reconstituted from CHrB30 membranes, to avoid 
possible contributions from other ATPases found in the CH’BSO membranes.
Densitometric analysis of photolabelled P-gp containing proteoliposomes showed that 
ATP was able to completely displace 8-azido[a-32P]ATP labelling of untreated protein 
(basal state) with an EC50 of 16|iM (figure 5.11). More significantly, there was also 
labelling of protein that had previously been trapped with nucleotide at a single NBD by 
treatment with vanadate. However, the extent of labelling of trapped protein was 
approximately 50% of that measured under basal or non-trapped conditions. The 50% 
reduction in the extent of 8-azido[a-32P]ATP labelling of fully trapped protein versus 
untreated control is indicative that binding is to one NBD. This finding demonstrated 
that the NBD, not actively involved in a catalytic cycle, could be labelled with 
nucleotide.
Having demonstrated that ATP can bind at the non-catalytically active NBD during a 
catalytic cycle, I wanted to ascertain whether this NBD can transmit a signal to the
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TMDs. I have already shown that binding of non-hydrolysable ATP analogues at the 
‘active’ NBD triggers the switch in the high affinity vinblastine binding site to low 
affinity. If binding of ATP at the ‘non-active’ site transmitted a similar signal, then the 
binding site may never regain its high affinity conformation prior to the next catalytic 
cycle! To discount this possibility, we wanted to examine the effect of AMP-PNP 
binding to the Mg-8-azido-ADP bound form of P-gp on drug binding. Binding of [3H]- 
vinblastine to Mg-8-azido-ADP bound P-gp was conducted using homologous 
displacement binding assays in the presence and absence of 2mM AMP-PNP. The 
presence of the non-hydrolysable ATP analogue, AMP-PNP, did not alter vinblastine 
binding to MgADP-bound P-gp (table 5.3). The Kd (85 ±  13 nM) (n=3) for vinblastine 
binding to MgADP-bound P-gp when AMP-PNP was present at the ‘non-active’ NBD, 
was not significantly different to that observed for MgADP-bound P-gp alone (K<j = 81 + 
39nM, (n=5)). The Kd for binding measured under both conditions did not differ 
significantly from binding to nucleotide free protein. The lack of effect of AMP-PNP on 
the binding of vinblastine is in stark contrast to the previously measured 15-fold increase 
in the Kd for [3H]-vinblastine binding measured in the presence of AMP-PNP alone. 
This finding suggests therefore that the ‘non-active’ NBD does not signal to the TMDs 
during a round of the catalytic cycle. If  the alternating catalytic sites model for P-gp 
function holds true then it may be hypothesised that the alternate NBD becomes ‘active’ 
in a subsequent round of catalysis, following dissociation of MgADP. A second 
molecule of drug may bind prior to dissociation of MgADP as we have shown that the 
drug binding site is in a high affinity conformation at this stage and ATP bound at the 
‘non-active’ NBD is not yet capable of transmitting a signal to the TMDs. The 
dissociation rate of Mg.ADP may be critical in propagation of coupled drug transport.
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Figure 5.11 Displacement of 8-azido[cc-32P]ATP photo-labelling of P-gp, purified and reconstituted 
from CH'B30 membranes, by increasing unlabelled ATP. Proteoliposomes (8pg) were incubated 
with 2fiM 8-azido[a-32P]ATP in the presence of increasing ATP (0.01-lmM ) at 37°C for 15 minutes. 
Nucleotide trapping by vanadate was carried out as described in methods. Labelling of nucleotide 
was measured in trapped P-gp (•) versus untreated P-gp (O). Inset', SDS-PAGE illustrating 
displacement of 8-azido[ct-32P]ATP labelling of proteoliposomes in trapped versus untrapped (basal) 
protein.
5.7 Summary
1 Signalling from the NBDs to the TMDs has been investigated in terms of drug 
binding as P-gp undergoes a catalytic cycle. The binding of ATP triggers the 
initial change in the conformation of the [3H]-vinblastine binding site as 
shown by low affinity binding measured in the presence of AMP-PNP.
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2 The low affinity conformation produced in the presence of nucleotide
consisted of a complete shift in the conformation of a single class of high 
affinity binding site.
3 Nucleotide-induced alteration of drug binding displayed specificity for the 
drug binding site occupied or perhaps the drug bound, as there was no effect 
of nucleotide binding on the [3H]-XR9576 binding site.
4 Vanadate-trapping experiments demonstrated that the low affinity 
conformation of the [3H]-vinblastine binding site persisted immediately post­
hydrolysis of nucleotide. The affinity of [3H]-XR9576 binding to vanadate 
trapped P-gp was altered as manifest by abrogation in the Bmax for binding.
5 The release of Pi from the post-hydrolysis nucleotide diphosphate complex 
was sufficient to restore the conformation of the [3H]-vinblastine binding site 
to high affinity.
6 It was concluded that hydrolysis of a single molecule of ATP is sufficient to 
support cycling of the [3H]-vinblastine between high and low affinity 
conformations during a catalytic cycle. It was hypothesised that one molecule 
of vinblastine may be transported per molecule of ATP hydrolysed.
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6.1 Introduction
The ability of P-gp to interact with and transport numerous different compounds has been 
a puzzling feature of P-gp activity. Does this imply that P-gp is in violation of the classic 
Tock and key* hypothesis for enzyme-substrate interaction? There is ample evidence 
from investigations of drug interaction with P-gp suggesting the presence of more than 
one binding site for drug on this protein. A primary objective of this thesis was to 
develop pharmacological probes to investigate further the molecular mechanism 
underlying P-gp’s ability to interact with, and mediate translocation of, multiple different 
compounds,
6.2 Characterisation of P-gp activity in CHrB30 membranes
A molecular pharmacological approach has been adopted in this thesis to directly 
investigate the mechanism of drug transport by P-gp. The transport activity of P-gp is 
dependent upon (i) the ability of drug to interact with the protein (ii) hydrolysis of ATP 
to provide the energy required for active translocation of drugs and (iii) transbilayer 
movement of drug to facilitate dissociation of drug to the extracellular milieu. When thé 
studies carried out in this thesis were embarked upon, there was a dearth of information 
concerning how multiple drugs interact with P-gp or the affinity of such interactions. 
Therefore a primary aim was to develop radioligand binding assays to directly and 
quantitatively measure drug interaction with P-gp. P-gp ligands were broadly classified 
as transported ligands (usually anticancer agents) or modulators of P-gp activity, some of 
which may also be transported by P-gp.
Radioligand binding assays demonstrated that the anticancer agents [3H]-vinblastine and 
[3H]-paclitaxel could directly interact with P-gp containing CHrB30 membranes with 
high affinity, as shown by Kd values in the low nanomolar range. The high affinity
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binding measured in CHrB30 membranes was shown to be specifically related to P-gp 
expression, as there was no measurable binding to membranes prepared from parental 
AuxBl cells. The high affinity binding observed for [3H]-vinblastine and [3H]-paclitaxel 
to hamster P-gp is in agreement with radioligand binding studies conducted on human P- 
gp in membranes from MCF7 cells by Ferry et al. (30, 155). The low value for the K<j of 
vinblastine binding measured in the radioligand binding experiments alluded to above, 
contrasts with the studies of Romsicki and Sharom (102) who report values for the Kd of 
vinblastine interaction, in the micromolar range. The discrepancy between this study and 
the radioligand binding studies is due to the indirect nature of the assay used. The latter 
study, unlike radioligand binding assays, did not derive the true value for Kd but rather 
the potency of vinblastine to allosterically quench the fluorescence of MLANS, which 
was covalently bound within the catalytic pocket of the NBDs.
Having established that the anticancer agents vinblastine and paclitaxel can bind to P-gp 
with high affinity, I wanted to investigate whether binding of these drugs could transmit 
a signal to the energy generating NBDs, to affect ATP hydrolytic activity. Given the fact 
that P-gp positive tumours are resistant to these agents and together with evidence from 
cytotoxicity assays, it has been suggested that these compounds are transported by P-gp. 
Therefore, as P-gp transport activity only occurs under ATP hydrolysis conditions, it was 
expected that ATP hydrolysis activity might be increased in the presence of either 
vinblastine or paclitaxel. However, there was no measurable effect of vinblastine on 
basal ATPase activity and only a modest stimulation of activity by paclitaxel (1.3-fold) 
in CHrB30 membrane vesicles. The lack of effect of vinblastine, on basal ATPase 
activity in CHrB30 membranes has previously been reported by others (1, 132). Does 
this then imply that binding of vinblastine or paclitaxel is not tightly coupled to ATP 
hydrolysis? Interestingly, it has recently been proposed that P-gp behaves like an
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uncoupled active transporter (69). This classification has been based on a number of 
observations from the P-gp literature including (i) a lack of variation in the extent to 
which different drugs alter the Vmax for ATP hydrolysis, even though the affinity of drug 
binding might vary several fold (ii) the lack of effect, or in some cases, inhibition of 
ATPase activity by drugs that are translocated by P-gp and (iii) the presence of a basal 
ATPase activity in purified and reconstituted P-gp. However, ATPase activity of human 
P-gp.in insect cells does display a low degree of stimulation by vinblastine (111). The 
difference may be related to the lipid environment encountered by P-gp in CHrB30 cells 
versus insect cells. There is evidence to suggest that the basal activity of P-gp is related 
to the presence of an endogenous lipid component, which may be transported by P-gp 
(132).
To investigate the ATP dependent transport of vinblastine and paclitaxel by P-gp, a 
whole cell assay was used to measure steady-state accumulation of these compounds in 
P-gp expressing versus parental cells. There was 8-fold less accumulation of [3H]- 
vinblastine or [3H]-paclitaxel in CHrB30 cells compared to parental AuxBl cells. It was 
not possible to measure the transport kinetics of either of these cytotoxics using the 
whole cell assay for reasons outlined in Chapter 1, section 1.9. Therefore, the Km or 
Vmax for the transport of vinblastine or paclitaxel by P-gp was not determined. However, 
the extent of the accumulation deficit for [3H]-vinblastine, measured in the multidrug 
resistant CHrB30 cells, was similar to that demonstrated by Cano-Gauci and Kiordan, 
(17).
This first series of experiments conducted to investigate the binding of cytotoxics with P- 
gp and the consequences of drug interaction for P-gp ATPase and transport functions 
show that (i) cytotoxics directly and specifically bind to P-gp with high affinity and (ii)
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drug binding results in ATP-dependent transport of these compounds. The fact that there 
was no measurable stimulation of the basal ATPase activity in CHrB30 membrane 
vesicles by the cytotoxics, poses interesting questions concerning the coupling of drug 
binding to ATP hydrolysis to mediate transport, and will provide a focus for future 
studies of P-gp transport activity.
As stated in the introduction to this discussion, if reversal of P-gp transport activity is to 
be used effectively to overcome MDR in the clinic, a greater understanding of how 
modulators interact with P-gp is required. As discussed in Chapter 1, section 1.3.2, many 
of the early modulatory compounds failed to effectively block P-gp transport activity due 
to the relatively poor potency of interaction of these compounds, relative to the more 
potent anticancer agents. A newer generation of modulatory compound emerged that 
was more efficacious in restoring sensitivity of resistant tumour cells to anticancer 
agents. However, no studies were conducted to directly measure interaction of these 
modulators with P-gp and compare the functional consequence of modulator binding on 
P-gp activity and the binding of cytotoxics.
I have shown that the third generation modulator [3H]-XR9576 directly binds with P-gp 
displaying high affinity (K<j in low nanomolar range). Binding was specific for P-gp, as 
there was no binding to membranes from the parental cell line. This was the highest 
affinity reported to date for any modulatory compound, and contrasts with the 1000-fold 
lower affinity reported for the first generation modulator, verapamil (81, 158). The 
affinity of [3H]-XR9576 interaction with P-gp was also 5- and 20-fold more potent than 
that observed for the cytotoxics vinblastine and paclitaxel, respectively.
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High affinity binding is an important factor underlying the effectiveness of XR9576 to 
reverse P-gp mediated MDR, reported in both in vitro and in vivo resistance models (89). 
But what consequence does binding of XR9576 have on the activity of P-gp? This 
question was addressed by measuring the ATPase activity of P-gp containing CH^B30 
membrane vesicles in the presence of XR9576. XR9576 potently inhibited the P-gp 
related ATPase activity, as did the other third generation modulators GF120918 and 
XR9051, investigated in this thesis. This is the first report showing that drugs can 
potently inhibit the ATPase activity of P-gp. The effect of these modulators on ATPase 
activity is in stark contrast to the ability of the first generation modulators verapamil and 
nicardipine to increase hydrolysis. The potent inhibition of P-gp mediated ATPase 
activity by the new generation high affinity modulators, implied that they were not 
ligands for P-gp transport activity. This was confirmed in transport assays where there 
was no difference in the extent of [3H]-XR9576 accumulated in CHrB30 cells, compared 
to parental cells. Furthermore, there was no saturability in drug accumulated over a wide 
range of concentrations, indicating that XR9576 distribution was passive, rather than 
carrier mediated. Thus it was concluded, that the newer generation modulators could 
directly bind P-gp with equal or greater affinity than cytotoxic drugs, but the signal 
transmitted to the NBDs was different leading to inhibition of ATPase activity. This 
difference in signalling possibly underlies the reason why cytotoxic drugs are transported 
by P-gp, and compounds such as XR9576, are not.
Inhibition of ATPase activity rather than competition for transport, may represent the 
mechanism by which XR9576 and GF 120918 effectively reversed the accumulation 
deficit observed for [3H]-vinblastine and [3H]-paclitaxel in CHrB30 cells. The 
mechanism employed by first generation modulators, such as verapamil and nicardipine, 
to block P-gp transport activity is not known. These compounds can stimulate ATPase
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activity and are proposed to be transport ligands for P-gp. However, there is as yet, no 
unequivocal evidence that verapamil or nicardipine are transported by P-gp (see review 
by Stein, (139)). As there were no radiolabelled versions of these compounds available, 
this possibility could not be tested in this thesis. An alternative hypothesis proposes that 
these agents modulate P-gp mediated transport by uncoupling the ATPase activity. 
Thereby the hydrolysis activity may be recruited by modulator, and is no longer available 
to transmit signal to the binding site(s) for transport ligands.
Additional information concerning the interaction of cytotoxic drug and modulator was 
obtained from study of the kinetics of drug binding. [3H]-XR9576 had a faster rale of 
onset, and a slower rate of offset, from P-gp than vinblastine. This observation is in 
agreement with the findings of a recent study conducted by Mistry et al. (89), who 
demonstrate that XR9576 could potently modify MDR in human and murine cancer cell 
lines, and was active up to 24 hours post administration. This is in contrast to the 
several-fold poorer efficacy, and shorter duration of action of CsA and verapamil, to 
reverse cellular drug resistance. The action of these two drugs is short-lived, since they 
were only effective for up to 60 minutes post-administration. The difference in the 
duration of action of these compounds on P-gp, may be due to the fact that CsA and 
verapamil are ligands for transport by P-gp, and are therefore transported out of the cell.
In summary, this characterisation of the interaction of the modulatory compound [3H]- 
XR9576 with P-gp, has shown the potential benefits of specifically designing 
pharmaceutical agents to target P-gp. XR9576 directly interacts with P-gp with high 
affinity and has a long duration of action. In fact, these features have been translated in 
vzvo, as XR9576 is currently undergoing Phase II clinical trials to determine its efficacy 
in restoring cancer resistance to chemotherapy (89).
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The radioligand binding studies described thus far, have provided a direct measure of the 
affinity of P-gp to bind the cytotoxic drugs vinblastine and paclitaxel, and the 
modulatory compound XR9576. Where drugs are not available in radiolabelled form, 
study of the antagonistic effect of drug on the binding of radiolabelled drug, is often used 
to determine the relative affinity of antagonist interaction. Inhibition of drug binding has 
been a methodology adopted by many investigators in the P-gp field to measure, either 
drug interaction with P-gp, or as an estimate antagonist ‘affinity’ (25, 30, 109). 
Displacement binding experiments provide IC50 values that denote the concentration of 
antagonist that produces 50% inhibition of binding. However, as this value is not a 
constant and is dependent on experimental factors such as the concentration of 
radioligand to be displaced and the amount of membranes used, it has been common 
practice to transform this parameter to provide an inhibition constant for antagonist 
action. One such transformation is that derived by Cheng-Prusoff (19), where the IC50 
value is converted to an inhibition constant or antagonist affinity constant (Kj value). 
However, the Kj value for antagonist action can only be equated with the Kd for binding 
of antagonist, where antagonist-drug interaction is competitive.
I performed a series of displacement binding experiments to measure the antagonistic 
potency of a range of drugs, both cytotoxic and modulatory on P-gp, as summarised in 
table 3.2 (Chapter 3, 3.7). IC50 values obtained from displacement binding curves were 
converted to Kj values to assess the potency of antagonist binding. Interestingly, the 
validity of the Cheng-Prusoff transformation was called in to question as there were a 
number of discrepancies between the Kj values for the antagonistic effect of some drugs, 
and their measured Kd values to interact with P-gp. In particular, vinblastine displaced 
the binding of [3H]-XR9576 with a K, value of 1.25pM and this deviated significantly 
from its measured Kd for binding to P-gp of 21nM (Chapter 3 (3.4.1)). There was also a
171
Chapter 6 Discussion
discrepancy between the Kj value for inhibition of [3H]-XR9576 binding by paclitaxel, 
which was 16-fold higher than its previously determined Kd of binding. Additionally, the 
Kj values describing interaction of nicardipine with each of the radioligand drugs 
investigated, ranged between 10 and 885nM. Taken together, these findings suggested 
that the Cheng-Prusoff transformation may not provide a valid estimate for the affinity of 
antagonist to bind P-gp. Moreover, this suggests that there are non-competitive 
interactions between drugs on P-gp, which in turn means there is more than one drug 
binding site on the protein.
6.3 Communication between multiple distinct sites On P-gp
This provided the impetus to determine how many binding sites there were on the 
protein, and what kind of interaction occurs between the sites. From the binding studies 
outlined in chapter 4, a multiple drug binding site model for P-gp has been produced 
depicting the presence of at least four distinct sites of drug interaction on P-gp that are 
allosterically linked (figure 6.1).
As discussed in Chapter 2 (2.4), examination of the effects of antagonist binding on the 
Bmax and Kd of drug, can yield important information concerning the type of interaction 
occurring between pairs of drugs at a receptor. This pharmacological principle was used 
to determine the number of binding sites (depicted in figure 6.1) and the kind of 
interactions occurring between them. An exhaustive series of radioligand binding 
experiments was therefore carried out, where complete saturation isotherms for either 
[3H]-vinblastine or [3H]-XR9576 were conducted in the presence of a range of 
concentrations of antagonist. Schild analysis was applied to the binding data to 
rigorously test for competitive interactions between drugs. The validity of using Schild 
analysis to discriminate between competitive and non-competitive antagonism has been
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discussed at length by Kenakin (66) and demonstrated to be applicable to the study of 
antagonist interaction at receptors (72). Decreases in the Bmax of binding were observed 
in many cases, strongly indicating non-competitive interactions. Measurement of the off- 
rate of radioligand in the presence of antagonist was used to verify these non-competitive 
effects (as discussed in Chapter 2 (2.4)).
Based on the results from Schild analysis and measurement of dissociation kinetics of 
drug, it was possible to identify distinct sites and to classify them according to the type of 
drug bound. " Therefore as shown in figure 6.1, sites I and II have been assigned to 
vinblastine and paclitaxel respectively, and are clearly capable of being involved in 
transport. Site IV of the model has been classified as a regulatory or modulatory site, 
although it has not been determined whether transport occurs from this site or not. This 
site was designated as a possible site common to the modulators nicardipine and 
GF120918, based on their ability to non-competitively inhibit binding of [3H]-vinblastine 
and [3H]-XR9576. However, due to the unavailability of radiolabelled versions of 
nicardipine and GF120918, it was not possible to determine whether these compounds 
interact competitively or not. Due to the relatively poor binding of [3H]-paclitaxel to 
CHrB30 membranes, the type of interaction occurring between paclitaxel and these 
modulators could not be determined. However, these compounds were assigned to a site 
other than the paclitaxel site, based on the results of a study by Woodhouse (155). This 
work showed that nicardipine binding elicited a 3-5 fold increase in the dissociation rate 
constant for [3H]-paclitaxel binding, which is indicative of a non-competitive interaction 
between these drugs.
The existence of more than one drug binding site on P-gp has been demonstrated in 
numerous studies, employing either measures of ATPase or transport activity, or from
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direct measurement of drug binding using photo-affinity or radioligand binding methods. 
For instance, Tamai and Safa (142) showed that vinblastine and CsA non-competitively 
inhibited the equilibrium binding of [3H]-azidopine.
vinblastine
a
IV
GF120918
nicardipine
n
paclitaxel
^ m >
Hoechst 33342 
XR9S76 
XR9051Rhodamine 123
Figure 6.1 Classification of four distinct drug binding sites on P-gp. Sites I, II and HI have a role in 
transport as a consequence of drug binding, although she HI can have a modulatory role depending 
upon ligand bound. She IV has been designated as modulatory only. Solid arrows indicate that the 
sites identified can communicate with each other. (Published in Martin et aL (83)).
By investigating the effect of drugs on the dissociation kinetics of [^-vinblastine. Ferry 
et al (29, 30) report the presence of at least two distinct binding sites for drug; a 
vinblastine selective site and one at which 1,4-dihydropyridine reversal agents bind. 
This result agrees with the non-competitive interaction observed between vinblastine and 
the 1,4-dihydropyridine nicardipine, reported in this thesis.
A common site on P-gp can elicit either transport or modulatory roles. The sites 
identified thus far in this thesis have been classified as eliciting either transport or
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modulatory roles. Therefore, the observation that the modulatory drugs XR9576 and 
XR9051 interacted competitively was not surprising (site IQ, figure 6.1). More 
especially, a competitive interaction between these agents was expected, given the 
structural similarity of these compounds as illustrated in Chapter 1 (1.3.2). This is 
related to the fact that XR9051 was a precursor molecule for XR9576, in a medicinal 
chemistry programme to develop high affinity inhibitors of P-gp activity.
There is evidence from the literature suggesting that drugs that are transported and those 
_ that are modulatory can interact at a common site on P-gp. For example, Tamai and Safa 
(141) showed that the modulator CsA could competitively inhibit the uptake of vinca 
alkaloids. However, the presence of a common site of interaction for vinca alkaloids and 
CsA was inferred from transport assays, and not through direct measurement of binding. 
Using radioligand binding studies I have unequivocally shown that site m  displayed a 
dual function in terms of transport and modulatory activity. A competitive interaction 
between [3H]-XR9576 and Hoechst 33342 was observed from Schild analysis, and was 
confirmed by the lack of effect of Hoechst 33342 on the dissociation rate constant for 
[3H]-XR9576. This result clearly demonstrates that a common site on P-gp can elicit 
either a transport or modulatory role. Therefore, it seems that the functional consequence 
of drug binding is not strictly dependent upon the site occupied, but is also related to the 
type of drug bound. For instance, binding of Hoechst 33342 at site Dl (figure 6.1) results 
in transport of the Hoechst 33342 molecule, and has been shown to have no measureable 
effect on ATPase activity (125). Conversely, XR9576 binding does not result in
' j
translocation of the XR9576 molecule, but rather inhibition of P-gp transport activity, 
which may be related to its ability to inhibit P-gp related ATPase activity. Does this then 
imply that these molecules transmit different signals to the energy-generating NBDs? 
Translocation of a drug molecule must involve alteration in the affinity and ‘re-
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orientation’of, the drug binding site. The signal to induce changes in the binding site 
must originate at the NBDs, because of the requirement for ATP hydrolysis to support 
transport. Why is there a different functional outcome arising from occupation of site III 
by XR9576 compared to Hoechst 33342? One possibility is that when XR9576 is bound, 
the site is unable to undergo ‘re-orientation’ to face the ‘opposite side’ of the membrane. 
This scenario is quite likely in view of the potent inhibition of ATPase activity observed 
in the presence of XR9576. Alternatively, XR9576 may dissociate very slowly from the 
binding site following ‘re-orientation’. However, a more in-depth discussion of 
signalling between the drug binding domain and the NBDs during a transport cycle will 
be dealt with later.
Classification of the site for interaction of the transport ligand rhodamine 123 has been 
problematic for a number of reasons. There was no effect of rhodamine 123 on the 
binding parameters of [3H]-XR9576, and this may reflect the relatively poorer affinity of 
rhodamine 123 to interact with P-gp compared to [3H]-XR9576. However, it was 
deduced that rhodamine 123 does not interact with the [3H]-XR9576 binding site, since 
this site is shared by Hoechst 33342, and it has been previously shown that Hoechst 
33342 and rhodamine 123 interact at distinct sites (127). Non-competitive interactions 
observed between [3H]-vinblastine and rhodamine 123, excluded this compound from 
interaction at site I. Due to the poor binding affinity of [3H]-paclitaxel to P-gp 
demonstrated in chapter 3, it has not been possible to examine the binding parameters of 
this drug in the presence of antagonist. Therefore I would tentatively suggest that 
rhodamine 123 interacts at the paclitaxel site as illustrated in figure 6.1, given that both 
ligands are transported by P-gp.
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Do multiple ligands simultaneously bind to P-gp? The presence of multiple distinct drug 
binding sites within the drug binding domain of P-gp, has been established by the work 
conducted in this thesis. Does this observation imply that P-gp can bind different drug 
molecules simultaneously? By studying the effect of ‘antagonist’ on the dissociation 
kinetics of either [3H]-vinblastine or [3H]-XR9576, it was established that all of the 
binding sites were linked by a communication network, as depicted by inter-connecting 
arrows between the binding sites in figure 6.1. The nature of the allosteric effect 
observed between the drugs tested in chapter 4, involves a negative heterotropic effect 
that manifests as an increase in the dissociation rate constant for drug. By analogy, this 
could be likened to drug being ‘pushed’ off its binding site by the binding of another 
unrelated drug at an alternative site. Therefore, drugs would not simultaneously bind to 
P-gp but would be governed by allosteric regulation. A model is presented in figure 6.2 
to illustrate how binding of multiple drugs to distinct sites on P-gp might be regulated.
Molecular mechanism fo r the binding o f multiple drugs to P-gp. The central tenet of the 
model in figure 6.2, suggests that the binding sites on P-gp can exist in either high or low 
affinity conformations for their specific ligand. The presence of high and low affinity 
sites for ligand has been demonstrated for other transport proteins. Drug binding studies 
of the L-type calcium channel revealed the presence of distinct but interacting sites for 
verapamil, 1,4,-dihydropyridines and cis-diltiazem. Each site could exist in either high 
or low affinity conformations due to either alterations in temperature or the binding of 
ions or drugs (37). The existence of high and low affinity sites for ligand on a receptor 
or protein molecule has also been demonstrated for the cholecystokinin receptor (90) and 
bilitranslocase, a carrier protein involved in the uptake of bilirubin at the sinusoidal 
domain of the liver cell plasma membrane (95). The model in figure 6.2 details the
177
Chapter 6 Discussion
movement of drug binding sites on P-gp between various states of occupancy with, and
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Figure 6.2 ‘Multiple she transition model* depicting possible molecular mechanism of drug binding 
to P-gp. Only two classes of she are shown for clarity and are connected by a line to depict 
interacting sites. Circles represent high affinity binding sites for T and M respectively. Rectangles 
depict low affinity conformation of the T and M sites. Ky, and Kmb are the equilibrium constants for 
binding of T and M to their high affinity sites. The switch in conformation of linked she due to drug 
binding is represented by a solid arrow. Conformational change in binding she due to drug binding 
is governed by either OtKmc (in the case of T altering M) and amKtc for alteration of T by M where a  
is the allosteric potency of drug to induce conformational change and Kmc and K* are the 
equilibrium constants describing shift between high and low affinity conformation. Published in 
Martin et aL, (83».
affinity for, their respective ligands. Only two of the sites identified on P-gp are shown 
for clarity, and are designated T and M. These sites are depicted as distinct but 
interacting drug binding sites. The binding site for drug T or M, can exist in either high 
or low affinity conformations, and the equilibrium between the conformations is 
governed by the constants Ktc and Kmc respectively (see bottom right hand comer of
17*
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figure 6.2). The top left hand comer of figure 6.2 depicts high affinity binding sites for 
both T and M on a single molecule of P-gp, and binding of T or M, is governed by the 
equilibrium constant for their respective binding reaction i.e. K& or Kmb. From the 
dissociation kinetic experiments conducted in chapter 4, it is known that the drug binding 
sites on P-gp are allosterically linked. For example, binding of T to its high affinity site 
will drive the conformation of the M site to low affinity (represented by switch from 
circle to rectangle). This conformational alteration is described by the equilibrium 
constant oqKmc where a t represents the allosteric potency of drug molecule T, to increase 
the propensity of the M site to exist in a low affinity conformation. The ability of drugs 
to interact with their respective high affinity binding sites will be dependent upon the 
relative affinities of the two drugs to bind, but also, and more especially, on the relative 
allosteric potencies of these drugs. The inter-connecting network of allosterically linked 
sites suggests that two molecules of drug may not simultaneously access their respective 
high affinity sites. Thus it is possible to conceptualise a mechanism for the binding of 
multiple ligands by P-gp, which is allosterically regulated via conformational signalling 
between binding sites, to facilitate ligand interactions at multiple sites.
Evidence for conformational signalling between drug binding sites has also come from 
studies of the transport activity of P-gp, conducted by Shapiro and Ling (123, 127). 
They suggested that binding of Hoechst 33342 and rhodamine 123 at their respective 
sites, resulted in positive co-operativity in the transport of each. Do these observations in 
transport studies disagree with the drug binding interactions of figure 6.2? This model 
provides information on the initial interaction of drugs with P-gp and cannot predict the 
functional outcome in terms of transport kinetics. Likewise, it is difficult to determine 
whether the positive co-operativity seen in the transport of Hoechst 33342 and 
rhodamine 123, is due to the nature of the allosteric communication that exists between
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the binding sites of these compounds. One could speculate that positive co-operativity in 
the transport of drug molecules from two different sites, could arise if they were linked 
. by negative allosteric communication. If the low affinity state actually corresponded to 
the “outward” facing orientation of a drug binding site, then the negative allosteric 
interaction could manifest as a co-operative transport process. Using this scenario, 
binding of drug could ‘push’ the binding site for the other drug to low affinity, leading to 
‘re-orientation’ and simultaneous transport of both.
Does specificity fo r multiple ligands make P-gp an atypical transporter? The fact that P- 
gp, a primary active transporter, contains multiple sites for drug recognition is an 
apparent contradiction of the classic Tock and key’ hypothesis for enzyme-substrate 
interaction. Other primary active transporters such as the Ca2+- and Na+, K+-ATPases 
display strong substrate specificity and tight coupling of ligand binding to ATP 
hydrolysis. However, other members of the ABC super-family of membrane transport 
proteins to which P-gp belongs, are also capable of interacting with and transporting 
multiple ligands. The multidrug resistance associated protein (MRP1) has a broad 
specificity for conjugated drugs and has been implicated as playing a role in MDR 
(reviewed by Borst et al., (12)). LmrA, an ABC transporter found in Lactococcus lactis, 
also mediates transport of multiple drugs (151). Other ABC proteins including Pdr5p 
and Yorlp in yeast, Cdrlp of C.albicans and Pfindrl in P. falciparum are each able to 
interact with and transport many different classes of drug.
Poly-specificity, a feature o f multidrug transporters. The concept of ‘poly-specificity’ in 
ligand interaction is not only restricted to members of the ABC superfamily, but also to 
proteins of the major-facilitator (MFS), small-multidrug resistance (SMR) and 
resistance-nodulation (RND) transport families. The drugs transported by multidrug
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transporters are structurally and chemically dissimilar, but they share common features 
such as lipophilicity, planarity and many contain a quaternary nitrogen group. How do 
multidrug transporters such as P-gp accommodate multiple binding sites on a single 
protein molecule? To accommodate the multi-site model depicted in figure 6.1, a large 
binding pocket can be visualised that most likely has contributions from both N- and C- 
terminal TMDs. The binding pocket may contain specific drug recognition elements that 
will become exposed or hidden dependent upon the ligand present. Allosteric regulation 
of binding as outlined in figure 6.2, will most likely involve conformational alteration in 
the availability of specific transmembrane elements required for high affinity interaction 
of ligand. Photoaffinity-labelling studies using analogues of different P-gp ligands, 
detected labelling of different membrane spanning segments located in each half of the 
protein (42, 91), suggesting contribution of TM elements from each half of the P-gp 
molecule in drug binding. In addition, the cross-linking studies of Loo and Clarke have 
produced a cyclone model proposing that TM segments 4,5,6 and 10,11,12 are directly 
involved in drug interaction (78-80). The only low-resolution structure available for P- 
gp to date, described in Rosenberg et al., (104), indicates that the P-gp molecule is 
toroidal in shape with a central membrane spanning pore that narrows towards the 
cytoplasmic face which could accommodate a large binding pocket comprising both 
halves of the protein molecule.
Study of the crystal structure of the unrelated transcriptional activator (BmrR) of Bmr, a 
multidrug transporter in B.subtilis, has been used as a model to provide a structure-based 
mechanism for interaction of a single transporter with multiple drugs The crystal 
structure data revealed the presence of a large binding pocket that contained flexible 
elements, allowing ligands of differing structures to access their appropriate binding 
residues (159). Although BmrR is not a transporter, it does interact with ligands that are
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transported by P-gp such as the hydrophobic cationic dyes rhodamine, ethidium and 
acridine and may help to shed light on how P-gp interacts with multiple drugs. The 
* induced fit’ model for BmrR, in the absence of high resolution structural data for P-gp, 
could be used to explain how different drugs might access their respective sites on P-gp, 
within a large flexible binding domain.
6.4 Binding of drug at discrete stages of the catalytic cycle
The studies conducted in chapter 3 and 4 have yielded important information concerning 
the molecular mechanism of multi-ligand binding by P-gp. The focus of chapter 5 has 
been elucidation of how drug binding events at the TMDs are linked to ATP hydrolysis 
at the NBDs to mediate translocation of drug. Conceptually, transport of a drug 
molecule can only occur following a sequence of events encompassing both (i) ‘re­
orientation’ of a binding site to the opposite side of the membrane and (ii) a switch in 
binding site from high to low affinity. P-gp has a strong requirement for ATP hydrolysis 
in order to transport drugs across the plasma membrane against a concentration gradient. 
Therefore, signalling must occur between the TMDs and the NBDs during a transport 
cycle. Radioligand binding assays were used to investigate drug binding at discrete 
stages of the catalytic cycle to (ij determine when the initial change is wrought on the 
drug binding site to initiate transport (ii) elucidate the kind of changes conferred on the 
drug binding site(s) and (iii) ascertain the signal required to restore the drug binding site 
to a ‘pre-transport’ conformation. A model has been devised putting forward a 
molecular mechanism that describes how the binding site for transport ligand adopts high 
and low affinity conformations during a catalytic cycle and by extension, a transport 
cycle of P-gp (figure 6.3).
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Figure 6 3  Based on study of the characteristics of [^ H] vinblastine binding at discrete stages of the 
catalytic cycle, a model for P-gp mediated drug transport is presented. The two transmembrane 
domains are represented by one large shaded square and the NBDs by two small clear squares. The 
catalytic sites within each NBD are depicted by ellipses, open represents ‘active’ catalytic site 
conformation and shaded ellipse ‘passive’ conformation. Upon nucleotide binding the‘active’ 
catalytic site is depicted by a circle to indicate that this NBD is actively participating in a catalytic 
cycle. Stage I depicts the pre-nucleotide binding state of P-gp where both NBDs are devoid of 
nucleotide and the drug binding site has a high affinity inward-facing conformation. ATP-bound or 
pre-hydrolysis state for P-gp is illustrated at stage m  and the drug binding site is now in a low 
affinity outward-facing orientation. Stage IV depicts protein following hydrolysis of ATP. 
Subsequent dissociation of phosphate restores drug binding to inward facing high affinity 
conformation prior to release of ADP as represented in V. Stage VI depicts P-gp following release of 
ADP from the active catalytic site with possible switching of this site to a passive conformation 
before entering a new catalytic cycle.
The model depicted in figure 6.3 was produced from direct measurement of drug 
binding, at each stage of the catalytic cycle of P-gp. In order to quantitate changes in the 
drug binding site as P-gp undergoes a catalytic cycle, the radioligand binding assay for
[ H]-vinblastine was modified to enable measurements to be made over a wider
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concentration range of ligand. In fact, the concentration range of vinblastine used was 
increased 30-fold as described in methods (chapter 2, 2.2.3). Therefore, interaction of 
vinblastine could be measured at concentrations up to 150-fold greater than its previously 
measured Kd of binding, enabling large alterations in the affinity of binding to be 
detected in binding assays.
At stage I—>11 of the model presented in figure 6.3, the binding of [3H]-vinblastine was 
measured in the absence of nucleotide using the refined radioligand binding assay 
alluded to above. A model describing binding of vinblastine to a single class of high 
affinity binding site best described the experimental data obtained. This uunfimied the 
findings of previous radioligand binding studies that show binding of [3H]-vinblastine to 
a single class of high affinity site on hamster (16) and human P-gp (30). Given that 
binding sites on transporters cycle between high and low affinity conformations, it was 
necessary to unequivocally establish that there was a single class of vinblastine site 
present under ‘basal’ conditions. This clarification was also required given the 
suggestion that there are two classes of vinblastine site of opposite affinity, on the related 
transporter LmrA (152). The authors report that interaction of vinblastine at a low 
affinity site promotes binding at a linked site of high affinity. LmrA is often described as 
a bacterial homologue of P-gp. However, differences observed in the binding of [3H]- 
vinblastine to P-gp versus LmrA, may be due to the fact that LmrA is a homodimer, 
whereas the functional unit for P-gp is believed to be monomeric. Each dimer subunit 
may contain a site of interaction for vinblastine accounting for the differences observed 
between LmrA and P-gp.
Indeed, the evidence presented in this thesis for binding of vinblastine to a single class of 
site is also at variance with some studies of P-gp concerned with measurement of
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vinblastine binding. Romsicki and Sharom (102) reported that vinblastine was 
interacting at a high and low affinity site on P-gp. This was interpreted from study of the 
ability of vinblastine to quench fluorescence of the sulfhydryl-reactive probe MIANS, 
bound at the Walker A cysteines. However, this is an indirect method with which to 
assess drug binding. Vinblastine quenching of bound MIANS produced a biphasic 
curve, interpreted to represent binding of vinblastine to two classes of binding site. It is 
quite likely that a biphasic quenching curve could have arisen due to quenching of
MIANS molecules bound at each NBD, a possibility not addressed by these authors.
'
Binding o f nucleotide triggers the first major conformational change in the vinblastine 
binding site. The ability of the catalytic cycle to influence [3H]-vinblastine interaction 
with P-gp at an early pre-hydrolysis stage was investigated by measuring binding in the 
presence of a non-hydrolysable analogue of ATP (stage II—►III). Preliminary 
experiments demonstrated that the non-hydrolysable ATP analogues ATP-y-S and AMP- 
PNP, had a pronounced effect on [3H]-vinblastine binding with up to 70% inhibition 
observed. The fact that there was no alteration in the binding of vinblastine when the 
NBDs were occupied with either NBD.C1 or MIANS, confirmed that signalling to the 
TMDs was specifically related to the binding of nucleotide. The type of change wrought 
on the [3H]-vinblastine binding site in the presence of nucleotide analogues was further 
investigated using complete binding curves for vinblastine binding. Analysis of the 
binding data produced at stage m  of the model in the presence of AMP-PNP, showed 
that (i) there was a 15-fold reduction in the affinity of binding (ii) a model describing 
interaction of vinblastine at a single class of site best fitted the data. Together these 
observations were taken as evidence that the binding of ATP induced a complete shift in 
the conformation of the vinblastine binding site from high to low affinity. If vinblastine 
was interacting at two sites of distinct affinities, a biphasic binding curve would have
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resulted as determined from the theoretical modelling studies reported in chapter 5 
(5.3.1.1). This is the first direct evidence to show that binding of ATP at the NBDs, prior 
to hydrolysis, was sufficient to provide the initial signal required to instigate a transport 
event.
The observation that binding of ATP can elicit conformational changes in the P-gp 
molecule is not unprecedented. There is evidence from numerous studies, using a variety 
of different techniques, to demonstrate that binding of nucleotide induces conformational 
changes in the P-gp molecule. For example, Urbatsch and Senior (148) reported 
decreased photoaffinity labelling of [3H]-azidopine to purified reconstituted hamster P- 
gp, in the presence of AMP-PNP. It has been shown that the accessibility of the UIC2 
antibody for its extracellularly located epitope on P-gp is reduced in the presence of 
bound ATP (87). Acrylamide quenching of endogenous tryptophan residues showed 
changes in tertiary structure upon binding of nucleotide (138) while non-hydrolysable 
analogues of ATP increased resistance of P-gp to trypsin digestion (60).
What is the role o f ATP hydrolysis in a transport cycle? The novel observation that the 
binding of ATP is sufficient to instigate the initial alterations in the binding site during a 
transport/catalytic cycle, goes against the proposition that hydrolysis of ATP is necessary 
to bring about an initial significant change in the drug binding sites. Therefore, it was 
important to elucidate any consequence of ATP hydrolysis for P-gp-drug interactions. 
This was achieved using the technique of vanadate trapping to stabilise the protein in the 
MgADP.Vi bound form, to mimic the step in the catalytic cycle that immediately follows 
ATP hydrolysis, but precedes dissociation of Pi. The low affinity vinblastine site 
detected in the presence of bound nucleotide persisted post hydrolysis of ATP (stage IV). 
However, the low affinity conformation observed at stage IV was different to that
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observed in the presence of bound AMP-PNP. This was reflected in a value for the K<j of 
binding to trapped protein that was significantly lower than the K<j measured in the 
presence of AMP-PNP. Thus the low affinity vinblastine binding site detected post­
hydrolysis of ATP was ‘intermediate’ in affinity between the high affinity site measured 
under ‘basal’ conditions and the low affinity site induced by the binding of nucleotide. 
This observation agrees with the low resolution structural data produced from crystals 
grown with P-gp under ‘basal’, vanadate trapping and AMP-PNP bound states. Three 
different conformations were observed and the vanadate trapped protein had a 
conformation that was ‘intermediate’ between the control and nucleotide bound proteins 
(Rosenberg et al. (103)). The functional relevance of the low/intermediate affinity 
conformation observed post-hydrolysis of ATP is not known. The lower value for Kd 
obtained is not due to ‘recovery’ of the vanadate trapped protein over the course of the 
binding assay, as vanadate was included in all of the binding buffers to prevent 
dissociation of bound species.
The presence of low affinity binding sites for ligand, when P-gp is in a vanadate trapped 
' conformation, is in agreement with photoaffinity labelling studies that demonstrate 
reduced labelling of the prazosin analogue [125I]-IAAP (96, 113, 115). However, there 
was no effect of ATP binding on [125I]-IAAP labelling, which is contrary to the effect of 
nucleotide on the binding of [3H]-vinblastine reported in this thesis. Interestingly, I 
found that the binding of nucleotide was also without effect on the interaction of [3H]- 
XR9576 with P-gp, whilst there was reduced binding of this modulator to vanadate 
trapped protein (chapter 5, 5.3-5.4). This implies that changes in drug binding site 
induced by ATP binding may be specific for the class of drug bound at the drug binding 
domain. I have previously demonstrated that the binding site occupied by drug may not 
be the prime determinant for the specificity of signalling between drug binding sites and
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the NBDs. As shown in the multi-site model'depicted in figure 6.1, the same binding site 
(site m ) can elicit either transport or modulatory roles. Can the lack of effect of 
nucleotide on the binding of [3H]-XR9576 and [125I]-IAAP be related to fact that these 
compounds are not transported by P-gp? It has been established that XR9576 is not 
transported by P-gp (Chapter 3 (3.2)), whereas vinblastine is. There is no published data 
to show whether or not prazosin is a transport ligand of P-gp. The fact that the binding 
of [3H]-XR9576 and [125I]-IAAP was only affected by ATP hydrolysis, might indicate 
that conformational signals arising from ATP binding and hydrolysis of nucleotide have 
different functional outcomes, in terms of drug binding, that may be related to the class 
of drug bound.
What signal restores the binding site to high affinity during a transport cycle? Thus far, I 
have demonstrated the stage of the catalytic cycle that induces - the first major 
conformational change in the drug binding site to instigate transport (stage II—►III). The 
low affinity conformation of the drug binding site persisted post-nucleotide hydrolysis at 
stage IV. In order to complete a transport cycle the drug binding site must regain a high 
affinity conformation once more. Subsequently, the trigger required to ‘reset’ the 
binding site was investigated. Therefore, vinblastine binding was measured at the next 
stage of the catalytic cycle that occurs immediately following release of Pi from the post- 
hydrolytic complex. P-gp was covalently labelled with 8 -azido-ADP (section 2.6.1) to 
mimic the MgADP.P-gp transition state. As shown in stage V of the model in figure 6.3, 
dissociation of Pi from the post-nucleotide diphosphate complex induced a major 
conformational change in the vinblastine binding site that enabled restoration of the high 
affinity state. Dissociation of Pi from the post-hydrolytic complex is proposed to be 
accompanied by a large release in free energy, (117) that may be harnessed to ‘reorient’
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the low affinity site to a high affinity orientation following release of translocated drug. 
This will enable the binding site to participate in a second round of transport.
One molecule o f ATP may be sufficient to support transport o f a single molecule o f drug. 
The transport model devised from the binding studies conducted at distinct steps of the 
catalytic cycle demonstrates that binding and hydrolysis of a single molecule of ATP is 
sufficient to completely cycle the vinblastine binding site between high—►low—►high 
affinity conformations. It is on this basis that one might speculate that hydrolysis of a 
single molecule of ATP is sufficient to support transport of one drug molecule. The 
expenditure of one molecule of ATP per molecule of drug transported has been reported 
in assays of P-gp mediated transport of rhodamine 123 (128) and valinomycin (28). This 
is further supported by a complete recovery of ATPase activity and drug binding in 
vanadate trapped P-gp in the absence of a further round of nucleotide hydrolysis (Chapter 
5, (5.3.4); (147)). In contrast, the studies of Sauna et al. (113, 114) demonstrate a 
requirement for the hydrolysis of a second molecule of ATP, to bring about restoration of 
the high affinity site for [125I]-IAAP following vanadate trapping of P-gp. These authors 
performed sequential vanadate trapping of P-gp, and although recovery of ATPase 
activity was achieved after the first round of hydrolysis/trapping upon dissociation of 
ADP and vanadate, hydrolysis of a second molecule of ATP was required to regain high 
affinity drug binding (114). A major criticism of this study lies in the use of a single 
concentration of [125I]-IAAP that was 150-fold lower than the value for the Kd of [m I]- 
LAAP binding to P-gp, that they had reported previously. Therefore, the ability of [125I]-* 
LAAP to bind during a catalytic cycle of P-gp was investigated using a concentration of 
drug where there was only fractional occupation of the drug binding sites. It is also 
known that the association of drug with its receptor is driven by the concentration of free
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drug and therefore the amount of free drug in the assay system could be of importance 
for the kinetics of drug binding to ‘recovering’ protein.
Does the ‘non-catalytic’ NBD participate in a catalytic/transport cycle? The 
participation of both NBDs during a catalytic cycle has been the subject of conjecture in 
studies of P-gp function and this topic has been touched upon in chapter 1 (1.10). The 
alternating catalytic sites model of Senior et a l, (117) states that although there is a strict 
requirement for two intact NBDs in hydrolysis, the NBDs do not simultaneously 
hydrolyse ATP. This was borne out in vanadate trapping experiments where Urbatsch ef 
al. (147) demonstrate trapping o f  only one molecule o f  nucleotide post-hydrolysis. 
Therefore during a single catalytic cycle, only one of the NBDs is ‘active’. The NBD 
that is not hydrolysing ATP will be referred to as the ‘passive’ NBD. Given the strong 
interplay that has been demonstrated by many studies to exist between the NBDs of P-gp, 
what role does the ‘passive’ NBD play in catalysis? I looked at the ability of ATP to 
bind to the ‘passive’ NBD by measuring ATP binding to P-gp that was previously 
trapped with vanadate. It was found that when ADP/Vi is bound at the ‘active’ NBD, 
ATP is able to access and bind to the catalytic site within the ‘passive’ NBD. There is 
communication between the NBDs of P-gp during catalysis, as the presence of mutations 
or inhibitors at either NBD disrupts hydrolysis. Therefore it seems reasonable to assume 
that the ‘passive’ NBD does transmit a signal to the active NBD during catalysis. Can 
the ‘passive’ NBD transmit a signal to the drug binding domain? Having established that 
ATP can bind to the ‘passive’ NBD it was imperative to ascertain whether binding of 
nucleotide at this NBD could also affect drug binding. If this were the case, the model 
produced in figure 6 . 3  would require revision; as the protein would never regain a high 
affinity conformation for drug, since ATP bound at the ‘passive’ NBD would not support 
this binding site conformation. Therefore, stage V of the cycle was further investigated
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by measuring binding of vinblastine when ADP was bound at the ‘active’ NBD, in the 
presence of saturating concentrations of AMP-PNP. The presence of AMP-PNP did not 
alter the conformation of the vinblastine site. This was an important finding as it 
demonstrated that the ‘passive’ NBD, whilst being essential for catalysis to occur at the 
‘active’ NBD, did not transmit a signal to the TMDs. If the alternating catalytic sites 
model is correct, I hypothesise that the NBDs switch roles before commencing another
t
round of catalysis, after ADP has dissociated from the ‘active’ NBD, as depicted at stage 
VI of figure 6.3. However, it is not known whether hydrolysis can occur until ATP is 
bound at both NBDs. According to the alternating catalytic sites model of Senior, it is 
hypothesised that both of the NBDs must be occupied by ATP, before hydrolysis can 
occur at a single NBD. This assumption has been based on the co-operativity that has 
been shown to exist between the NBDs of P-gp (118) Direct evidence for allosteric 
communication between the NBDs of ABC proteins was shown for MRP1 a transporter 
that is also involved in MDR. Hou et al., (53) demonstrated that binding of ATP at the 
passive NBD allosterically promoted hydrolysis of nucleotide at the alternate active 
NBD. Perhaps the role of the ‘passive’ NBD during a cycle of catalysis is to 
allosterically promote hydrolysis at the ‘active’ NBD as it has been shown in this thesis 
that the ‘passive’ NBD does not transmit a signal to the binding domain.
At what stage does drug bind to begin a second cycle o f transport? It has been 
established that the binding site for vinblastine has been ‘reset’ to a high affinity 
conformation for ligand at stage V of the model in figure 6.3 and is ready to bind an 
additional molecule of drug to commence the next round of transport. But when does the 
protein bind the next molecule of vinblastine? Theoretically, a second molecule of drug 
could bind at stage V, prior to dissociation of ADP, as the binding site is in a high 
affinity orientation. Alternatively, release of ADP may take place before another
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molecule of vinblastine can interact with the protein. It has been suggested by a recent 
study investigating the effect of drug on ATP hydrolysis and vanadate trapping, that the 
release of ADP is the rate-limiting step in the catalytic cycle of P-gp (67). However if 
the ‘passive’ NBD, which already has ATP bound, becomes ‘active’ following release of 
ADP, then the binding site may be switched to a low affinity state before a second 
molecule of drug can bind. Therefore, it seems more likely that a second molecule of 
drug binds prior to dissociation of ADP (stage V) as bound ADP may function to 
‘anchor’ the protein in a high affinity conformation for drug, before the NBDs undergo 
another round of catalysis.
In summary, the work conducted in this thesis has both confirmed and augmented studies 
of P-gp-drug interaction and transport activity. Different drugs were used as 
pharmacological probes in radioligand binding assays to produce models for drug 
binding and transport processes:
• It has been shown that P-gp directly interacts with a diverse range of drugs 
including cytotoxics used in chemotherapy and compounds that inhibit P-gp 
activity.
• The molecular basis of this apparent lack of ligand specificity is the presence of 
at least four distinct drug interaction sites.
• A model has been put forward depicting allosteric regulation governing binding 
of multiple ligands at distinct sites on P-gp.
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The binding studies were extended to investigate communication between the NBDs and 
TMDs during catalysis to elucidate further the mechanism of P-gp transport activity.
• The binding site for the transport ligand vinblastine, cycled between high and low 
affinity conformations during a catalytic cycle.
•  Binding of ATP, prior to hydrolysis, elicited the initial major change in the 
conformation of the binding site from high to low affinity to initiate drug 
transport.
• The trigger to restore the binding site to its high affinity conformation was 
provided post-hydrolysis of nucleotide following release of Pi, but prior to release 
of ADP from the catalytic site.
• It has been proposed that hydrolysis of a single molecule of ATP is sufficient to 
support transport of one molecule of drug
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APPENDIX I
The Adair Equation: description of binding to two sites on a receptor.
In the scenario described below the receptor protein [P] contains two drug [D] binding 
sites. An initial equilibrium may be established with association and dissociation rate 
constants o fk i and k_i respectively.
[P] + [D]
k i A
V
k -i
[PD] 2.1
The [PD] complex may then bind a further drug with association and dissociation rate 
constants o fk i and k_2 respectively.
[P] + [PD] AVk_c
[PD2] 2.2
The dissociation rate constants for the two binding reactions may be expressed as:
K —
[ P D ]
These may be re-arranged as follows:
K 2 =
[ « ? ] » [  j ]
[ P D i ]
[P] =
[PD \»h
[D] ki
The fraction of total receptor bound (/) may be expressed as:
[PD\+2[PDi]
f  ~
2([p]+[ro]+[pz)2])
And by substituting for [P] and [PD2] the fraction bound can be described as:
'[ r o M z j p
[P/)]+2
/  =
ki
[ D ] ki
Simphfying this relationship yields the Adair Equation:
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*2 .[Z>]+2 [Z) ] 2
J  = ----------------------------------------------------
l[k U k 2  + k2»[D]+[D¥)
APPENDIX II
Determination of the association rate constant for drug binding to a receptor.
The rate of formation of a drug receptor complex [PD] over time is dependent upon the 
difference between the rate at which drug associates with receptor and the dissociation of 
drug receptor complexes:
P] + P I v = ^  PD]
* 2
To follow this reaction we require a relationship between the amount of bound protein as 
a function of time.
^ P - = k x '[ P ] '[ D \ - k i P D ]
Let [P r]= [P ]+ [/>£»] and [P] = [P t-]-[PO]
Substituting;
M Z>](IPr]-[P£>])- ki.[PD] 
t , . [ D ] . [ P r ] - * , . [ D ] . [ P D ] - kiP D ]
= * 1  • [P>] • [Pr] -  [PD] • (* i♦ [D] + * 2)
Integrating this function with time;
| ^ 3  = .  [B lP r ]. ( e + ' W » »  )
dT
therefore;
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kx.  [D ].[P r]-[PD ]# (k\ •  [Z)]+^) = kx» [d]« [Pr].(e"(“ ,|D,,‘2>' )
rearranging and simplifying this relationship;
-  [PD]« (Al • [£>]+ kl) = -A l.  [d ] .  [P r]. (e-(*1,[clf*2)" )
k  .
smce =  Kd
[PD\ = —  • (l -  j
[d \ + K d
the amount bound at equilibrium [PD]eq is;
[ p * . f c k N
[d ]+Kd
therefore fractional saturation is;
[ p d ]
- \ - e - (  * !•[ D ]¥k 2 )»t
let Kots = k\^  [z>] + ki
therefore the fraction of protein bound at any time prior to equilibrium is;
M  
[pdV,
= \ - e -Kobs»t
APPENDIX m  
Schild Analysis to investigate competitive binding inhibition
The receptor may bind a specific drug [D] or a competitive inhibitor [A] as follows;
k ,
[P] + [D ]v = = ^  [PD] 
K2
A 
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k u x
[P] + [A] [PA]
K2a
At equilibrium
k\ • [/)] •  [p] =k^^  [PZ>] and k\a •  \â\ •  [p] = ^ 2 0  •  \PÂ\
therefore
k i [D]«[P] k. M'M
h  [ m ]  k i. [Pv4]
[p] _  [p] Ka
[p d ] [d ] [p a ] [a ]
[d ] K,
the total number of receptors is given by;
[Pr] = [p] +  [PZ>]+[ft4]
therefore;
[ p ] = N - M - M
and dividing by [PD];
[P] [Pr] [PD] [PA]
[p d ] [p d ] [p d ] [p d ]
[a ]»Kd»[PD]
substituting from above for [PA] with
Kd „ [P]
and w i th  for
Ka »[d ]
[£)] [PD]
K d [Pr] [a ] » K d »[ p d \
[D] [PD] [PD] • £ < • [ £ ]
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rearranging gives;
M  Ko Ko
[PZ>] [Z>] K a *[d ]
[Pt\ _ K d »Ka  ^ [ d ] » K a [a ] » K d 
[pz>] [d ] » K a [d ] » K a [d ]» K a
[Pr] _ K d » K a + K a »[D] + [ A ] » K d 
[P S ] [d ]o Ka
inverting to express as fractional saturation of binding;
[p d ] __________Ka »[d \_________
[Pr] ^ • [ d ] + K a » K d  + [a)»Kd
[p d ] [D]
[Pr] [ D ] + & * ( l  +  [ ^ ] / ^ )
The fractional saturation of receptor at a drug concentration [D], in the absence of 
antagonist, is given by:
[ p p ]  [p]
[Pr] [d ]  +  K d
A concentration of [D’] is required to give the same fractional saturation at an antagonist 
concentration of [A] (where [O’] > [D]);
[PD] [D-]
i.e. —
[Pr] [D^+Kv ^  + ^ K a)
therefore;
[p] [p'j
Kv [d ] [D ']+A i»(l + [ ^ ] /^ )  
which simplifies to;
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[d \»K d *^. + [a ]IKa)=[D']»Kd
the ratio of drug concentrations to give equivalent fractional saturation of the receptor 
([D’]/[D]) is known as the dose-ratio (DR);
Z)S=1 + —
Ka
K a
which may be transformed into the linear Schild relationship with a slope of n; 
log(DR - 1) = » * log[>4] -  log Ka
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